[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f-7o31sRXEKTi3BWfWUNmh6C6Vl8nPrY7hZdIeaGzBbA":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":37,"phaseBuckets":88,"rows":95},"UNICANCER",[4],215,false,91,66,285016,115,42,[14,17,20,23,26,29,32,35],{"name":15,"count":16},"Breast Cancer",30,{"name":18,"count":19},"Colorectal Cancer",15,{"name":21,"count":22},"Prostate Cancer",13,{"name":24,"count":25},"Metastatic Breast Cancer",10,{"name":27,"count":28},"Metastatic Colorectal Cancer",8,{"name":30,"count":31},"Metastatic Cancer",6,{"name":33,"count":34},"Sarcoma",5,{"name":36,"count":34},"Head and Neck Cancer",[38,43,48,53,58,63,68,73,78,83],{"nctId":39,"briefTitle":40,"date":41,"intervention":42},"NCT00470223","Combined Chemotherapy With or Without Zoledronic Acid for Patients With Osteosarcoma","2015-12","cisplatin",{"nctId":44,"briefTitle":45,"date":46,"intervention":47},"NCT02304809","Phase 2 Study Assessing Secured Access to Vemurafenib for Patients With Tumors Harboring BRAF Genomic Alterations","2019-05-07","Vemurafenib",{"nctId":49,"briefTitle":50,"date":51,"intervention":52},"NCT01805271","Safety Study of Adding Everolimus to Adjuvant Hormone Therapy in Women With High Risk of Relapse, ER+ and HER2- Primary Breast Cancer, Free of Disease After Receiving at Least One Year of Adjuvant Hormone Therapy","2020-06","Everolimus",{"nctId":54,"briefTitle":55,"date":56,"intervention":57},"NCT01957436","A Phase III Study for Patients With Metastatic Hormone-naïve Prostate Cancer","2021-08-18","abiraterone acetate",{"nctId":59,"briefTitle":60,"date":61,"intervention":62},"NCT01994239","Comparison of HT Concomitant With RT vs RT Alone in Patients With a Detectable PSA After Prostatectomy","2022-03","Degarelix",{"nctId":64,"briefTitle":65,"date":66,"intervention":67},"NCT01564056","Adjuvant Systemic Treatment for (ER)-Positive HER2-negative Breast Carcinoma in Women Over 70 According to Genomic Grade (GG): Chemotherapy + Endocrine Treatment Versus Endocrine Treatment","2022-04-11","HORMONOTHERAPY",{"nctId":69,"briefTitle":70,"date":71,"intervention":72},"NCT02299999","SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer","2022-12","AZD2014",{"nctId":74,"briefTitle":75,"date":76,"intervention":77},"NCT01376752","Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) in Relapse Ovarian Cancer Treatment","2023-01-08","HIPEC",{"nctId":79,"briefTitle":80,"date":81,"intervention":82},"NCT04053322","Durvalumab, With Olaparib and Fulvestrant in Advanced ER+, HER2- Breast Cancer Patients.","2023-11-15","Durvalumab",{"nctId":84,"briefTitle":85,"date":86,"intervention":87},"NCT03870919","Locoregional Treatment and Palbociclib in de Novo, Treatment Naive, Stage IV ER+, HER2- Breast Cancer Patients","2024-08-18","Palbociclib",[89,90,91,92,93,94],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[96,206,314,455,558,716,794,877,1076,1197,1223,1262,1297,1327,1359,1381,1403,1440,1462,1577,1624,1666,1699,1736,1775,1802,1831,1861,1886,1908,1926,1944,1966,1984,2013,2031,2054,2080,2098,2116,2134,2152,2170,2188,2213,2231,2267,2285,2303,2321,2339,2357,2383,2401,2427,2445,2470,2496,2514,2609,2642,2699,2774,2800,2822,2875,2901,2923,2952,2980,3002,3024,3046,3068,3090,3112,3134,3156,3181,3205,3223,3249,3267,3292,3310,3328,3354,3372,3390,3414,3441,3459,3485,3510,3528,3555,3573,3592,3610,3628,3646,3664,3682,3700,3718,3736,3754,3780,3798,3816,3841,3859,3877,3907,3929,3955,4059,4105,4147,4181,4211,4246,4276,4302,4328,4354,4380,4402,4424,4446,4468,4490,4512,4547,4577,4604,4622,4640,4658,4676,4694,4712,4730,4748,4766,4784,4802,4820,4838,4856,4874,4892,4910,4928,4946,4964,4982,5044,5072,5090,5108,5132,5158,5176,5194,5212,5230,5255,5273,5297,5321,5347,5371,5395,5419,5442,5466,5484,5510,5528,5546,5564,5590,5608,5626,5644,5670,5688,5712,5737,5755,5781,5799,5817,5835,5857,5882,5900,5925,5950,5968],{"intervention":97,"totalTrials":98,"cells":99},"Pembrolizumab",7,{"EARLY_PHASE1":100,"PHASE1":103,"PHASE2":105,"PHASE3":164,"PHASE4":202,"NA":204},{"trials":101,"activeCount":102},[],0,{"trials":104,"activeCount":102},[],{"trials":106,"activeCount":163,"soonestReadout":154},[107,124,137,149],{"nctId":108,"briefTitle":109,"status":110,"phases":111,"primaryCompletion":112,"completion":113,"start":114,"enrollment":115,"conditions":116,"interventions":123},"NCT03012620","Secured Access to Pembrolizumab for Patients With Selected Rare Cancer Types","COMPLETED",[91],"2022-12-26","2023-12-14","2017-07-05",334,[33,117,118,119,120,121,122],"Ovarian Neoplasm","Central Nervous System Neoplasm","Thyroid Neoplasm","Carcinoma, Neuroendocrine","Neoplasms, Germ Cell and Embryonal","NK\u002FT-cell Lymphoma",[97],{"nctId":125,"briefTitle":126,"status":127,"phases":128,"primaryCompletion":129,"completion":130,"start":131,"enrollment":132,"conditions":133,"interventions":135},"NCT07360743","Immunotherapy Without Chemotherapy for Advanced Lung Cancer Patients With High PD-L1 Levels","NOT_YET_RECRUITING",[91],"2028-06","2032-04","2026-04",275,[134],"Non Small Cell Lung Cancer (Squamous or Non Squamous)",[97,136],"Cemiplimab",{"nctId":138,"briefTitle":139,"status":140,"phases":141,"primaryCompletion":142,"completion":142,"start":143,"enrollment":144,"conditions":145,"interventions":147},"NCT05973864","Capecitabine Plus Pembrolizumab in Patients With Triple Negative Breast Cancer After Chemo-immunotherapy and Surgery","RECRUITING",[91],"2028-08","2025-03-11",220,[146],"Triple Negative Breast Neoplasms",[97,148],"Capecitabine",{"nctId":150,"briefTitle":151,"status":152,"phases":153,"primaryCompletion":154,"completion":154,"start":155,"enrollment":25,"conditions":156,"interventions":160},"NCT04074096","Binimetinib Encorafenib Pembrolizumab +\u002F- Stereotactic Radiosurgery in BRAFV600 Melanoma With Brain Metastasis","ACTIVE_NOT_RECRUITING",[91],"2026-03-27","2022-09-05",[157,158,159],"Malignant Melanoma","BRAF V600 Mutation","Brain Metastases",[161,162,97],"Binimetinib Oral","Encorafenib Oral",3,{"trials":165,"activeCount":163,"soonestReadout":170},[166,178,190],{"nctId":167,"briefTitle":168,"status":140,"phases":169,"primaryCompletion":170,"completion":171,"start":172,"enrollment":173,"conditions":174,"interventions":176},"NCT04747054","Study on the Efficacy of Treatment by Radiotherapy and Pembrolizumab in Newly Diagnosed Metastatic Head & Neck Cancers",[92],"2025-10-01","2029-10-01","2021-12-01",102,[175],"Squamous Cell Carcinoma of Head and Neck",[97,177],"Chemotherapy",{"nctId":179,"briefTitle":180,"status":152,"phases":181,"primaryCompletion":182,"completion":182,"start":183,"enrollment":184,"conditions":185,"interventions":189},"NCT03774732","PD-1 Inhibitor and Chemotherapy With Concurrent Irradiation at Varied Tumour Sites in Advanced Non-small Cell Lung Cancer",[92],"2026-12-22","2018-01-24",327,[186,187,188],"Non Small Cell Lung Cancer","Non Small Cell Lung Cancer Metastatic","Non-Small Cell Carcinoma of Lung, TNM Stage 4",[97,177],{"nctId":191,"briefTitle":192,"status":140,"phases":193,"primaryCompletion":194,"completion":195,"start":196,"enrollment":197,"conditions":198,"interventions":201},"NCT06606730","Personalizing the Use of Pembrolizumab for Patients Who Have a Strong Response in Early Triple Negative Breast Cancer",[92],"2033-01-01","2039-06-01","2025-07-23",2454,[199,200],"Breast Cancers","Triple Negative Breast Cancer (TNBC)",[97],{"trials":203,"activeCount":102},[],{"trials":205,"activeCount":102},[],{"intervention":207,"totalTrials":98,"cells":208},"FOLFOX regimen",{"EARLY_PHASE1":209,"PHASE1":211,"PHASE2":213,"PHASE3":296,"PHASE4":310,"NA":312},{"trials":210,"activeCount":102},[],{"trials":212,"activeCount":102},[],{"trials":214,"activeCount":295,"soonestReadout":271},[215,227,243,257,267,283],{"nctId":216,"briefTitle":217,"status":140,"phases":218,"primaryCompletion":219,"completion":220,"start":221,"enrollment":222,"conditions":223,"interventions":225},"NCT06529718","Testing Ivonescimab Versus FOLFOX in Advanced Biliary Tract Cancer Patients",[91],"2027-08-03","2029-01-30","2025-10-09",72,[224],"Biliary Tract Cancer",[226,207],"Ivonescimab",{"nctId":228,"briefTitle":229,"status":140,"phases":230,"primaryCompletion":231,"completion":232,"start":233,"enrollment":234,"conditions":235,"interventions":240},"NCT06846346","Testing Ivonescimab in Combination With Chemotherapy in Advanced or Metastatic Gastric\u002FGastroesophageal Adenocarcinoma",[91],"2027-09","2028-09","2025-11-20",88,[236,237,238,239],"Metastatic Esophageal Adenocarcinoma","Advanced Esophageal Adenocarcinoma","Metastatic Gastric Adenocarcinoma","Advanced Gastric Adenocarcinoma",[226,207,241,242],"Irinotecan","Paclitaxel",{"nctId":244,"briefTitle":245,"status":110,"phases":246,"primaryCompletion":247,"completion":248,"start":249,"conditions":250,"interventions":251},"NCT00066274","Comparison of Combination Chemotherapy Regimens in Treating Patients With Metastatic Colorectal Cancer",[91],"2005-11-04","2007-04-01","2002-07-23",[18],[252,207,253,254,255,256],"FOLFIRI regimen","fluorouracil","irinotecan hydrochloride","leucovorin calcium","oxaliplatin",{"nctId":258,"briefTitle":259,"status":110,"phases":260,"primaryCompletion":261,"completion":262,"start":263,"conditions":264,"interventions":265},"NCT00006050","Combination Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver",[91],"2001-12-31","2003-04-04","1999-04-04",[18,30],[207,253,266,255,256],"isolated perfusion",{"nctId":268,"briefTitle":269,"status":140,"phases":270,"primaryCompletion":271,"completion":272,"start":273,"enrollment":274,"conditions":275,"interventions":279},"NCT05476796","Oxaliplatin ± Nivolumab in Combination With Trifluridine\u002FTipiracil or 5-fluorouracile in Frail Patients With Advanced, Recurrent or Metastatic Gastric, Oesophageal or Gastroesophageal Junction Cancer",[91],"2026-01","2027-01","2023-06-23",118,[276,277,278],"Gastric Adenocarcinoma","Esophagus Adenocarcinoma","Gastroesophageal Junction Adenocarcinoma",[280,281,207,282],"Trifluridine\u002FTipiracil","Oxaliplatin","Nivolumab",{"nctId":284,"briefTitle":285,"status":140,"phases":286,"primaryCompletion":287,"completion":288,"start":289,"enrollment":290,"conditions":291,"interventions":293},"NCT06475352","Dose Individualization of Chemotherapy in Patients With Gastrointestinal Cancers Lacking a Specific Liver Enzyme",[91],"2027-04","2030-01","2025-01-20",400,[292,18],"Digestive Cancer",[207,294],"CAPOX regimen",4,{"trials":297,"activeCount":309,"soonestReadout":302},[298],{"nctId":299,"briefTitle":300,"status":127,"phases":301,"primaryCompletion":302,"completion":303,"start":304,"enrollment":305,"conditions":306,"interventions":307},"NCT07340567","Personalizing Chemotherapy Selection After Surgery for Patients With Stage III Colorectal Cancer Using a Blood Test",[92],"2032-11-01","2035-11-01","2026-05-01",2450,[18],[148,281,308,207],"Folfirinox",1,{"trials":311,"activeCount":102},[],{"trials":313,"activeCount":102},[],{"intervention":148,"totalTrials":315,"cells":316},12,{"EARLY_PHASE1":317,"PHASE1":319,"PHASE2":321,"PHASE3":398,"PHASE4":451,"NA":453},{"trials":318,"activeCount":102},[],{"trials":320,"activeCount":102},[],{"trials":322,"activeCount":397,"soonestReadout":387},[323,335,345,349,362,372,383],{"nctId":324,"briefTitle":325,"status":110,"phases":326,"primaryCompletion":327,"completion":328,"start":329,"enrollment":330,"conditions":331,"interventions":332},"NCT00423696","Bevacizumab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed By Surgery",[91],"2008-07-28","2011-08-01","2006-03-23",145,[18],[333,334,253,254,255],"bevacizumab","capecitabine",{"nctId":336,"briefTitle":337,"status":110,"phases":338,"primaryCompletion":339,"completion":340,"start":341,"enrollment":342,"conditions":343,"interventions":344},"NCT00104689","Capecitabine and Oxaliplatin in Treating Older Patients With Metastatic Colorectal Cancer",[91],"2007-03-31","2008-01","2003-06-30",60,[18],[334,256],{"nctId":138,"briefTitle":139,"status":140,"phases":346,"primaryCompletion":142,"completion":142,"start":143,"enrollment":144,"conditions":347,"interventions":348},[91],[146],[97,148],{"nctId":350,"briefTitle":351,"status":110,"phases":352,"primaryCompletion":353,"completion":354,"start":355,"enrollment":356,"conditions":357,"interventions":360},"NCT03383679","Study on Androgen Receptor and Triple Negative Breast Cancer",[91],"2021-11-30","2022-07-20","2018-03-14",94,[358,359],"Breast Cancer Female","Triple Negative and Androgen Receptor Positive",[361,148],"Darolutamide",{"nctId":363,"briefTitle":364,"status":110,"phases":365,"primaryCompletion":366,"start":367,"enrollment":368,"conditions":369,"interventions":370},"NCT00967031","Lapatinib Ditosylate and Capecitabine in Treating Patients With Stage IV Breast Cancer and Brain Metastases",[91],"2012-02","2009-04",45,[15,30],[334,371],"lapatinib ditosylate",{"nctId":373,"briefTitle":374,"status":375,"phases":376,"primaryCompletion":377,"completion":377,"start":378,"enrollment":379,"conditions":380,"interventions":381},"NCT00541112","Radiation Therapy, Chemotherapy, and Cetuximab Followed by Surgery, Chemotherapy, and Cetuximab in Treating Patients With Locally Advanced or Metastatic Rectal Cancer That Can Be Removed by Surgery","TERMINATED",[91],"2010-01-29","2007-10-29",19,[18],[382,334,253,255,256],"cetuximab",{"nctId":384,"briefTitle":385,"status":140,"phases":386,"primaryCompletion":387,"completion":388,"start":389,"enrollment":16,"conditions":390,"interventions":394},"NCT05800275","Capecitabine, Tucatinib, and Intrathecal Trastuzumab for Breast Cancer Patients With Leptomeningeal Disease",[91],"2026-12","2027-06","2023-12-18",[391,392,393],"Leptomeningeal Metastasis","Leptomeningeal Disease","HER2-positive Metastatic Breast Cancer",[395,148,396],"Tucatinib Oral","Trastuzumab",2,{"trials":399,"activeCount":397,"soonestReadout":441},[400,411,415,427,437],{"nctId":401,"briefTitle":402,"status":110,"phases":403,"primaryCompletion":404,"completion":405,"start":406,"enrollment":407,"conditions":408,"interventions":410},"NCT02551237","Neoadjuvant Treatment for Advanced Rectal Carcinoma",[92],"2020-08-29","2022-06","2016-01-07",103,[409],"Rectal Carcinoma",[148],{"nctId":299,"briefTitle":300,"status":127,"phases":412,"primaryCompletion":302,"completion":303,"start":304,"enrollment":305,"conditions":413,"interventions":414},[92],[18],[148,281,308,207],{"nctId":416,"briefTitle":417,"status":110,"phases":418,"primaryCompletion":419,"completion":419,"start":420,"enrollment":421,"conditions":422,"interventions":424},"NCT01804790","Efficacy of Neoadjuvant Folfirinox Regimen in Patients With Resectable Locally Advanced Rectal Cancer",[92],"2023-07-01","2012-01",461,[423],"Cancer of the Rectum",[425,148,426],"mFolfirinox","mFolfox6 or capecitabine",{"nctId":428,"briefTitle":429,"status":110,"phases":430,"primaryCompletion":431,"completion":432,"start":433,"enrollment":434,"conditions":435,"interventions":436},"NCT00227747","Radiation Therapy and Capecitabine With or Without Oxaliplatin in Treating Patients Who Are Undergoing Surgery for Stage II or Stage III Rectal Cancer",[92],"2008-10-22","2013-07-15","2005-11-08",598,[18],[334,256],{"nctId":438,"briefTitle":439,"status":152,"phases":440,"primaryCompletion":441,"completion":129,"start":442,"enrollment":443,"conditions":444,"interventions":446},"NCT04158362","Endocrine Therapy With Abemaciclib or Chemotherapy as Initial Metastatic Treatment in ER+\u002FHER2- Breast Cancer",[92],"2025-04-30","2020-06-11",180,[445],"Cancer Metastatic",[242,148,447,448,449,450],"Letrozole 2.5mg","Anastrozole 1mg","Fulvestrant Prefilled Syringe","Abemaciclib",{"trials":452,"activeCount":102},[],{"trials":454,"activeCount":102},[],{"intervention":396,"totalTrials":98,"cells":456},{"EARLY_PHASE1":457,"PHASE1":459,"PHASE2":461,"PHASE3":520,"PHASE4":554,"NA":556},{"trials":458,"activeCount":102},[],{"trials":460,"activeCount":102},[],{"trials":462,"activeCount":163,"soonestReadout":441},[463,477,492,503,516],{"nctId":464,"briefTitle":465,"status":110,"phases":466,"primaryCompletion":467,"completion":468,"start":469,"enrollment":470,"conditions":471,"interventions":472},"NCT02339532","Neoadjuvant Phase II Trial in Patients With T1c Operable, HER2-positive Breast Cancer According to TOP2A Status",[91],"2019-10-07","2024-07-08","2015-01",86,[15],[473,474,396,475,476],"FEC100","Docetaxel","Pertuzumab","Carboplatin",{"nctId":478,"briefTitle":479,"status":140,"phases":480,"primaryCompletion":481,"completion":482,"start":483,"enrollment":484,"conditions":485,"interventions":488},"NCT06245356","Safety of Trifluridine\u002FTipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal Cancer",[91],"2026-10-22","2028-10-21","2025-03-21",73,[27,486,487],"Metastatic Gastroesophageal Adenocarcinoma","DPD Deficiency",[489,281,490,491,396,282],"Lonsurf","Panitumumab","Bevacizumab",{"nctId":493,"briefTitle":494,"status":375,"phases":495,"primaryCompletion":496,"start":497,"enrollment":498,"conditions":499,"interventions":500},"NCT00674414","Trastuzumab With or Without Everolimus in Treating Women With Breast Cancer That Can Be Removed By Surgery",[91],"2013-01","2008-04",82,[15],[501,502],"trastuzumab","everolimus",{"nctId":504,"briefTitle":505,"status":152,"phases":506,"primaryCompletion":441,"completion":507,"start":508,"enrollment":509,"conditions":510,"interventions":512},"NCT05041842","Treatment With Tucatinib in Patients With an Isolated Brain Progression of a Metastatic Breast Cancer",[91],"2026-04-30","2021-12-17",53,[511],"Metastatic Breast Cancer With a Isolated Brain Progression",[513,475,396,514,515],"Tucatinib","Hormone therapy","Pertuzumab\u002F Trastuzumab",{"nctId":384,"briefTitle":385,"status":140,"phases":517,"primaryCompletion":387,"completion":388,"start":389,"enrollment":16,"conditions":518,"interventions":519},[91],[391,392,393],[395,148,396],{"trials":521,"activeCount":309,"soonestReadout":388},[522,540],{"nctId":523,"briefTitle":524,"status":140,"phases":525,"primaryCompletion":388,"completion":129,"start":526,"enrollment":527,"conditions":528,"interventions":530},"NCT05615818","Personalized Medicine for Advanced Biliary Cancer Patients",[92],"2024-07-18",800,[529],"Biliary Tract Neoplasms",[531,532,533,396,534,535,536,537,538,539],"Futibatinib","Ivosidenib","Zanidatamab","Neratinib","Encorafenib","Binimetinib","Niraparib","Cisplatin","Gemcitabine",{"nctId":541,"briefTitle":542,"status":110,"phases":543,"primaryCompletion":544,"completion":545,"start":546,"enrollment":547,"conditions":548,"interventions":549},"NCT00054587","Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer",[92],"2009-06","2009-12","2001-06",3010,[15],[396,550,551,552,553],"Cyclophosphamide","docetaxel","Epirubicin","Fluorouracil",{"trials":555,"activeCount":102},[],{"trials":557,"activeCount":102},[],{"intervention":256,"totalTrials":559,"cells":560},17,{"EARLY_PHASE1":561,"PHASE1":563,"PHASE2":565,"PHASE3":628,"PHASE4":712,"NA":714},{"trials":562,"activeCount":102},[],{"trials":564,"activeCount":102},[],{"trials":566,"activeCount":397,"soonestReadout":271},[567,583,587,598,602,606,610,620,624],{"nctId":568,"briefTitle":569,"status":110,"phases":570,"primaryCompletion":571,"completion":572,"start":573,"enrollment":574,"conditions":575,"interventions":578},"NCT01443065","MEGA (Met or EGFR Inhibition in Gastroesophageal Adenocarcinoma): FOLFOX Alone or in Combination With AMG 102 or Panitumumab as First-line Treatment in Patients With Advanced Gastroesophageal Adenocarcinoma",[91],"2014-03","2018-09","2011-01",162,[576,577],"Malignant Neoplasm of Esophagus","Malignant Neoplasm of Stomach",[281,579,580,581,582],"Folinic Acid","5-fluoro-uracil","panitumumab","AMG102",{"nctId":336,"briefTitle":337,"status":110,"phases":584,"primaryCompletion":339,"completion":340,"start":341,"enrollment":342,"conditions":585,"interventions":586},[91],[18],[334,256],{"nctId":588,"briefTitle":589,"status":110,"phases":590,"primaryCompletion":41,"completion":591,"start":592,"enrollment":593,"conditions":594,"interventions":595},"NCT01442935","Chemotherapies Associated With Targeted Therapies on the Resection Rate of Hepatic Metastases",[91],"2021-01","2011-02",256,[18],[281,579,596,241,241,491,597],"5-FU","Cetuximab",{"nctId":244,"briefTitle":245,"status":110,"phases":599,"primaryCompletion":247,"completion":248,"start":249,"conditions":600,"interventions":601},[91],[18],[252,207,253,254,255,256],{"nctId":478,"briefTitle":479,"status":140,"phases":603,"primaryCompletion":481,"completion":482,"start":483,"enrollment":484,"conditions":604,"interventions":605},[91],[27,486,487],[489,281,490,491,396,282],{"nctId":258,"briefTitle":259,"status":110,"phases":607,"primaryCompletion":261,"completion":262,"start":263,"conditions":608,"interventions":609},[91],[18,30],[207,253,266,255,256],{"nctId":611,"briefTitle":612,"status":110,"phases":613,"primaryCompletion":614,"completion":615,"start":616,"enrollment":617,"conditions":618,"interventions":619},"NCT01442649","Efficacy of Chemotherapy, Associated to Either Cetuximab or Bevacizumab, in KRAS Wild-type Metastatic Colorectal Cancer Patients With Progressive Disease After Receiving First-line Treatment With Bevacizumab",[91],"2015-10","2017-12-31","2010-12",133,[18],[281,579,580,241,491,597],{"nctId":268,"briefTitle":269,"status":140,"phases":621,"primaryCompletion":271,"completion":272,"start":273,"enrollment":274,"conditions":622,"interventions":623},[91],[276,277,278],[280,281,207,282],{"nctId":373,"briefTitle":374,"status":375,"phases":625,"primaryCompletion":377,"completion":377,"start":378,"enrollment":379,"conditions":626,"interventions":627},[91],[18],[382,334,253,255,256],{"trials":629,"activeCount":309,"soonestReadout":302},[630,644,655,659,672,676,685,702],{"nctId":631,"briefTitle":632,"status":110,"phases":633,"primaryCompletion":634,"completion":635,"start":636,"enrollment":637,"conditions":638,"interventions":641},"NCT02539537","A Randomized Phase III Trial Comparing Folfirinox to Gemcitabine in Locally Advanced Pancreatic Carcinoma",[92],"2022-02","2023-09-25","2015-10-23",171,[639,640],"Pancreatic Cancer","Carcinoma",[539,579,642,281,241,643],"5-Fluoro-uracil","L-folinic",{"nctId":645,"briefTitle":646,"status":110,"phases":647,"primaryCompletion":648,"completion":649,"start":650,"enrollment":651,"conditions":652,"interventions":654},"NCT00861094","Radiation Therapy + Combination Chemotherapy as 1st-Line Therapy for Patients With Inoperable Esophageal Cancer",[91,92],"2011-09","2012-12","2008-03",266,[653],"Esophageal Cancer",[42,596,256,579],{"nctId":299,"briefTitle":300,"status":127,"phases":656,"primaryCompletion":302,"completion":303,"start":304,"enrollment":305,"conditions":657,"interventions":658},[92],[18],[148,281,308,207],{"nctId":660,"briefTitle":661,"status":110,"phases":662,"primaryCompletion":663,"completion":663,"start":664,"enrollment":665,"conditions":666,"interventions":670},"NCT01313377","Gemcitabine Hydrochloride and Oxaliplatin or Observation in Treating Patients With Biliary Tract Cancer That Has Been Removed by Surgery",[92],"2016-06","2009-07",190,[667,668,669],"Extrahepatic Bile Duct Cancer","Gallbladder Cancer","Liver Cancer",[671,256],"gemcitabine hydrochloride",{"nctId":428,"briefTitle":429,"status":110,"phases":673,"primaryCompletion":431,"completion":432,"start":433,"enrollment":434,"conditions":674,"interventions":675},[92],[18],[334,256],{"nctId":677,"briefTitle":678,"status":110,"phases":679,"primaryCompletion":41,"start":680,"enrollment":681,"conditions":682,"interventions":684},"NCT00769405","Systemic Chemotherapy With or Without Intraperitoneal Chemohyperthermia in Treating Patients Undergoing Surgery for Peritoneal Carcinomatosis From Colorectal Cancer",[92],"2008-02",264,[18,683],"Primary Peritoneal Cavity Cancer",[253,255,256],{"nctId":686,"briefTitle":687,"status":110,"phases":688,"primaryCompletion":689,"completion":690,"start":691,"enrollment":692,"conditions":693,"interventions":697},"NCT00104676","Combination Chemotherapy in Treating Patients With Stage II or Stage III Germ Cell Tumors",[92],"2012-03-29","2023-02-08","2003-11-26",263,[694,695,696],"Extragonadal Germ Cell Tumor","Teratoma","Testicular Germ Cell Tumor",[698,42,699,700,256,701],"bleomycin sulfate","etoposide","ifosfamide","paclitaxel",{"nctId":703,"briefTitle":704,"status":110,"phases":705,"primaryCompletion":706,"completion":707,"start":708,"enrollment":709,"conditions":710,"interventions":711},"NCT00112658","Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Pancreatic Cancer",[91,92],"2010-06","2010-06-30","2004-11",342,[639],[253,671,254,255,256],{"trials":713,"activeCount":102},[],{"trials":715,"activeCount":102},[],{"intervention":701,"totalTrials":28,"cells":717},{"EARLY_PHASE1":718,"PHASE1":720,"PHASE2":722,"PHASE3":761,"PHASE4":781,"NA":783},{"trials":719,"activeCount":102},[],{"trials":721,"activeCount":102},[],{"trials":723,"activeCount":397,"soonestReadout":231},[724,728,739,754],{"nctId":228,"briefTitle":229,"status":140,"phases":725,"primaryCompletion":231,"completion":232,"start":233,"enrollment":234,"conditions":726,"interventions":727},[91],[236,237,238,239],[226,207,241,242],{"nctId":729,"briefTitle":730,"status":140,"phases":731,"primaryCompletion":732,"completion":732,"start":733,"enrollment":734,"conditions":735,"interventions":737},"NCT06078384","Pembrolizumab and Chemotherapy Treatment or no Treatment Guided by the Level of TILs in Resected Early-stage TNBC",[91],"2032-01-01","2024-12-27",354,[736],"Triple-negative Breast Cancer",[738,242],"Pembrolizumab 25 mg\u002Fml",{"nctId":740,"briefTitle":741,"status":375,"phases":742,"primaryCompletion":743,"completion":743,"start":744,"enrollment":368,"conditions":745,"interventions":748},"NCT00003852","Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Germ Cell Tumors",[91],"2000-03","1998-03",[746,694,747,696],"Childhood Germ Cell Tumor","Ovarian Cancer",[749,750,751,752,699,700,701,753],"filgrastim","carboplatin","cyclophosphamide","epirubicin hydrochloride","thiotepa",{"nctId":755,"briefTitle":756,"status":110,"phases":757,"primaryCompletion":497,"completion":420,"start":758,"enrollment":16,"conditions":759,"interventions":760},"NCT00217607","Paclitaxel in Treating Patients With Locally Advanced or Metastatic Soft Tissue Angiosarcoma or Lymphangiosarcoma That Cannot Be Removed By Surgery",[91],"2005-02",[33],[701],{"trials":762,"activeCount":309,"soonestReadout":441},[763,767,771],{"nctId":438,"briefTitle":439,"status":152,"phases":764,"primaryCompletion":441,"completion":129,"start":442,"enrollment":443,"conditions":765,"interventions":766},[92],[445],[242,148,447,448,449,450],{"nctId":686,"briefTitle":687,"status":110,"phases":768,"primaryCompletion":689,"completion":690,"start":691,"enrollment":692,"conditions":769,"interventions":770},[92],[694,695,696],[698,42,699,700,256,701],{"nctId":772,"briefTitle":773,"status":110,"phases":774,"primaryCompletion":775,"completion":775,"start":776,"enrollment":777,"conditions":778,"interventions":780},"NCT03943667","Gemcitabine and Paclitaxel vs Gemcitabine Alone After FOLFIRINOX Failure in Metastatic Pancreatic Ductal Adenocarcinoma",[92],"2022-04-26","2019-05-23",211,[779],"Metastatic Pancreatic Adenocarcinoma",[539,242],{"trials":782,"activeCount":102},[],{"trials":784,"activeCount":102},[785],{"nctId":786,"briefTitle":787,"status":110,"phases":788,"primaryCompletion":405,"completion":71,"start":789,"enrollment":790,"conditions":791,"interventions":793},"NCT01745757","Cohort Study of Prospective Validation of Predictive Factors and Biological Imaging of Response to Bevacizumab and Paclitaxel in Patients With Metastatic Breast Cancer",[],"2012-06",510,[792,15],"Metastatic",[491,701],{"intervention":177,"totalTrials":98,"cells":795},{"EARLY_PHASE1":796,"PHASE1":798,"PHASE2":800,"PHASE3":842,"PHASE4":862,"NA":864},{"trials":797,"activeCount":102},[],{"trials":799,"activeCount":102},[],{"trials":801,"activeCount":309,"soonestReadout":828},[802,813,824],{"nctId":803,"briefTitle":804,"status":375,"phases":805,"primaryCompletion":806,"completion":806,"start":807,"enrollment":808,"conditions":809,"interventions":811},"NCT03386162","SAFIR-PI3K A Phase II Randomized Maintenance Trial Comparing Alpelisib and Fulvestrant Versus Chemotherapy in PIK3CA Mutated Advanced Breast Cancer",[91],"2022-11-18","2018-03-15",31,[810],"Breast Cancer, PI3K, Alpelisib",[812,177],"Alpelisib",{"nctId":814,"briefTitle":815,"status":375,"phases":816,"primaryCompletion":817,"completion":818,"start":819,"conditions":820,"interventions":821},"NCT00005944","Second-look Surgery With or Without Intraperitoneal Chemotherapy in Treating Patients With Recurrent Colorectal Cancer",[91],"2000-10-24","2003-10-01","1999-07-01",[18,30,683],[822,253,255,823],"chemotherapy","mitomycin C",{"nctId":825,"briefTitle":826,"status":140,"phases":827,"primaryCompletion":828,"completion":829,"start":830,"enrollment":831,"conditions":832,"interventions":840},"NCT06333314","Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal\u002FNon-endometrial) With Tumor dMMR\u002FMSI",[91],"2028-10","2030-09","2024-07-23",120,[833,834,835,836,837,838,839,276],"Pancreatic Adenocarcinoma","Ampulla of Vater Carcinoma","Adrenocortical Carcinoma","Neuroendocrine Carcinoma","Soft Tissue Sarcoma","Small Bowel Adenocarcinoma","Duodenum Adenocarcinoma",[841,177],"Dostarlimab",{"trials":843,"activeCount":397,"soonestReadout":170},[844,854,858],{"nctId":845,"briefTitle":846,"status":110,"phases":847,"primaryCompletion":848,"completion":849,"start":706,"enrollment":617,"conditions":850,"interventions":853},"NCT02818725","I-MVAC +\u002F- Panitumumab as First-line Treatment of Advanced Urothelial Carcinoma Without H-Ras Nor K-Ras Mutations",[92],"2016-09","2017-09",[851,852],"Infiltrating Urothelial Carcinoma","KRAS Gene Mutation",[177,490],{"nctId":167,"briefTitle":168,"status":140,"phases":855,"primaryCompletion":170,"completion":171,"start":172,"enrollment":173,"conditions":856,"interventions":857},[92],[175],[97,177],{"nctId":179,"briefTitle":180,"status":152,"phases":859,"primaryCompletion":182,"completion":182,"start":183,"enrollment":184,"conditions":860,"interventions":861},[92],[186,187,188],[97,177],{"trials":863,"activeCount":102},[],{"trials":865,"activeCount":102},[866],{"nctId":867,"briefTitle":868,"status":869,"phases":870,"primaryCompletion":871,"completion":872,"start":873,"enrollment":102,"conditions":874,"interventions":876},"NCT03532204","Oligometastases of the LIVer Treated With Chemotherapy With ou Without Extracranial Stereotactic Body Radiation Therapy in Patients With Colorectal Cancer","WITHDRAWN",[94],"2021-12-15","2023-08-15","2019-04-15",[875,18],"Liver Metastases",[177],{"intervention":751,"totalTrials":878,"cells":879},16,{"EARLY_PHASE1":880,"PHASE1":882,"PHASE2":884,"PHASE3":964,"PHASE4":1072,"NA":1074},{"trials":881,"activeCount":102},[],{"trials":883,"activeCount":102},[],{"trials":885,"activeCount":309,"soonestReadout":71},[886,901,905,915,927,950],{"nctId":887,"briefTitle":888,"status":110,"phases":889,"primaryCompletion":340,"completion":890,"start":891,"enrollment":892,"conditions":893,"interventions":898},"NCT00424203","Doxorubicin and Cyclophosphamide in Treating Older Women With Stage I, Stage II, or Stage III Breast Cancer That Has Been Removed By Surgery",[91],"2011-11","2006-01",40,[15,894,895,896,897],"Cognitive\u002FFunctional Effects","Depression","Malnutrition","Psychosocial Effects of Cancer and Its Treatment",[899,751,900],"AC regimen","doxorubicin hydrochloride",{"nctId":740,"briefTitle":741,"status":375,"phases":902,"primaryCompletion":743,"completion":743,"start":744,"enrollment":368,"conditions":903,"interventions":904},[91],[746,694,747,696],[749,750,751,752,699,700,701,753],{"nctId":906,"briefTitle":907,"status":110,"phases":908,"primaryCompletion":909,"completion":910,"start":911,"enrollment":912,"conditions":913,"interventions":914},"NCT00820547","Efficacy and Tolerance Study of Bevacizumab in Her2- Inflammatory Breast Cancer Patients",[91],"2015-04","2019-09","2009-01",100,[15],[333,751,551,752,253],{"nctId":916,"briefTitle":917,"status":110,"phases":918,"primaryCompletion":919,"completion":920,"start":469,"enrollment":921,"conditions":922,"interventions":924},"NCT02400567","Efficacy of Letrozole + Palbociclib Combination as Neoadjuvant Treatment of Stage II-IIIA PAM 50 ROR-defined Low or Intermediate Risk Luminal Breast Cancer, in Postmenopausal Women",[91],"2018-01","2020-09",125,[923],"Neoadjuvant Operable Breast Cancer",[925,552,550,926,87],"Fluorouracile","Letrozole",{"nctId":69,"briefTitle":70,"status":152,"phases":928,"primaryCompletion":71,"completion":929,"start":930,"enrollment":931,"conditions":932,"interventions":933},[91],"2025-12","2014-04-07",1460,[24],[72,934,935,936,937,938,939,940,941,942,751,943,944,945,946,491,947,948,949],"AZD4547","AZD5363","AZD8931","Selumetinib","Vandetanib","Bicalutamide","Olaparib","Anthracyclines","Taxanes","DNA intercalators","Methotrexate","vinca alkaloids","Platinum based chemotherapies","Mitomycin C","Eribulin","MEDI4736",{"nctId":951,"briefTitle":952,"status":110,"phases":953,"primaryCompletion":954,"completion":955,"start":956,"enrollment":957,"conditions":958,"interventions":960},"NCT00056095","Allogeneic Stem Cell Transplant in Treating Patients With Metastatic Kidney Cancer",[91],"2008-02-13","2016-08-17","2002-11-04",57,[959],"Kidney Cancer",[961,751,962,963],"therapeutic allogeneic lymphocytes","cyclosporine","fludarabine phosphate",{"trials":965,"activeCount":309,"soonestReadout":1021},[966,976,985,1006,1017,1029,1040,1049,1060,1068],{"nctId":967,"briefTitle":968,"status":110,"phases":969,"primaryCompletion":970,"completion":546,"start":971,"enrollment":972,"conditions":973,"interventions":975},"NCT00003606","Combination Chemotherapy in Treating Patients With Extensive Stage Small Cell Lung Cancer",[92],"1999-10-01","1996-03",216,[974],"Lung Cancer",[42,751,752,699],{"nctId":977,"briefTitle":978,"status":110,"phases":979,"primaryCompletion":789,"completion":980,"start":981,"enrollment":982,"conditions":983,"interventions":984},"NCT00055679","Combination Chemotherapy in Treating Women With Stage I Breast Cancer",[92],"2013-06","2002-08",1512,[15],[751,752,253],{"nctId":986,"briefTitle":987,"status":110,"phases":988,"primaryCompletion":989,"completion":990,"start":991,"enrollment":992,"conditions":993,"interventions":995},"NCT00003650","Combination Chemotherapy in Treating Children With Non-Hodgkin's Lymphoma",[92],"2008-12","2013-11","1997-02",179,[994],"Lymphoma",[996,751,997,998,999,699,1000,1001,1002,1003,1004,1005],"asparaginase","cytarabine","daunorubicin hydrochloride","dexamethasone","mercaptopurine","methotrexate","methylprednisolone","mitoxantrone hydrochloride","prednisone","vincristine sulfate",{"nctId":1007,"briefTitle":1008,"status":110,"phases":1009,"primaryCompletion":1010,"completion":1011,"start":1012,"enrollment":1013,"conditions":1014,"interventions":1015},"NCT00630032","Safety and Efficacy Comparison of Docetaxel and Ixabepilone in Non Metastatic Poor Prognosis Breast Cancer",[92],"2017-06","2020-09-03","2007-09",762,[15],[751,474,752,253,1016],"ixabepilone",{"nctId":1018,"briefTitle":1019,"status":140,"phases":1020,"primaryCompletion":1021,"completion":131,"start":1022,"enrollment":1023,"conditions":1024,"interventions":1027},"NCT04757337","Comparison of Oral Cyclophosphamide vs Doxorubicin in ≥65 Years Old Advanced or Metastatic Soft Tissue Sarcoma Patients",[92],"2025-07","2021-06-18",214,[1025,1026],"Advanced Soft-tissue Sarcoma","Metastatic Soft-tissue Sarcoma",[1028,550],"Doxorubicin",{"nctId":1030,"briefTitle":1031,"status":110,"phases":1032,"primaryCompletion":1033,"completion":1034,"start":1035,"enrollment":1036,"conditions":1037,"interventions":1038},"NCT00002566","Combination Chemotherapy With Bone Marrow Transplantation in Treating Men With Germ Cell Tumors",[92],"2001-12","2003-12","1994-02",280,[694,696],[750,42,751,699,700,1039],"vinblastine sulfate",{"nctId":1041,"briefTitle":1042,"status":110,"phases":1043,"primaryCompletion":649,"completion":469,"start":1044,"enrollment":1045,"conditions":1046,"interventions":1048},"NCT02324088","Interest of Maintenance Chemotherapy After Induction Treatment for Inflammatory Breast Cancer",[92],"2000-10",174,[1047],"Inflammatory Breast Cancer",[474,550,552],{"nctId":1050,"briefTitle":1051,"status":375,"phases":1052,"primaryCompletion":1053,"start":1054,"conditions":1055,"interventions":1056},"NCT00053911","Combination Chemotherapy Compared With Observation After Surgery in Treating Women With Relapsed Nonmetastatic Breast Cancer",[92],"2004-04","2002-11",[15],[1057,751,551,752,253,1058,1059],"anastrozole","goserelin acetate","tamoxifen citrate",{"nctId":1061,"briefTitle":1062,"status":110,"phases":1063,"primaryCompletion":1064,"completion":1064,"start":1065,"enrollment":443,"conditions":1066,"interventions":1067},"NCT00002870","High Dose Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Standard Therapy in Treating Women With Locally Recurrent or Metastatic Breast Cancer",[92],"2002-01","1994-12",[15],[749,751,752,253,753],{"nctId":541,"briefTitle":542,"status":110,"phases":1069,"primaryCompletion":544,"completion":545,"start":546,"enrollment":547,"conditions":1070,"interventions":1071},[92],[15],[396,550,551,552,553],{"trials":1073,"activeCount":102},[],{"trials":1075,"activeCount":102},[],{"intervention":42,"totalTrials":1077,"cells":1078},14,{"EARLY_PHASE1":1079,"PHASE1":1081,"PHASE2":1094,"PHASE3":1135,"PHASE4":1193,"NA":1195},{"trials":1080,"activeCount":102},[],{"trials":1082,"activeCount":102},[1083],{"nctId":1084,"briefTitle":1085,"status":110,"phases":1086,"primaryCompletion":1087,"completion":1088,"start":706,"enrollment":1089,"conditions":1090,"interventions":1092},"NCT01165385","Study With Pazopanib in Combination With Cisplatin (CDDP) in Patients With Advanced Solid Tumors",[90],"2013-10","2014-10",35,[1091,30],"Solid Tumors",[42,1093],"Pazopanib",{"trials":1095,"activeCount":102},[1096,1106,1114,1126],{"nctId":1097,"briefTitle":1098,"status":110,"phases":1099,"primaryCompletion":1100,"completion":1101,"start":1102,"enrollment":1103,"conditions":1104,"interventions":1105},"NCT00112697","Radiation Therapy and Docetaxel With Either Fluorouracil or Cisplatin as First-Line Therapy in Treating Patients With Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery",[91],"2008-08-01","2012-03-01","2003-10-06",71,[639],[42,551,253],{"nctId":1107,"briefTitle":1108,"status":110,"phases":1109,"primaryCompletion":981,"completion":1110,"start":1111,"conditions":1112,"interventions":1113},"NCT00006051","Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Head and Neck Cancer",[91],"2005-09","1999-02",[36],[42,253],{"nctId":1115,"briefTitle":1116,"status":110,"phases":1117,"primaryCompletion":1118,"completion":1119,"start":1120,"enrollment":509,"conditions":1121,"interventions":1125},"NCT00006111","Surgery Plus Combination Chemotherapy and Radiation Therapy in Treating Patients With Cancer of the Urinary Tract",[91],"2003-01","2008-06","1999-04",[1122,1123,1124],"Bladder Cancer","Transitional Cell Cancer of the Renal Pelvis and Ureter","Urethral Cancer",[42,253],{"nctId":1127,"briefTitle":1128,"status":375,"phases":1129,"primaryCompletion":1130,"completion":1130,"start":1131,"enrollment":878,"conditions":1132,"interventions":1134},"NCT00955240","Radiation Therapy, Cisplatin, Fluorouracil, and Cetuximab in Treating Patients With Locally Advanced Anal Cancer",[91],"2010-11-26","2009-03",[1133],"Anal Cancer",[382,42,253],{"trials":1136,"activeCount":397,"soonestReadout":41},[1137,1141,1152,1156,1165,1169,1176,1180,1189],{"nctId":967,"briefTitle":968,"status":110,"phases":1138,"primaryCompletion":970,"completion":546,"start":971,"enrollment":972,"conditions":1139,"interventions":1140},[92],[974],[42,751,752,699],{"nctId":1142,"briefTitle":1143,"status":110,"phases":1144,"primaryCompletion":1145,"completion":1146,"start":1147,"enrollment":1148,"conditions":1149,"interventions":1151},"NCT00002883","Surgery With or Without Combination Chemotherapy in Treating Patients With Cancer of the Esophagus",[92],"2006-11","2010-08","1996-10",250,[653,1150],"Gastric Cancer",[42,253],{"nctId":645,"briefTitle":646,"status":110,"phases":1153,"primaryCompletion":648,"completion":649,"start":650,"enrollment":651,"conditions":1154,"interventions":1155},[91,92],[653],[42,596,256,579],{"nctId":1157,"briefTitle":1158,"status":110,"phases":1159,"primaryCompletion":1160,"completion":339,"start":1161,"enrollment":1162,"conditions":1163,"interventions":1164},"NCT00003652","Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer",[92],"2006-04-01","1999-01-04",350,[1133],[42,253],{"nctId":523,"briefTitle":524,"status":140,"phases":1166,"primaryCompletion":388,"completion":129,"start":526,"enrollment":527,"conditions":1167,"interventions":1168},[92],[529],[531,532,533,396,534,535,536,537,538,539],{"nctId":39,"briefTitle":40,"status":152,"phases":1170,"primaryCompletion":41,"completion":387,"start":1171,"enrollment":1172,"conditions":1173,"interventions":1174},[92],"2007-03",318,[33],[42,900,699,700,1001,1175],"zoledronic acid",{"nctId":1030,"briefTitle":1031,"status":110,"phases":1177,"primaryCompletion":1033,"completion":1034,"start":1035,"enrollment":1036,"conditions":1178,"interventions":1179},[92],[694,696],[750,42,751,699,700,1039],{"nctId":1181,"briefTitle":1182,"status":110,"phases":1183,"primaryCompletion":1184,"completion":573,"start":1185,"enrollment":1186,"conditions":1187,"interventions":1188},"NCT00003627","Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Advanced Cancer of the Oropharynx or Hypopharynx",[92],"2005-12","1998-10",160,[36],[42,253],{"nctId":686,"briefTitle":687,"status":110,"phases":1190,"primaryCompletion":689,"completion":690,"start":691,"enrollment":692,"conditions":1191,"interventions":1192},[92],[694,695,696],[698,42,699,700,256,701],{"trials":1194,"activeCount":102},[],{"trials":1196,"activeCount":102},[],{"intervention":1001,"totalTrials":163,"cells":1198},{"EARLY_PHASE1":1199,"PHASE1":1201,"PHASE2":1203,"PHASE3":1209,"PHASE4":1219,"NA":1221},{"trials":1200,"activeCount":102},[],{"trials":1202,"activeCount":102},[],{"trials":1204,"activeCount":309,"soonestReadout":71},[1205],{"nctId":69,"briefTitle":70,"status":152,"phases":1206,"primaryCompletion":71,"completion":929,"start":930,"enrollment":931,"conditions":1207,"interventions":1208},[91],[24],[72,934,935,936,937,938,939,940,941,942,751,943,944,945,946,491,947,948,949],{"trials":1210,"activeCount":309,"soonestReadout":41},[1211,1215],{"nctId":986,"briefTitle":987,"status":110,"phases":1212,"primaryCompletion":989,"completion":990,"start":991,"enrollment":992,"conditions":1213,"interventions":1214},[92],[994],[996,751,997,998,999,699,1000,1001,1002,1003,1004,1005],{"nctId":39,"briefTitle":40,"status":152,"phases":1216,"primaryCompletion":41,"completion":387,"start":1171,"enrollment":1172,"conditions":1217,"interventions":1218},[92],[33],[42,900,699,700,1001,1175],{"trials":1220,"activeCount":102},[],{"trials":1222,"activeCount":102},[],{"intervention":1224,"totalTrials":397,"cells":1225},"Standard of care",{"EARLY_PHASE1":1226,"PHASE1":1228,"PHASE2":1230,"PHASE3":1232,"PHASE4":1258,"NA":1260},{"trials":1227,"activeCount":102},[],{"trials":1229,"activeCount":102},[],{"trials":1231,"activeCount":102},[],{"trials":1233,"activeCount":397,"soonestReadout":1238},[1234,1245],{"nctId":1235,"briefTitle":1236,"status":152,"phases":1237,"primaryCompletion":1238,"completion":1239,"start":1240,"enrollment":1241,"conditions":1242,"interventions":1244},"NCT04115007","Prostate-cancer Treatment Using Stereotactic Radiotherapy for Oligometastases Ablation in Hormone-sensitive Patients",[92],"2026-06-23","2031-02-28","2020-06-23",550,[1243],"Oligometastatic Hormone Sensitive Prostate Cancer",[1224],{"nctId":1246,"briefTitle":1247,"status":140,"phases":1248,"primaryCompletion":1249,"completion":1250,"start":1251,"enrollment":1252,"conditions":1253,"interventions":1255},"NCT06496581","Standard of Care +\u002F- 177Lu-PSMA-617 In de Novo mHSPC Patients With Poor PSA Response (PEACE6-Poor Responders)",[92],"2033-02-01","2039-08-01","2024-09-12",500,[1254],"Prostate Cancer Metastatic",[1256,1257],"177Lu-PMSA-617","Standard of Care",{"trials":1259,"activeCount":102},[],{"trials":1261,"activeCount":102},[],{"intervention":1263,"totalTrials":397,"cells":1264},"Atezolizumab",{"EARLY_PHASE1":1265,"PHASE1":1267,"PHASE2":1269,"PHASE3":1281,"PHASE4":1293,"NA":1295},{"trials":1266,"activeCount":102},[],{"trials":1268,"activeCount":102},[],{"trials":1270,"activeCount":309,"soonestReadout":1275},[1271],{"nctId":1272,"briefTitle":1273,"status":152,"phases":1274,"primaryCompletion":1275,"completion":1276,"start":1277,"enrollment":1278,"conditions":1279,"interventions":1280},"NCT03697850","Atezolizumab After Chemo-radiotherapy for MIBC Patients Not Eligible for Radical Cystectomy",[91],"2025-06-15","2029-02-15","2018-12-14",79,[1122],[1263],{"trials":1282,"activeCount":309,"soonestReadout":1287},[1283],{"nctId":1284,"briefTitle":1285,"status":152,"phases":1286,"primaryCompletion":1287,"completion":828,"start":1288,"enrollment":1289,"conditions":1290,"interventions":1291},"NCT03799835","Atezolizumab Plus One-year BCG Bladder Instillation in BCG-naive High-risk Non-muscle Invasive Bladder Cancer Patients",[92],"2025-06","2019-01-17",517,[1122],[1292,1263],"BCG",{"trials":1294,"activeCount":102},[],{"trials":1296,"activeCount":102},[],{"intervention":1028,"totalTrials":397,"cells":1298},{"EARLY_PHASE1":1299,"PHASE1":1301,"PHASE2":1303,"PHASE3":1317,"PHASE4":1323,"NA":1325},{"trials":1300,"activeCount":102},[],{"trials":1302,"activeCount":102},[],{"trials":1304,"activeCount":309,"soonestReadout":1309},[1305],{"nctId":1306,"briefTitle":1307,"status":140,"phases":1308,"primaryCompletion":1309,"completion":1310,"start":1311,"enrollment":1312,"conditions":1313,"interventions":1315},"NCT06524583","Interest of Post-operative Chemotherapy in Patients With Localised Uterine Leiomyosarcoma Suspected of Having a High Risk of Recurrence Based on a Biological Test Performed on the Tumour",[91],"2029-12","2030-12","2025-01-27",198,[1314],"Leiomyosarcoma Uterus",[1028,1316],"Trabectedin",{"trials":1318,"activeCount":309,"soonestReadout":1021},[1319],{"nctId":1018,"briefTitle":1019,"status":140,"phases":1320,"primaryCompletion":1021,"completion":131,"start":1022,"enrollment":1023,"conditions":1321,"interventions":1322},[92],[1025,1026],[1028,550],{"trials":1324,"activeCount":102},[],{"trials":1326,"activeCount":102},[],{"intervention":533,"totalTrials":397,"cells":1328},{"EARLY_PHASE1":1329,"PHASE1":1331,"PHASE2":1333,"PHASE3":1349,"PHASE4":1355,"NA":1357},{"trials":1330,"activeCount":102},[],{"trials":1332,"activeCount":102},[],{"trials":1334,"activeCount":309,"soonestReadout":1339},[1335],{"nctId":1336,"briefTitle":1337,"status":140,"phases":1338,"primaryCompletion":1339,"completion":1340,"start":1341,"enrollment":1342,"conditions":1343,"interventions":1348},"NCT07192068","Clinical Trial Evaluating the Activity of Zanidatamab for the Treatment of Patients With Solid Tumors With an Alteration of the HER2 Gene.",[91],"2028-03-13","2030-06-24","2025-10-30",105,[1344,33,1345,1346,1347],"Non-Small Cell Lung Cancer","Head &Amp; Neck Cancer","Colorectal Carcinoma","Endometrial",[533],{"trials":1350,"activeCount":309,"soonestReadout":388},[1351],{"nctId":523,"briefTitle":524,"status":140,"phases":1352,"primaryCompletion":388,"completion":129,"start":526,"enrollment":527,"conditions":1353,"interventions":1354},[92],[529],[531,532,533,396,534,535,536,537,538,539],{"trials":1356,"activeCount":102},[],{"trials":1358,"activeCount":102},[],{"intervention":535,"totalTrials":397,"cells":1360},{"EARLY_PHASE1":1361,"PHASE1":1363,"PHASE2":1365,"PHASE3":1371,"PHASE4":1377,"NA":1379},{"trials":1362,"activeCount":102},[],{"trials":1364,"activeCount":102},[],{"trials":1366,"activeCount":309,"soonestReadout":154},[1367],{"nctId":150,"briefTitle":151,"status":152,"phases":1368,"primaryCompletion":154,"completion":154,"start":155,"enrollment":25,"conditions":1369,"interventions":1370},[91],[157,158,159],[161,162,97],{"trials":1372,"activeCount":309,"soonestReadout":388},[1373],{"nctId":523,"briefTitle":524,"status":140,"phases":1374,"primaryCompletion":388,"completion":129,"start":526,"enrollment":527,"conditions":1375,"interventions":1376},[92],[529],[531,532,533,396,534,535,536,537,538,539],{"trials":1378,"activeCount":102},[],{"trials":1380,"activeCount":102},[],{"intervention":536,"totalTrials":397,"cells":1382},{"EARLY_PHASE1":1383,"PHASE1":1385,"PHASE2":1387,"PHASE3":1393,"PHASE4":1399,"NA":1401},{"trials":1384,"activeCount":102},[],{"trials":1386,"activeCount":102},[],{"trials":1388,"activeCount":309,"soonestReadout":154},[1389],{"nctId":150,"briefTitle":151,"status":152,"phases":1390,"primaryCompletion":154,"completion":154,"start":155,"enrollment":25,"conditions":1391,"interventions":1392},[91],[157,158,159],[161,162,97],{"trials":1394,"activeCount":309,"soonestReadout":388},[1395],{"nctId":523,"briefTitle":524,"status":140,"phases":1396,"primaryCompletion":388,"completion":129,"start":526,"enrollment":527,"conditions":1397,"interventions":1398},[92],[529],[531,532,533,396,534,535,536,537,538,539],{"trials":1400,"activeCount":102},[],{"trials":1402,"activeCount":102},[],{"intervention":1404,"totalTrials":397,"cells":1405},"Darolutamide 300 mg",{"EARLY_PHASE1":1406,"PHASE1":1408,"PHASE2":1410,"PHASE3":1412,"PHASE4":1436,"NA":1438},{"trials":1407,"activeCount":102},[],{"trials":1409,"activeCount":102},[],{"trials":1411,"activeCount":102},[],{"trials":1413,"activeCount":397,"soonestReadout":1430},[1414,1426],{"nctId":1415,"briefTitle":1416,"status":140,"phases":1417,"primaryCompletion":1418,"completion":1419,"start":1420,"enrollment":1421,"conditions":1422,"interventions":1424},"NCT06276465","Treatment With Darolutamide +\u002F- Radiation Therapy for Patients With a Castration Resistant Cancer and Metastases Detected by Functional Imaging",[92],"2029-10-15","2032-10-07","2024-10-07",336,[1423],"Prostatic Cancer, Castration-Resistant",[1404,1425],"Androgen deprivation therapy",{"nctId":1427,"briefTitle":1428,"status":140,"phases":1429,"primaryCompletion":1430,"completion":1431,"start":1432,"enrollment":1433,"conditions":1434,"interventions":1435},"NCT04916613","ADT +\u002F- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerable)",[92],"2028-03","2037-09","2022-04-19",300,[1254],[1404,1425],{"trials":1437,"activeCount":102},[],{"trials":1439,"activeCount":102},[],{"intervention":1425,"totalTrials":397,"cells":1441},{"EARLY_PHASE1":1442,"PHASE1":1444,"PHASE2":1446,"PHASE3":1448,"PHASE4":1458,"NA":1460},{"trials":1443,"activeCount":102},[],{"trials":1445,"activeCount":102},[],{"trials":1447,"activeCount":102},[],{"trials":1449,"activeCount":397,"soonestReadout":1430},[1450,1454],{"nctId":1415,"briefTitle":1416,"status":140,"phases":1451,"primaryCompletion":1418,"completion":1419,"start":1420,"enrollment":1421,"conditions":1452,"interventions":1453},[92],[1423],[1404,1425],{"nctId":1427,"briefTitle":1428,"status":140,"phases":1455,"primaryCompletion":1430,"completion":1431,"start":1432,"enrollment":1433,"conditions":1456,"interventions":1457},[92],[1254],[1404,1425],{"trials":1459,"activeCount":102},[],{"trials":1461,"activeCount":102},[],{"intervention":551,"totalTrials":1077,"cells":1463},{"EARLY_PHASE1":1464,"PHASE1":1466,"PHASE2":1468,"PHASE3":1522,"PHASE4":1573,"NA":1575},{"trials":1465,"activeCount":102},[],{"trials":1467,"activeCount":102},[],{"trials":1469,"activeCount":102},[1470,1482,1491,1501,1505,1509,1518],{"nctId":1471,"briefTitle":1472,"status":110,"phases":1473,"primaryCompletion":1474,"completion":1474,"start":1475,"enrollment":892,"conditions":1476,"interventions":1480},"NCT03101046","Treatment of Metastatic Castrate Resistant Prostate Cancer Patients According to Circulating Tumor Cells Kinetic",[91],"2021-12-31","2018-11-15",[1477,1478,1479,177],"Prostate Carcinoma","Castration-resistant Prostate Cancer","Circulating Tumor Cells",[1481,474],"Cabazitaxel",{"nctId":1483,"briefTitle":1484,"status":110,"phases":1485,"completion":1486,"start":1487,"enrollment":1488,"conditions":1489,"interventions":1490},"NCT00227708","Docetaxel in Treating Older Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer",[91],"2006-08-29","2005-06",58,[974],[551],{"nctId":1492,"briefTitle":1493,"status":110,"phases":1494,"primaryCompletion":1495,"completion":1496,"start":1497,"enrollment":1498,"conditions":1499,"interventions":1500},"NCT00227669","Gemcitabine With or Without Docetaxel as Second-Line Therapy in Treating Patients With Metastatic or Relapsed, Unresectable Uterine or Soft Tissue Leiomyosarcoma",[91],"2010-02","2012-08","2005-10",90,[33],[551,671],{"nctId":464,"briefTitle":465,"status":110,"phases":1502,"primaryCompletion":467,"completion":468,"start":469,"enrollment":470,"conditions":1503,"interventions":1504},[91],[15],[473,474,396,475,476],{"nctId":1097,"briefTitle":1098,"status":110,"phases":1506,"primaryCompletion":1100,"completion":1101,"start":1102,"enrollment":1103,"conditions":1507,"interventions":1508},[91],[639],[42,551,253],{"nctId":1510,"briefTitle":1511,"status":375,"phases":1512,"primaryCompletion":1513,"completion":1514,"start":1515,"enrollment":509,"conditions":1516,"interventions":1517},"NCT00104624","Docetaxel in Treating Older Women With Metastatic Breast Cancer",[91],"2007-07","2008-07","2005-05",[15],[551],{"nctId":906,"briefTitle":907,"status":110,"phases":1519,"primaryCompletion":909,"completion":910,"start":911,"enrollment":912,"conditions":1520,"interventions":1521},[91],[15],[333,751,551,752,253],{"trials":1523,"activeCount":309,"soonestReadout":56},[1524,1528,1532,1543,1547,1555,1559],{"nctId":1007,"briefTitle":1008,"status":110,"phases":1525,"primaryCompletion":1010,"completion":1011,"start":1012,"enrollment":1013,"conditions":1526,"interventions":1527},[92],[15],[751,474,752,253,1016],{"nctId":1041,"briefTitle":1042,"status":110,"phases":1529,"primaryCompletion":649,"completion":469,"start":1044,"enrollment":1045,"conditions":1530,"interventions":1531},[92],[1047],[474,550,552],{"nctId":1533,"briefTitle":1534,"status":110,"phases":1535,"primaryCompletion":1536,"completion":1537,"start":1538,"enrollment":1539,"conditions":1540,"interventions":1541},"NCT00104715","Hormone Therapy and Docetaxel or Hormone Therapy Alone in Treating Patients With Metastatic Prostate Cancer",[92],"2011-12-04","2015-12-15","2004-10-18",385,[21],[1542,551,1058],"antiandrogen therapy",{"nctId":1050,"briefTitle":1051,"status":375,"phases":1544,"primaryCompletion":1053,"start":1054,"conditions":1545,"interventions":1546},[92],[15],[1057,751,551,752,253,1058,1059],{"nctId":54,"briefTitle":55,"status":152,"phases":1548,"primaryCompletion":56,"completion":1549,"start":1550,"enrollment":1551,"conditions":1552,"interventions":1554},[92],"2032-12","2013-11-13",1173,[1553],"Metastatic Prostate Cancer",[57,474],{"nctId":541,"briefTitle":542,"status":110,"phases":1556,"primaryCompletion":544,"completion":545,"start":546,"enrollment":547,"conditions":1557,"interventions":1558},[92],[15],[396,550,551,552,553],{"nctId":1560,"briefTitle":1561,"status":110,"phases":1562,"primaryCompletion":1563,"completion":1564,"start":1565,"enrollment":1566,"conditions":1567,"interventions":1568},"NCT00055731","Hormone Therapy With or Without Docetaxel And Estramustine in Treating Patients With Prostate Cancer That is Locally Advanced or At High Risk of Relapse",[92],"2010-12-21","2022-12-31","2002-11-14",413,[21],[1569,1570,551,1571,1572],"bicalutamide","Goserelin Acetate","Estramustine phosphate sodium","acetylsalicylic acid",{"trials":1574,"activeCount":102},[],{"trials":1576,"activeCount":102},[],{"intervention":699,"totalTrials":98,"cells":1578},{"EARLY_PHASE1":1579,"PHASE1":1581,"PHASE2":1583,"PHASE3":1598,"PHASE4":1620,"NA":1622},{"trials":1580,"activeCount":102},[],{"trials":1582,"activeCount":102},[],{"trials":1584,"activeCount":102},[1585,1594],{"nctId":1586,"briefTitle":1587,"status":110,"phases":1588,"primaryCompletion":1589,"completion":1110,"start":1590,"enrollment":1591,"conditions":1592,"interventions":1593},"NCT00003860","Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Small Cell Lung Cancer",[91],"2000-08","1998-09",36,[974],[749,750,699,700],{"nctId":740,"briefTitle":741,"status":375,"phases":1595,"primaryCompletion":743,"completion":743,"start":744,"enrollment":368,"conditions":1596,"interventions":1597},[91],[746,694,747,696],[749,750,751,752,699,700,701,753],{"trials":1599,"activeCount":309,"soonestReadout":41},[1600,1604,1608,1612,1616],{"nctId":967,"briefTitle":968,"status":110,"phases":1601,"primaryCompletion":970,"completion":546,"start":971,"enrollment":972,"conditions":1602,"interventions":1603},[92],[974],[42,751,752,699],{"nctId":986,"briefTitle":987,"status":110,"phases":1605,"primaryCompletion":989,"completion":990,"start":991,"enrollment":992,"conditions":1606,"interventions":1607},[92],[994],[996,751,997,998,999,699,1000,1001,1002,1003,1004,1005],{"nctId":39,"briefTitle":40,"status":152,"phases":1609,"primaryCompletion":41,"completion":387,"start":1171,"enrollment":1172,"conditions":1610,"interventions":1611},[92],[33],[42,900,699,700,1001,1175],{"nctId":1030,"briefTitle":1031,"status":110,"phases":1613,"primaryCompletion":1033,"completion":1034,"start":1035,"enrollment":1036,"conditions":1614,"interventions":1615},[92],[694,696],[750,42,751,699,700,1039],{"nctId":686,"briefTitle":687,"status":110,"phases":1617,"primaryCompletion":689,"completion":690,"start":691,"enrollment":692,"conditions":1618,"interventions":1619},[92],[694,695,696],[698,42,699,700,256,701],{"trials":1621,"activeCount":102},[],{"trials":1623,"activeCount":102},[],{"intervention":700,"totalTrials":31,"cells":1625},{"EARLY_PHASE1":1626,"PHASE1":1628,"PHASE2":1630,"PHASE3":1648,"PHASE4":1662,"NA":1664},{"trials":1627,"activeCount":102},[],{"trials":1629,"activeCount":102},[],{"trials":1631,"activeCount":102},[1632,1636,1644],{"nctId":1586,"briefTitle":1587,"status":110,"phases":1633,"primaryCompletion":1589,"completion":1110,"start":1590,"enrollment":1591,"conditions":1634,"interventions":1635},[91],[974],[749,750,699,700],{"nctId":1637,"briefTitle":1638,"status":110,"phases":1639,"primaryCompletion":1640,"completion":1641,"start":744,"enrollment":892,"conditions":1642,"interventions":1643},"NCT00003683","Combination Chemotherapy in Treating Patients With Metastatic Kidney Cancer",[91],"2000-11-05","2002-04",[959],[900,700],{"nctId":740,"briefTitle":741,"status":375,"phases":1645,"primaryCompletion":743,"completion":743,"start":744,"enrollment":368,"conditions":1646,"interventions":1647},[91],[746,694,747,696],[749,750,751,752,699,700,701,753],{"trials":1649,"activeCount":309,"soonestReadout":41},[1650,1654,1658],{"nctId":39,"briefTitle":40,"status":152,"phases":1651,"primaryCompletion":41,"completion":387,"start":1171,"enrollment":1172,"conditions":1652,"interventions":1653},[92],[33],[42,900,699,700,1001,1175],{"nctId":1030,"briefTitle":1031,"status":110,"phases":1655,"primaryCompletion":1033,"completion":1034,"start":1035,"enrollment":1036,"conditions":1656,"interventions":1657},[92],[694,696],[750,42,751,699,700,1039],{"nctId":686,"briefTitle":687,"status":110,"phases":1659,"primaryCompletion":689,"completion":690,"start":691,"enrollment":692,"conditions":1660,"interventions":1661},[92],[694,695,696],[698,42,699,700,256,701],{"trials":1663,"activeCount":102},[],{"trials":1665,"activeCount":102},[],{"intervention":900,"totalTrials":295,"cells":1667},{"EARLY_PHASE1":1668,"PHASE1":1670,"PHASE2":1672,"PHASE3":1682,"PHASE4":1695,"NA":1697},{"trials":1669,"activeCount":102},[],{"trials":1671,"activeCount":102},[],{"trials":1673,"activeCount":102},[1674,1678],{"nctId":887,"briefTitle":888,"status":110,"phases":1675,"primaryCompletion":340,"completion":890,"start":891,"enrollment":892,"conditions":1676,"interventions":1677},[91],[15,894,895,896,897],[899,751,900],{"nctId":1637,"briefTitle":1638,"status":110,"phases":1679,"primaryCompletion":1640,"completion":1641,"start":744,"enrollment":892,"conditions":1680,"interventions":1681},[91],[959],[900,700],{"trials":1683,"activeCount":309,"soonestReadout":41},[1684,1691],{"nctId":1685,"briefTitle":1686,"status":375,"phases":1687,"primaryCompletion":1688,"completion":1688,"start":1185,"enrollment":1186,"conditions":1689,"interventions":1690},"NCT00003682","Methylprednisolone With or Without Doxorubicin in Treating Patients With Metastatic Prostate Cancer",[92],"2001-03",[21],[900,1002],{"nctId":39,"briefTitle":40,"status":152,"phases":1692,"primaryCompletion":41,"completion":387,"start":1171,"enrollment":1172,"conditions":1693,"interventions":1694},[92],[33],[42,900,699,700,1001,1175],{"trials":1696,"activeCount":102},[],{"trials":1698,"activeCount":102},[],{"intervention":539,"totalTrials":295,"cells":1700},{"EARLY_PHASE1":1701,"PHASE1":1703,"PHASE2":1705,"PHASE3":1707,"PHASE4":1732,"NA":1734},{"trials":1702,"activeCount":102},[],{"trials":1704,"activeCount":102},[],{"trials":1706,"activeCount":102},[],{"trials":1708,"activeCount":309,"soonestReadout":388},[1709,1720,1724,1728],{"nctId":1710,"briefTitle":1711,"status":110,"phases":1712,"primaryCompletion":1713,"completion":1714,"start":1715,"enrollment":1716,"conditions":1717,"interventions":1719},"NCT01526135","Trial Comparing Adjuvant Chemotherapy With Gemcitabine Versus mFolfirinox to Treat Resected Pancreatic Adenocarcinoma",[92],"2018-03","2021-07-16","2012-04-16",493,[1718],"Pancreatic Adenocarcinoma (Ductal Adenocarcinoma)",[425,539],{"nctId":631,"briefTitle":632,"status":110,"phases":1721,"primaryCompletion":634,"completion":635,"start":636,"enrollment":637,"conditions":1722,"interventions":1723},[92],[639,640],[539,579,642,281,241,643],{"nctId":523,"briefTitle":524,"status":140,"phases":1725,"primaryCompletion":388,"completion":129,"start":526,"enrollment":527,"conditions":1726,"interventions":1727},[92],[529],[531,532,533,396,534,535,536,537,538,539],{"nctId":772,"briefTitle":773,"status":110,"phases":1729,"primaryCompletion":775,"completion":775,"start":776,"enrollment":777,"conditions":1730,"interventions":1731},[92],[779],[539,242],{"trials":1733,"activeCount":102},[],{"trials":1735,"activeCount":102},[],{"intervention":1481,"totalTrials":163,"cells":1737},{"EARLY_PHASE1":1738,"PHASE1":1740,"PHASE2":1742,"PHASE3":1758,"PHASE4":1771,"NA":1773},{"trials":1739,"activeCount":102},[],{"trials":1741,"activeCount":102},[],{"trials":1743,"activeCount":102},[1744,1748],{"nctId":1471,"briefTitle":1472,"status":110,"phases":1745,"primaryCompletion":1474,"completion":1474,"start":1475,"enrollment":892,"conditions":1746,"interventions":1747},[91],[1477,1478,1479,177],[1481,474],{"nctId":1749,"briefTitle":1750,"status":110,"phases":1751,"primaryCompletion":980,"completion":1752,"start":1753,"enrollment":808,"conditions":1754,"interventions":1757},"NCT01620242","A Phase II, Open-Label, Multicenter Trial of Cabazitaxel in Patients With Recurrent or Metastatic Head and Neck Cancer After Failure Of Cisplatin, Cetuximab and Taxanes",[91],"2014-05-27","2012-04",[1755,1756],"Recurrent Head and Neck Cancer","Metastatic Head and Neck Cancer",[1481],{"trials":1759,"activeCount":309,"soonestReadout":929},[1760],{"nctId":1761,"briefTitle":1762,"status":152,"phases":1763,"primaryCompletion":929,"completion":1764,"start":1765,"enrollment":1766,"conditions":1767,"interventions":1770},"NCT01952223","A Phase III of Cabazitaxel and Pelvic Radiotherapy in Localized Prostate Cancer and High-risk Features of Relapse",[92],"2041-07","2013-12",761,[1768,1769],"Adenocarcinoma of Prostate","Progression of Prostate Cancer",[1481],{"trials":1772,"activeCount":102},[],{"trials":1774,"activeCount":102},[],{"intervention":52,"totalTrials":397,"cells":1776},{"EARLY_PHASE1":1777,"PHASE1":1779,"PHASE2":1781,"PHASE3":1787,"PHASE4":1798,"NA":1800},{"trials":1778,"activeCount":102},[],{"trials":1780,"activeCount":102},[],{"trials":1782,"activeCount":102},[1783],{"nctId":493,"briefTitle":494,"status":375,"phases":1784,"primaryCompletion":496,"start":497,"enrollment":498,"conditions":1785,"interventions":1786},[91],[15],[501,502],{"trials":1788,"activeCount":309,"soonestReadout":51},[1789],{"nctId":49,"briefTitle":50,"status":152,"phases":1790,"primaryCompletion":51,"completion":1791,"start":1792,"enrollment":1793,"conditions":1794,"interventions":1797},[92],"2030-06","2013-03",1278,[1795,1796],"Primary Non-metastatic Breast Cancer","Who Remain Disease-free",[52],{"trials":1799,"activeCount":102},[],{"trials":1801,"activeCount":102},[],{"intervention":1803,"totalTrials":397,"cells":1804},"Abiraterone Acetate",{"EARLY_PHASE1":1805,"PHASE1":1807,"PHASE2":1809,"PHASE3":1821,"PHASE4":1827,"NA":1829},{"trials":1806,"activeCount":102},[],{"trials":1808,"activeCount":102},[],{"trials":1810,"activeCount":102},[1811],{"nctId":1812,"briefTitle":1813,"status":110,"phases":1814,"primaryCompletion":1815,"completion":1816,"start":1817,"enrollment":1818,"conditions":1819,"interventions":1820},"NCT01842321","Abiraterone Acetate in Molecular Apocrine Breast Cancer",[91],"2015-07-15","2018-07-04","2013-07",34,[15],[1803],{"trials":1822,"activeCount":309,"soonestReadout":56},[1823],{"nctId":54,"briefTitle":55,"status":152,"phases":1824,"primaryCompletion":56,"completion":1549,"start":1550,"enrollment":1551,"conditions":1825,"interventions":1826},[92],[1553],[57,474],{"trials":1828,"activeCount":102},[],{"trials":1830,"activeCount":102},[],{"intervention":361,"totalTrials":397,"cells":1832},{"EARLY_PHASE1":1833,"PHASE1":1835,"PHASE2":1837,"PHASE3":1843,"PHASE4":1857,"NA":1859},{"trials":1834,"activeCount":102},[],{"trials":1836,"activeCount":102},[],{"trials":1838,"activeCount":102},[1839],{"nctId":350,"briefTitle":351,"status":110,"phases":1840,"primaryCompletion":353,"completion":354,"start":355,"enrollment":356,"conditions":1841,"interventions":1842},[91],[358,359],[361,148],{"trials":1844,"activeCount":309,"soonestReadout":1849},[1845],{"nctId":1846,"briefTitle":1847,"status":140,"phases":1848,"primaryCompletion":1849,"completion":1850,"start":1851,"enrollment":1852,"conditions":1853,"interventions":1855},"NCT06625970","Study Evaluating the Efficacy and Safety of Darolutamide and Stereotactic Dose Escalated Radiotherapy in Patients With Localized Prostate Cancer and High-risk Features of Relapse",[92],"2033-10","2045-10","2025-04-10",700,[1854,21],"High Risk Prostate Carcinoma",[361,1856],"ADT",{"trials":1858,"activeCount":102},[],{"trials":1860,"activeCount":102},[],{"intervention":1862,"totalTrials":309,"cells":1863},"FOLFOX4s",{"EARLY_PHASE1":1864,"PHASE1":1866,"PHASE2":1868,"PHASE3":1870,"PHASE4":1882,"NA":1884},{"trials":1865,"activeCount":102},[],{"trials":1867,"activeCount":102},[],{"trials":1869,"activeCount":102},[],{"trials":1871,"activeCount":309,"soonestReadout":1876},[1872],{"nctId":1873,"briefTitle":1874,"status":127,"phases":1875,"primaryCompletion":1876,"completion":1877,"start":1878,"enrollment":1186,"conditions":1879,"interventions":1881},"NCT07118800","Study Evaluating Two Treatment Strategies for Rectal Cancer in Patients ≥75 Years Old",[92],"2030-12-15","2032-01-15","2025-12-15",[1880],"Locally Advanced Rectal Adenocarcinoma",[1862],{"trials":1883,"activeCount":102},[],{"trials":1885,"activeCount":102},[],{"intervention":67,"totalTrials":309,"cells":1887},{"EARLY_PHASE1":1888,"PHASE1":1890,"PHASE2":1892,"PHASE3":1894,"PHASE4":1904,"NA":1906},{"trials":1889,"activeCount":102},[],{"trials":1891,"activeCount":102},[],{"trials":1893,"activeCount":102},[],{"trials":1895,"activeCount":309,"soonestReadout":66},[1896],{"nctId":64,"briefTitle":65,"status":152,"phases":1897,"primaryCompletion":66,"completion":1898,"start":1899,"enrollment":1900,"conditions":1901,"interventions":1902},[92],"2026-03","2012-04-12",1989,[15],[67,1903],"CHEMOTHERAPY then HORMONOTHERAPY",{"trials":1905,"activeCount":102},[],{"trials":1907,"activeCount":102},[],{"intervention":1903,"totalTrials":309,"cells":1909},{"EARLY_PHASE1":1910,"PHASE1":1912,"PHASE2":1914,"PHASE3":1916,"PHASE4":1922,"NA":1924},{"trials":1911,"activeCount":102},[],{"trials":1913,"activeCount":102},[],{"trials":1915,"activeCount":102},[],{"trials":1917,"activeCount":309,"soonestReadout":66},[1918],{"nctId":64,"briefTitle":65,"status":152,"phases":1919,"primaryCompletion":66,"completion":1898,"start":1899,"enrollment":1900,"conditions":1920,"interventions":1921},[92],[15],[67,1903],{"trials":1923,"activeCount":102},[],{"trials":1925,"activeCount":102},[],{"intervention":1856,"totalTrials":309,"cells":1927},{"EARLY_PHASE1":1928,"PHASE1":1930,"PHASE2":1932,"PHASE3":1934,"PHASE4":1940,"NA":1942},{"trials":1929,"activeCount":102},[],{"trials":1931,"activeCount":102},[],{"trials":1933,"activeCount":102},[],{"trials":1935,"activeCount":309,"soonestReadout":1849},[1936],{"nctId":1846,"briefTitle":1847,"status":140,"phases":1937,"primaryCompletion":1849,"completion":1850,"start":1851,"enrollment":1852,"conditions":1938,"interventions":1939},[92],[1854,21],[361,1856],{"trials":1941,"activeCount":102},[],{"trials":1943,"activeCount":102},[],{"intervention":77,"totalTrials":309,"cells":1945},{"EARLY_PHASE1":1946,"PHASE1":1948,"PHASE2":1950,"PHASE3":1952,"PHASE4":1962,"NA":1964},{"trials":1947,"activeCount":102},[],{"trials":1949,"activeCount":102},[],{"trials":1951,"activeCount":102},[],{"trials":1953,"activeCount":309,"soonestReadout":76},[1954],{"nctId":74,"briefTitle":75,"status":152,"phases":1955,"primaryCompletion":76,"completion":1956,"start":1957,"enrollment":1958,"conditions":1959,"interventions":1961},[92],"2027-05-14","2011-04-26",415,[1960],"Ovarian Epithelial Cancer Recurrent",[77],{"trials":1963,"activeCount":102},[],{"trials":1965,"activeCount":102},[],{"intervention":308,"totalTrials":309,"cells":1967},{"EARLY_PHASE1":1968,"PHASE1":1970,"PHASE2":1972,"PHASE3":1974,"PHASE4":1980,"NA":1982},{"trials":1969,"activeCount":102},[],{"trials":1971,"activeCount":102},[],{"trials":1973,"activeCount":102},[],{"trials":1975,"activeCount":309,"soonestReadout":302},[1976],{"nctId":299,"briefTitle":300,"status":127,"phases":1977,"primaryCompletion":302,"completion":303,"start":304,"enrollment":305,"conditions":1978,"interventions":1979},[92],[18],[148,281,308,207],{"trials":1981,"activeCount":102},[],{"trials":1983,"activeCount":102},[],{"intervention":1985,"totalTrials":309,"cells":1986},"test-directed treatment: allocated treatment will depend on the PAM50 score result (centrally assessed) : chemo-endocrine therapy or endocrine therapy alone",{"EARLY_PHASE1":1987,"PHASE1":1989,"PHASE2":1991,"PHASE3":1993,"PHASE4":2009,"NA":2011},{"trials":1988,"activeCount":102},[],{"trials":1990,"activeCount":102},[],{"trials":1992,"activeCount":102},[],{"trials":1994,"activeCount":309,"soonestReadout":1999},[1995],{"nctId":1996,"briefTitle":1997,"status":127,"phases":1998,"primaryCompletion":1999,"completion":2000,"start":2001,"enrollment":2002,"conditions":2003,"interventions":2007},"NCT07106632","Optimising Adjuvant Chemotherapy Prescription in Young Patients With Hormone-dependent Breast Cancer Using Genomic Tests",[92],"2031-08-15","2038-08-15","2026-04-01",3380,[2004,2005,2006],"Early Breast Cancer","Premenopausal Breast Cancer","HR+\u002FHER2- Breast Cancer",[1985,2008],"In the control arm, the treatment will be as standard of care : chemo-endocrine therapy",{"trials":2010,"activeCount":102},[],{"trials":2012,"activeCount":102},[],{"intervention":2008,"totalTrials":309,"cells":2014},{"EARLY_PHASE1":2015,"PHASE1":2017,"PHASE2":2019,"PHASE3":2021,"PHASE4":2027,"NA":2029},{"trials":2016,"activeCount":102},[],{"trials":2018,"activeCount":102},[],{"trials":2020,"activeCount":102},[],{"trials":2022,"activeCount":309,"soonestReadout":1999},[2023],{"nctId":1996,"briefTitle":1997,"status":127,"phases":2024,"primaryCompletion":1999,"completion":2000,"start":2001,"enrollment":2002,"conditions":2025,"interventions":2026},[92],[2004,2005,2006],[1985,2008],{"trials":2028,"activeCount":102},[],{"trials":2030,"activeCount":102},[],{"intervention":2032,"totalTrials":309,"cells":2033},"Leuprorelin Acetate",{"EARLY_PHASE1":2034,"PHASE1":2036,"PHASE2":2038,"PHASE3":2040,"PHASE4":2050,"NA":2052},{"trials":2035,"activeCount":102},[],{"trials":2037,"activeCount":102},[],{"trials":2039,"activeCount":102},[],{"trials":2041,"activeCount":309,"soonestReadout":231},[2042],{"nctId":2043,"briefTitle":2044,"status":152,"phases":2045,"primaryCompletion":231,"completion":231,"start":2046,"enrollment":1852,"conditions":2047,"interventions":2049},"NCT01442246","Evaluation of Adjuvant Hormonal Treatment for 24 Months After Radical Prostatectomy in High Risk of Recurrence Patients.",[92],"2011-07",[2048],"Metastases",[2032],{"trials":2051,"activeCount":102},[],{"trials":2053,"activeCount":102},[],{"intervention":2055,"totalTrials":309,"cells":2056},"Durvalumab Plus Tremelimumab",{"EARLY_PHASE1":2057,"PHASE1":2059,"PHASE2":2061,"PHASE3":2063,"PHASE4":2076,"NA":2078},{"trials":2058,"activeCount":102},[],{"trials":2060,"activeCount":102},[],{"trials":2062,"activeCount":102},[],{"trials":2064,"activeCount":309,"soonestReadout":2069},[2065],{"nctId":2066,"briefTitle":2067,"status":140,"phases":2068,"primaryCompletion":2069,"completion":829,"start":2070,"enrollment":2071,"conditions":2072,"interventions":2074},"NCT06904170","Durvalumab and Tremelimumab With or Without Hepatic Arterial Infusion of Chemotherapy in Hepatocellular Carcinoma",[91,92],"2029-09-14","2025-11-14",196,[2073],"Hepatocellular Carcinoma",[2055,2075],"HAIC",{"trials":2077,"activeCount":102},[],{"trials":2079,"activeCount":102},[],{"intervention":2075,"totalTrials":309,"cells":2081},{"EARLY_PHASE1":2082,"PHASE1":2084,"PHASE2":2086,"PHASE3":2088,"PHASE4":2094,"NA":2096},{"trials":2083,"activeCount":102},[],{"trials":2085,"activeCount":102},[],{"trials":2087,"activeCount":102},[],{"trials":2089,"activeCount":309,"soonestReadout":2069},[2090],{"nctId":2066,"briefTitle":2067,"status":140,"phases":2091,"primaryCompletion":2069,"completion":829,"start":2070,"enrollment":2071,"conditions":2092,"interventions":2093},[91,92],[2073],[2055,2075],{"trials":2095,"activeCount":102},[],{"trials":2097,"activeCount":102},[],{"intervention":531,"totalTrials":309,"cells":2099},{"EARLY_PHASE1":2100,"PHASE1":2102,"PHASE2":2104,"PHASE3":2106,"PHASE4":2112,"NA":2114},{"trials":2101,"activeCount":102},[],{"trials":2103,"activeCount":102},[],{"trials":2105,"activeCount":102},[],{"trials":2107,"activeCount":309,"soonestReadout":388},[2108],{"nctId":523,"briefTitle":524,"status":140,"phases":2109,"primaryCompletion":388,"completion":129,"start":526,"enrollment":527,"conditions":2110,"interventions":2111},[92],[529],[531,532,533,396,534,535,536,537,538,539],{"trials":2113,"activeCount":102},[],{"trials":2115,"activeCount":102},[],{"intervention":532,"totalTrials":309,"cells":2117},{"EARLY_PHASE1":2118,"PHASE1":2120,"PHASE2":2122,"PHASE3":2124,"PHASE4":2130,"NA":2132},{"trials":2119,"activeCount":102},[],{"trials":2121,"activeCount":102},[],{"trials":2123,"activeCount":102},[],{"trials":2125,"activeCount":309,"soonestReadout":388},[2126],{"nctId":523,"briefTitle":524,"status":140,"phases":2127,"primaryCompletion":388,"completion":129,"start":526,"enrollment":527,"conditions":2128,"interventions":2129},[92],[529],[531,532,533,396,534,535,536,537,538,539],{"trials":2131,"activeCount":102},[],{"trials":2133,"activeCount":102},[],{"intervention":534,"totalTrials":309,"cells":2135},{"EARLY_PHASE1":2136,"PHASE1":2138,"PHASE2":2140,"PHASE3":2142,"PHASE4":2148,"NA":2150},{"trials":2137,"activeCount":102},[],{"trials":2139,"activeCount":102},[],{"trials":2141,"activeCount":102},[],{"trials":2143,"activeCount":309,"soonestReadout":388},[2144],{"nctId":523,"briefTitle":524,"status":140,"phases":2145,"primaryCompletion":388,"completion":129,"start":526,"enrollment":527,"conditions":2146,"interventions":2147},[92],[529],[531,532,533,396,534,535,536,537,538,539],{"trials":2149,"activeCount":102},[],{"trials":2151,"activeCount":102},[],{"intervention":537,"totalTrials":309,"cells":2153},{"EARLY_PHASE1":2154,"PHASE1":2156,"PHASE2":2158,"PHASE3":2160,"PHASE4":2166,"NA":2168},{"trials":2155,"activeCount":102},[],{"trials":2157,"activeCount":102},[],{"trials":2159,"activeCount":102},[],{"trials":2161,"activeCount":309,"soonestReadout":388},[2162],{"nctId":523,"briefTitle":524,"status":140,"phases":2163,"primaryCompletion":388,"completion":129,"start":526,"enrollment":527,"conditions":2164,"interventions":2165},[92],[529],[531,532,533,396,534,535,536,537,538,539],{"trials":2167,"activeCount":102},[],{"trials":2169,"activeCount":102},[],{"intervention":1175,"totalTrials":309,"cells":2171},{"EARLY_PHASE1":2172,"PHASE1":2174,"PHASE2":2176,"PHASE3":2178,"PHASE4":2184,"NA":2186},{"trials":2173,"activeCount":102},[],{"trials":2175,"activeCount":102},[],{"trials":2177,"activeCount":102},[],{"trials":2179,"activeCount":309,"soonestReadout":41},[2180],{"nctId":39,"briefTitle":40,"status":152,"phases":2181,"primaryCompletion":41,"completion":387,"start":1171,"enrollment":1172,"conditions":2182,"interventions":2183},[92],[33],[42,900,699,700,1001,1175],{"trials":2185,"activeCount":102},[],{"trials":2187,"activeCount":102},[],{"intervention":2189,"totalTrials":309,"cells":2190},"Sacituzumab govitecan",{"EARLY_PHASE1":2191,"PHASE1":2193,"PHASE2":2195,"PHASE3":2197,"PHASE4":2209,"NA":2211},{"trials":2192,"activeCount":102},[],{"trials":2194,"activeCount":102},[],{"trials":2196,"activeCount":102},[],{"trials":2198,"activeCount":309,"soonestReadout":304},[2199],{"nctId":2200,"briefTitle":2201,"status":140,"phases":2202,"primaryCompletion":304,"completion":2203,"start":2204,"enrollment":2205,"conditions":2206,"interventions":2208},"NCT05552001","Safety and Efficacy Analysis of an Antibody Associated With a Chemotherapy for Patients With a Triple Negative Metastatic Breast Cancer",[92],"2028-05-06","2023-10-05",96,[2207,24],"Triple Negative Breast Cancer",[2189],{"trials":2210,"activeCount":102},[],{"trials":2212,"activeCount":102},[],{"intervention":1256,"totalTrials":309,"cells":2214},{"EARLY_PHASE1":2215,"PHASE1":2217,"PHASE2":2219,"PHASE3":2221,"PHASE4":2227,"NA":2229},{"trials":2216,"activeCount":102},[],{"trials":2218,"activeCount":102},[],{"trials":2220,"activeCount":102},[],{"trials":2222,"activeCount":309,"soonestReadout":1249},[2223],{"nctId":1246,"briefTitle":1247,"status":140,"phases":2224,"primaryCompletion":1249,"completion":1250,"start":1251,"enrollment":1252,"conditions":2225,"interventions":2226},[92],[1254],[1256,1257],{"trials":2228,"activeCount":102},[],{"trials":2230,"activeCount":102},[],{"intervention":2232,"totalTrials":309,"cells":2233},"Reduced dose intensity of IO",{"EARLY_PHASE1":2234,"PHASE1":2236,"PHASE2":2238,"PHASE3":2240,"PHASE4":2263,"NA":2265},{"trials":2235,"activeCount":102},[],{"trials":2237,"activeCount":102},[],{"trials":2239,"activeCount":102},[],{"trials":2241,"activeCount":309,"soonestReadout":2246},[2242],{"nctId":2243,"briefTitle":2244,"status":140,"phases":2245,"primaryCompletion":2246,"completion":2246,"start":2247,"enrollment":2248,"conditions":2249,"interventions":2262},"NCT05078047","Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO",[92],"2027-03-07","2022-03-08",646,[2250,2251,36,2207,2252,2073,2253,2254,2255,2256,2257,2258,2259,2260,2261],"Lung Cancer Metastatic","Renal Cell Carcinoma","Merkel Cell Carcinoma","Melanoma","Urothelial Carcinoma","Colorectal Carcinoma With Microsatellite Instability","Esophageal Squamous Cell Carcinoma","Endometrial Carcinoma","Cervical Cancer","Gastric\u002FGastro-esophageal Junction\u002FEsophageal Adenocarcinoma","Basal Cell Carcinoma","Squamous Skin Carcinoma",[2232],{"trials":2264,"activeCount":102},[],{"trials":2266,"activeCount":102},[],{"intervention":447,"totalTrials":309,"cells":2268},{"EARLY_PHASE1":2269,"PHASE1":2271,"PHASE2":2273,"PHASE3":2275,"PHASE4":2281,"NA":2283},{"trials":2270,"activeCount":102},[],{"trials":2272,"activeCount":102},[],{"trials":2274,"activeCount":102},[],{"trials":2276,"activeCount":309,"soonestReadout":441},[2277],{"nctId":438,"briefTitle":439,"status":152,"phases":2278,"primaryCompletion":441,"completion":129,"start":442,"enrollment":443,"conditions":2279,"interventions":2280},[92],[445],[242,148,447,448,449,450],{"trials":2282,"activeCount":102},[],{"trials":2284,"activeCount":102},[],{"intervention":448,"totalTrials":309,"cells":2286},{"EARLY_PHASE1":2287,"PHASE1":2289,"PHASE2":2291,"PHASE3":2293,"PHASE4":2299,"NA":2301},{"trials":2288,"activeCount":102},[],{"trials":2290,"activeCount":102},[],{"trials":2292,"activeCount":102},[],{"trials":2294,"activeCount":309,"soonestReadout":441},[2295],{"nctId":438,"briefTitle":439,"status":152,"phases":2296,"primaryCompletion":441,"completion":129,"start":442,"enrollment":443,"conditions":2297,"interventions":2298},[92],[445],[242,148,447,448,449,450],{"trials":2300,"activeCount":102},[],{"trials":2302,"activeCount":102},[],{"intervention":449,"totalTrials":309,"cells":2304},{"EARLY_PHASE1":2305,"PHASE1":2307,"PHASE2":2309,"PHASE3":2311,"PHASE4":2317,"NA":2319},{"trials":2306,"activeCount":102},[],{"trials":2308,"activeCount":102},[],{"trials":2310,"activeCount":102},[],{"trials":2312,"activeCount":309,"soonestReadout":441},[2313],{"nctId":438,"briefTitle":439,"status":152,"phases":2314,"primaryCompletion":441,"completion":129,"start":442,"enrollment":443,"conditions":2315,"interventions":2316},[92],[445],[242,148,447,448,449,450],{"trials":2318,"activeCount":102},[],{"trials":2320,"activeCount":102},[],{"intervention":450,"totalTrials":309,"cells":2322},{"EARLY_PHASE1":2323,"PHASE1":2325,"PHASE2":2327,"PHASE3":2329,"PHASE4":2335,"NA":2337},{"trials":2324,"activeCount":102},[],{"trials":2326,"activeCount":102},[],{"trials":2328,"activeCount":102},[],{"trials":2330,"activeCount":309,"soonestReadout":441},[2331],{"nctId":438,"briefTitle":439,"status":152,"phases":2332,"primaryCompletion":441,"completion":129,"start":442,"enrollment":443,"conditions":2333,"interventions":2334},[92],[445],[242,148,447,448,449,450],{"trials":2336,"activeCount":102},[],{"trials":2338,"activeCount":102},[],{"intervention":1292,"totalTrials":309,"cells":2340},{"EARLY_PHASE1":2341,"PHASE1":2343,"PHASE2":2345,"PHASE3":2347,"PHASE4":2353,"NA":2355},{"trials":2342,"activeCount":102},[],{"trials":2344,"activeCount":102},[],{"trials":2346,"activeCount":102},[],{"trials":2348,"activeCount":309,"soonestReadout":1287},[2349],{"nctId":1284,"briefTitle":1285,"status":152,"phases":2350,"primaryCompletion":1287,"completion":828,"start":1288,"enrollment":1289,"conditions":2351,"interventions":2352},[92],[1122],[1292,1263],{"trials":2354,"activeCount":102},[],{"trials":2356,"activeCount":102},[],{"intervention":2358,"totalTrials":309,"cells":2359},"mFOLFOX regimen",{"EARLY_PHASE1":2360,"PHASE1":2362,"PHASE2":2364,"PHASE3":2366,"PHASE4":2379,"NA":2381},{"trials":2361,"activeCount":102},[],{"trials":2363,"activeCount":102},[],{"trials":2365,"activeCount":102},[],{"trials":2367,"activeCount":309,"soonestReadout":2372},[2368],{"nctId":2369,"briefTitle":2370,"status":127,"phases":2371,"primaryCompletion":2372,"completion":2373,"start":2374,"enrollment":1186,"conditions":2375,"interventions":2377},"NCT07437287","Testing Mitazalimab in Combination With Standard Chemotherapy in Immunotherapy Resistant Advanced Biliary Tract Cancers",[91,92],"2030-04","2031-10","2026-07",[2376],"Biliary Tract Cancer (BTC)",[2358,2378],"Mitazalimab",{"trials":2380,"activeCount":102},[],{"trials":2382,"activeCount":102},[],{"intervention":2378,"totalTrials":309,"cells":2384},{"EARLY_PHASE1":2385,"PHASE1":2387,"PHASE2":2389,"PHASE3":2391,"PHASE4":2397,"NA":2399},{"trials":2386,"activeCount":102},[],{"trials":2388,"activeCount":102},[],{"trials":2390,"activeCount":102},[],{"trials":2392,"activeCount":309,"soonestReadout":2372},[2393],{"nctId":2369,"briefTitle":2370,"status":127,"phases":2394,"primaryCompletion":2372,"completion":2373,"start":2374,"enrollment":1186,"conditions":2395,"interventions":2396},[91,92],[2376],[2358,2378],{"trials":2398,"activeCount":102},[],{"trials":2400,"activeCount":102},[],{"intervention":2402,"totalTrials":309,"cells":2403},"Arterial catheter infusion chemotherapy",{"EARLY_PHASE1":2404,"PHASE1":2406,"PHASE2":2408,"PHASE3":2410,"PHASE4":2423,"NA":2425},{"trials":2405,"activeCount":102},[],{"trials":2407,"activeCount":102},[],{"trials":2409,"activeCount":102},[],{"trials":2411,"activeCount":309,"soonestReadout":2416},[2412],{"nctId":2413,"briefTitle":2414,"status":127,"phases":2415,"primaryCompletion":2416,"completion":2417,"start":2374,"enrollment":2418,"conditions":2419,"interventions":2421},"NCT07284394","Liver-directed Chemotherapy After Surgery of Liver Metastases of Colorectal Cancer in Patients With High Risk of Recurrence of Their Disease",[92],"2031-01","2035-01",272,[2420,18],"Colorectal Adenocarcinoma Metastatic in the Liver",[2402,2422],"IV Chemotherapy",{"trials":2424,"activeCount":102},[],{"trials":2426,"activeCount":102},[],{"intervention":2422,"totalTrials":309,"cells":2428},{"EARLY_PHASE1":2429,"PHASE1":2431,"PHASE2":2433,"PHASE3":2435,"PHASE4":2441,"NA":2443},{"trials":2430,"activeCount":102},[],{"trials":2432,"activeCount":102},[],{"trials":2434,"activeCount":102},[],{"trials":2436,"activeCount":309,"soonestReadout":2416},[2437],{"nctId":2413,"briefTitle":2414,"status":127,"phases":2438,"primaryCompletion":2416,"completion":2417,"start":2374,"enrollment":2418,"conditions":2439,"interventions":2440},[92],[2420,18],[2402,2422],{"trials":2442,"activeCount":102},[],{"trials":2444,"activeCount":102},[],{"intervention":2446,"totalTrials":309,"cells":2447},"Chemotherapy followed by endocrine therapy and ribociclib treatment",{"EARLY_PHASE1":2448,"PHASE1":2450,"PHASE2":2452,"PHASE3":2454,"PHASE4":2466,"NA":2468},{"trials":2449,"activeCount":102},[],{"trials":2451,"activeCount":102},[],{"trials":2453,"activeCount":102},[],{"trials":2455,"activeCount":309,"soonestReadout":2460},[2456],{"nctId":2457,"briefTitle":2458,"status":140,"phases":2459,"primaryCompletion":2460,"completion":2461,"start":2462,"enrollment":2463,"conditions":2464,"interventions":2465},"NCT07237256","Chemotherapy De-escalation in HR +, HER2-, Intermediate-risk Early Breast Cancer Treated With Adjuvant Ribociclib",[92],"2033-11-30","2037-12-31","2025-12-18",3902,[15],[2446],{"trials":2467,"activeCount":102},[],{"trials":2469,"activeCount":102},[],{"intervention":2471,"totalTrials":309,"cells":2472},"Apalutamide",{"EARLY_PHASE1":2473,"PHASE1":2475,"PHASE2":2477,"PHASE3":2479,"PHASE4":2492,"NA":2494},{"trials":2474,"activeCount":102},[],{"trials":2476,"activeCount":102},[],{"trials":2478,"activeCount":102},[],{"trials":2480,"activeCount":309,"soonestReadout":2485},[2481],{"nctId":2482,"briefTitle":2483,"status":152,"phases":2484,"primaryCompletion":2485,"completion":2486,"start":2487,"enrollment":2488,"conditions":2489,"interventions":2490},"NCT04181203","Combined Apalutamide, Radiotherapy, and LHRH Agonist in Prostate Cancer Patients After Prostatectomy",[92],"2028-09-28","2033-12-28","2020-01-09",490,[21],[2471,2491],"Luteinising Hormone Releasing Hormone agonist",{"trials":2493,"activeCount":102},[],{"trials":2495,"activeCount":102},[],{"intervention":2491,"totalTrials":309,"cells":2497},{"EARLY_PHASE1":2498,"PHASE1":2500,"PHASE2":2502,"PHASE3":2504,"PHASE4":2510,"NA":2512},{"trials":2499,"activeCount":102},[],{"trials":2501,"activeCount":102},[],{"trials":2503,"activeCount":102},[],{"trials":2505,"activeCount":309,"soonestReadout":2485},[2506],{"nctId":2482,"briefTitle":2483,"status":152,"phases":2507,"primaryCompletion":2485,"completion":2486,"start":2487,"enrollment":2488,"conditions":2508,"interventions":2509},[92],[21],[2471,2491],{"trials":2511,"activeCount":102},[],{"trials":2513,"activeCount":102},[],{"intervention":282,"totalTrials":28,"cells":2515},{"EARLY_PHASE1":2516,"PHASE1":2518,"PHASE2":2520,"PHASE3":2603,"PHASE4":2605,"NA":2607},{"trials":2517,"activeCount":102},[],{"trials":2519,"activeCount":102},[],{"trials":2521,"activeCount":163,"soonestReadout":271},[2522,2533,2545,2549,2559,2563,2576,2587],{"nctId":2523,"briefTitle":2524,"status":110,"phases":2525,"primaryCompletion":2526,"completion":2527,"start":2528,"enrollment":2529,"conditions":2530,"interventions":2532},"NCT03838263","Feasibility and Tolerance of Nivolumab Neoadjuvant Immunotherapy in High Risk HPV Driven Oropharynx Cancer",[91],"2022-04-01","2024-11-20","2019-07-25",62,[2531],"Oropharynx Cancer",[282],{"nctId":2534,"briefTitle":2535,"status":110,"phases":2536,"primaryCompletion":2537,"completion":2538,"start":2539,"enrollment":2540,"conditions":2541,"interventions":2544},"NCT03132038","Nivolumab in Recurrent or Metastatic Salivary Gland Carcinoma of the Head and Neck",[91],"2019-01-01","2021-10-20","2017-03-24",98,[2542,30,2543],"Salivary Gland Carcinoma","Recurrent Cancer",[282],{"nctId":478,"briefTitle":479,"status":140,"phases":2546,"primaryCompletion":481,"completion":482,"start":483,"enrollment":484,"conditions":2547,"interventions":2548},[91],[27,486,487],[489,281,490,491,396,282],{"nctId":2550,"briefTitle":2551,"status":110,"phases":2552,"primaryCompletion":615,"completion":2553,"start":2554,"enrollment":2555,"conditions":2556,"interventions":2558},"NCT03226756","Nivolumab in Recurrent and\u002For Metastatic SCCHN",[91],"2022-05-31","2017-07-07",351,[2557],"Recurrent and\u002For Metastatic Platinum-refractory SCCHN",[282],{"nctId":268,"briefTitle":269,"status":140,"phases":2560,"primaryCompletion":271,"completion":272,"start":273,"enrollment":274,"conditions":2561,"interventions":2562},[91],[276,277,278],[280,281,207,282],{"nctId":2564,"briefTitle":2565,"status":140,"phases":2566,"primaryCompletion":2567,"completion":2568,"start":2569,"enrollment":2570,"conditions":2571,"interventions":2574},"NCT07230613","Neo-adjuvant Immunotherapy in Patients With Localized Melanoma",[91],"2027-12","2033-12","2026-01-12",50,[2572,2573],"Cutaneous Melanoma, Stage III","Mucosal Melanoma",[2575,282],"Ipilimumab",{"nctId":2577,"briefTitle":2578,"status":110,"phases":2579,"primaryCompletion":2580,"completion":2581,"start":2582,"enrollment":2583,"conditions":2584,"interventions":2586},"NCT03013335","Nivolumab in Patients With Metastatic Renal Cell Carcinoma Who Have Progresses During or After Prior Systemic Anti-angiogenic Regimen",[91],"2018-06","2021-06-30","2016-01",730,[2585],"Metastatic Renal Cell Carcinoma",[282],{"nctId":2588,"briefTitle":2589,"status":110,"phases":2590,"primaryCompletion":2591,"completion":2592,"start":2593,"enrollment":2594,"conditions":2595,"interventions":2602},"NCT03012581","Secured Access to Nivolumab for Adult Patients With Selected Rare Cancer Types",[91],"2022-12-22","2023-11-11","2017-06-16",269,[2596,2597,2598,2599,2600,2601],"Carcinoma, Renal Cell","Head and Neck Neoplasm","Skin Neoplasms","Microsatellite Instability","Penile Neoplasms","Cancer With POLE Exonucleasic Domain Mutation",[282],{"trials":2604,"activeCount":102},[],{"trials":2606,"activeCount":102},[],{"trials":2608,"activeCount":102},[],{"intervention":226,"totalTrials":163,"cells":2610},{"EARLY_PHASE1":2611,"PHASE1":2613,"PHASE2":2615,"PHASE3":2636,"PHASE4":2638,"NA":2640},{"trials":2612,"activeCount":102},[],{"trials":2614,"activeCount":102},[],{"trials":2616,"activeCount":163,"soonestReadout":219},[2617,2621,2632],{"nctId":216,"briefTitle":217,"status":140,"phases":2618,"primaryCompletion":219,"completion":220,"start":221,"enrollment":222,"conditions":2619,"interventions":2620},[91],[224],[226,207],{"nctId":2622,"briefTitle":2623,"status":127,"phases":2624,"primaryCompletion":2625,"completion":2626,"start":2627,"enrollment":2628,"conditions":2629,"interventions":2630},"NCT07359456","Testing Ivonescimab in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancers Without Liver Metastases",[91],"2029-08","2033-08","2026-08-31",130,[27],[226,491,2631],"FOLFIRI Protocol",{"nctId":228,"briefTitle":229,"status":140,"phases":2633,"primaryCompletion":231,"completion":232,"start":233,"enrollment":234,"conditions":2634,"interventions":2635},[91],[236,237,238,239],[226,207,241,242],{"trials":2637,"activeCount":102},[],{"trials":2639,"activeCount":102},[],{"trials":2641,"activeCount":102},[],{"intervention":491,"totalTrials":2643,"cells":2644},9,{"EARLY_PHASE1":2645,"PHASE1":2647,"PHASE2":2649,"PHASE3":2689,"PHASE4":2691,"NA":2693},{"trials":2646,"activeCount":102},[],{"trials":2648,"activeCount":102},[],{"trials":2650,"activeCount":163,"soonestReadout":71},[2651,2655,2659,2663,2667,2671,2675,2679],{"nctId":324,"briefTitle":325,"status":110,"phases":2652,"primaryCompletion":327,"completion":328,"start":329,"enrollment":330,"conditions":2653,"interventions":2654},[91],[18],[333,334,253,254,255],{"nctId":2622,"briefTitle":2623,"status":127,"phases":2656,"primaryCompletion":2625,"completion":2626,"start":2627,"enrollment":2628,"conditions":2657,"interventions":2658},[91],[27],[226,491,2631],{"nctId":588,"briefTitle":589,"status":110,"phases":2660,"primaryCompletion":41,"completion":591,"start":592,"enrollment":593,"conditions":2661,"interventions":2662},[91],[18],[281,579,596,241,241,491,597],{"nctId":478,"briefTitle":479,"status":140,"phases":2664,"primaryCompletion":481,"completion":482,"start":483,"enrollment":484,"conditions":2665,"interventions":2666},[91],[27,486,487],[489,281,490,491,396,282],{"nctId":906,"briefTitle":907,"status":110,"phases":2668,"primaryCompletion":909,"completion":910,"start":911,"enrollment":912,"conditions":2669,"interventions":2670},[91],[15],[333,751,551,752,253],{"nctId":611,"briefTitle":612,"status":110,"phases":2672,"primaryCompletion":614,"completion":615,"start":616,"enrollment":617,"conditions":2673,"interventions":2674},[91],[18],[281,579,580,241,491,597],{"nctId":69,"briefTitle":70,"status":152,"phases":2676,"primaryCompletion":71,"completion":929,"start":930,"enrollment":931,"conditions":2677,"interventions":2678},[91],[24],[72,934,935,936,937,938,939,940,941,942,751,943,944,945,946,491,947,948,949],{"nctId":2680,"briefTitle":2681,"status":110,"phases":2682,"primaryCompletion":2683,"completion":2684,"start":2685,"enrollment":1591,"conditions":2686,"interventions":2688},"NCT02363751","Study of Gemcitabine+Platinum Salt+Bevacizumab Combination for Metastatic Collecting Duct Carcinoma (GETUG-AFU 24)",[91],"2020-03","2020-08","2014-12",[2687],"Collecting Duct Carcinoma (Kidney)",[491],{"trials":2690,"activeCount":102},[],{"trials":2692,"activeCount":102},[],{"trials":2694,"activeCount":102},[2695],{"nctId":786,"briefTitle":787,"status":110,"phases":2696,"primaryCompletion":405,"completion":71,"start":789,"enrollment":790,"conditions":2697,"interventions":2698},[],[792,15],[491,701],{"intervention":82,"totalTrials":34,"cells":2700},{"EARLY_PHASE1":2701,"PHASE1":2703,"PHASE2":2705,"PHASE3":2768,"PHASE4":2770,"NA":2772},{"trials":2702,"activeCount":102},[],{"trials":2704,"activeCount":102},[],{"trials":2706,"activeCount":397,"soonestReadout":81},[2707,2717,2731,2741,2754],{"nctId":79,"briefTitle":80,"status":152,"phases":2708,"primaryCompletion":81,"completion":2709,"start":2710,"enrollment":2711,"conditions":2712,"interventions":2715},[91],"2027-08","2019-08-26",172,[2713,2714],"ER-positive and HER2-negative Metastatic or Locally Advanced Breast Cancer","a Germline or Somatic BRCA Mutation, or a Deleterious Alteration of Other Genes Involved in Homologous Recombination Repair (HRR) or in MSI Status",[82,940,2716],"Fulvestrant",{"nctId":2718,"briefTitle":2719,"status":110,"phases":2720,"primaryCompletion":2721,"completion":2722,"start":2723,"enrollment":2724,"conditions":2725,"interventions":2727},"NCT02117167","SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC Patients",[91],"2018-12-22","2023-12","2014-04-23",999,[2726],"Non-small Cell Lung Cancer Metastatic",[72,934,935,936,937,938,2728,2729,82,2730,940],"Standard maintenance for squamous NSCLC","Pemetrexed","savolitinib",{"nctId":2732,"briefTitle":2733,"status":152,"phases":2734,"primaryCompletion":2735,"completion":2736,"start":2737,"enrollment":912,"conditions":2738,"interventions":2740},"NCT05617963","Durvalumab Maintenance After Thoracic Chemoradiotherapy in Frail Small Cell Lung Cancer Patients Whose Disease is Limited to the Thorax",[91],"2028-02-24","2030-02-24","2023-03-24",[2739],"Small Cell Lung Carcinoma",[82],{"nctId":2742,"briefTitle":2743,"status":110,"phases":2744,"primaryCompletion":2745,"completion":2746,"start":2747,"enrollment":2748,"conditions":2749,"interventions":2752},"NCT03777813","Association of Radiochemotherapy and Immunotherapy for the Treatment of Unresectable Oesophageal caNcer",[91],"2024-05-24","2024-12-01","2018-12-05",112,[2750,2751],"Esophagus Cancer","Unresectable Malignant Neoplasm",[82,2753],"IMRT 50 Gy + FOLFOX4 simplifIed",{"nctId":2755,"briefTitle":2756,"status":110,"phases":2757,"primaryCompletion":2758,"completion":2759,"start":2760,"enrollment":2761,"conditions":2762,"interventions":2766},"NCT02997995","Durvalumab and Endocrine Therapy in ER+\u002FHer2- Breast Cancer After CD8+ Infiltration Effective Immune-Attractant Exposure",[91],"2019-07-15","2020-08-28","2017-02-15",61,[15,2763,2764,2765],"Estrogen Receptor Positive Tumor","Menopause","Hormone Antagonist",[2767,82],"Immune-attractant",{"trials":2769,"activeCount":102},[],{"trials":2771,"activeCount":102},[],{"trials":2773,"activeCount":102},[],{"intervention":940,"totalTrials":163,"cells":2775},{"EARLY_PHASE1":2776,"PHASE1":2778,"PHASE2":2780,"PHASE3":2794,"PHASE4":2796,"NA":2798},{"trials":2777,"activeCount":102},[],{"trials":2779,"activeCount":102},[],{"trials":2781,"activeCount":397,"soonestReadout":71},[2782,2786,2790],{"nctId":79,"briefTitle":80,"status":152,"phases":2783,"primaryCompletion":81,"completion":2709,"start":2710,"enrollment":2711,"conditions":2784,"interventions":2785},[91],[2713,2714],[82,940,2716],{"nctId":2718,"briefTitle":2719,"status":110,"phases":2787,"primaryCompletion":2721,"completion":2722,"start":2723,"enrollment":2724,"conditions":2788,"interventions":2789},[91],[2726],[72,934,935,936,937,938,2728,2729,82,2730,940],{"nctId":69,"briefTitle":70,"status":152,"phases":2791,"primaryCompletion":71,"completion":929,"start":930,"enrollment":931,"conditions":2792,"interventions":2793},[91],[24],[72,934,935,936,937,938,939,940,941,942,751,943,944,945,946,491,947,948,949],{"trials":2795,"activeCount":102},[],{"trials":2797,"activeCount":102},[],{"trials":2799,"activeCount":102},[],{"intervention":513,"totalTrials":397,"cells":2801},{"EARLY_PHASE1":2802,"PHASE1":2804,"PHASE2":2806,"PHASE3":2816,"PHASE4":2818,"NA":2820},{"trials":2803,"activeCount":102},[],{"trials":2805,"activeCount":102},[],{"trials":2807,"activeCount":397,"soonestReadout":441},[2808,2812],{"nctId":504,"briefTitle":505,"status":152,"phases":2809,"primaryCompletion":441,"completion":507,"start":508,"enrollment":509,"conditions":2810,"interventions":2811},[91],[511],[513,475,396,514,515],{"nctId":384,"briefTitle":385,"status":140,"phases":2813,"primaryCompletion":387,"completion":388,"start":389,"enrollment":16,"conditions":2814,"interventions":2815},[91],[391,392,393],[395,148,396],{"trials":2817,"activeCount":102},[],{"trials":2819,"activeCount":102},[],{"trials":2821,"activeCount":102},[],{"intervention":241,"totalTrials":31,"cells":2823},{"EARLY_PHASE1":2824,"PHASE1":2826,"PHASE2":2828,"PHASE3":2854,"PHASE4":2871,"NA":2873},{"trials":2825,"activeCount":102},[],{"trials":2827,"activeCount":102},[],{"trials":2829,"activeCount":309,"soonestReadout":231},[2830,2842,2846,2850],{"nctId":2831,"briefTitle":2832,"status":375,"phases":2833,"primaryCompletion":2834,"completion":2834,"start":2835,"enrollment":2836,"conditions":2837,"interventions":2840},"NCT03722108","Regorafenib Combined With Irinotecan as Second-line in Patients With Metastatic Gastro-oesophageal Adenocarcinomas",[90,91],"2022-05-19","2019-02-07",89,[2838,2839],"Adenocarcinoma of the Stomach","Adenocarcinoma of the Gastroesophageal Junction",[2841,241],"Regorafenib and Irinotecan",{"nctId":588,"briefTitle":589,"status":110,"phases":2843,"primaryCompletion":41,"completion":591,"start":592,"enrollment":593,"conditions":2844,"interventions":2845},[91],[18],[281,579,596,241,241,491,597],{"nctId":228,"briefTitle":229,"status":140,"phases":2847,"primaryCompletion":231,"completion":232,"start":233,"enrollment":234,"conditions":2848,"interventions":2849},[91],[236,237,238,239],[226,207,241,242],{"nctId":611,"briefTitle":612,"status":110,"phases":2851,"primaryCompletion":614,"completion":615,"start":616,"enrollment":617,"conditions":2852,"interventions":2853},[91],[18],[281,579,580,241,491,597],{"trials":2855,"activeCount":102},[2856,2860],{"nctId":631,"briefTitle":632,"status":110,"phases":2857,"primaryCompletion":634,"completion":635,"start":636,"enrollment":637,"conditions":2858,"interventions":2859},[92],[639,640],[539,579,642,281,241,643],{"nctId":2861,"briefTitle":2862,"status":110,"phases":2863,"primaryCompletion":1275,"completion":2864,"start":2865,"enrollment":2866,"conditions":2867,"interventions":2869},"NCT02967289","IRinotecan and Oxaliplatin for Colon Cancer in Adjuvant Setting",[92],"2025-07-15","2017-03-27",792,[2868],"Colon Cancer (High-risk Stage III: pT4N1 or pT1 to 4 N2)",[241,2870],"Folfox Protocol",{"trials":2872,"activeCount":102},[],{"trials":2874,"activeCount":102},[],{"intervention":490,"totalTrials":163,"cells":2876},{"EARLY_PHASE1":2877,"PHASE1":2879,"PHASE2":2881,"PHASE3":2891,"PHASE4":2897,"NA":2899},{"trials":2878,"activeCount":102},[],{"trials":2880,"activeCount":102},[],{"trials":2882,"activeCount":309,"soonestReadout":481},[2883,2887],{"nctId":568,"briefTitle":569,"status":110,"phases":2884,"primaryCompletion":571,"completion":572,"start":573,"enrollment":574,"conditions":2885,"interventions":2886},[91],[576,577],[281,579,580,581,582],{"nctId":478,"briefTitle":479,"status":140,"phases":2888,"primaryCompletion":481,"completion":482,"start":483,"enrollment":484,"conditions":2889,"interventions":2890},[91],[27,486,487],[489,281,490,491,396,282],{"trials":2892,"activeCount":102},[2893],{"nctId":845,"briefTitle":846,"status":110,"phases":2894,"primaryCompletion":848,"completion":849,"start":706,"enrollment":617,"conditions":2895,"interventions":2896},[92],[851,852],[177,490],{"trials":2898,"activeCount":102},[],{"trials":2900,"activeCount":102},[],{"intervention":939,"totalTrials":397,"cells":2902},{"EARLY_PHASE1":2903,"PHASE1":2905,"PHASE2":2907,"PHASE3":2913,"PHASE4":2919,"NA":2921},{"trials":2904,"activeCount":102},[],{"trials":2906,"activeCount":102},[],{"trials":2908,"activeCount":309,"soonestReadout":71},[2909],{"nctId":69,"briefTitle":70,"status":152,"phases":2910,"primaryCompletion":71,"completion":929,"start":930,"enrollment":931,"conditions":2911,"interventions":2912},[91],[24],[72,934,935,936,937,938,939,940,941,942,751,943,944,945,946,491,947,948,949],{"trials":2914,"activeCount":102},[2915],{"nctId":1560,"briefTitle":1561,"status":110,"phases":2916,"primaryCompletion":1563,"completion":1564,"start":1565,"enrollment":1566,"conditions":2917,"interventions":2918},[92],[21],[1569,1570,551,1571,1572],{"trials":2920,"activeCount":102},[],{"trials":2922,"activeCount":102},[],{"intervention":2716,"totalTrials":397,"cells":2924},{"EARLY_PHASE1":2925,"PHASE1":2927,"PHASE2":2929,"PHASE3":2946,"PHASE4":2948,"NA":2950},{"trials":2926,"activeCount":102},[],{"trials":2928,"activeCount":102},[],{"trials":2930,"activeCount":309,"soonestReadout":81},[2931,2935],{"nctId":79,"briefTitle":80,"status":152,"phases":2932,"primaryCompletion":81,"completion":2709,"start":2710,"enrollment":2711,"conditions":2933,"interventions":2934},[91],[2713,2714],[82,940,2716],{"nctId":2936,"briefTitle":2937,"status":110,"phases":2938,"primaryCompletion":2939,"completion":2940,"start":2941,"enrollment":2942,"conditions":2943,"interventions":2944},"NCT00629616","Efficacy of Anastrozole and Fulvestrant in Patients With ER Positive, HER2 Negative, Operable Breast Cancer",[91],"2015-06","2018-04","2007-10",116,[15],[1057,2945],"fulvestrant",{"trials":2947,"activeCount":102},[],{"trials":2949,"activeCount":102},[],{"trials":2951,"activeCount":102},[],{"intervention":812,"totalTrials":397,"cells":2953},{"EARLY_PHASE1":2954,"PHASE1":2956,"PHASE2":2958,"PHASE3":2974,"PHASE4":2976,"NA":2978},{"trials":2955,"activeCount":102},[],{"trials":2957,"activeCount":102},[],{"trials":2959,"activeCount":309,"soonestReadout":2968},[2960,2964],{"nctId":803,"briefTitle":804,"status":375,"phases":2961,"primaryCompletion":806,"completion":806,"start":807,"enrollment":808,"conditions":2962,"interventions":2963},[91],[810],[812,177],{"nctId":2965,"briefTitle":2966,"status":152,"phases":2967,"primaryCompletion":2968,"completion":1791,"start":2969,"enrollment":574,"conditions":2970,"interventions":2972},"NCT05625087","Detection of Tumor DNA in the Blood of Patients Receiving Standard Therapy for Hormone Receptor-positive (HR+) Non-HER2 Expressing (HER2-) Metastatic Breast Cancer as a Tool to Select Those Who May Benefit From the Next Course of Fulvestrant in Combination With Alpelisib or Ribociclib",[91],"2028-07","2023-10-19",[2971],"Breast Cancer Stage IV",[812,2973],"Ribociclib",{"trials":2975,"activeCount":102},[],{"trials":2977,"activeCount":102},[],{"trials":2979,"activeCount":102},[],{"intervention":823,"totalTrials":397,"cells":2981},{"EARLY_PHASE1":2982,"PHASE1":2984,"PHASE2":2986,"PHASE3":2996,"PHASE4":2998,"NA":3000},{"trials":2983,"activeCount":102},[],{"trials":2985,"activeCount":102},[],{"trials":2987,"activeCount":309,"soonestReadout":71},[2988,2992],{"nctId":814,"briefTitle":815,"status":375,"phases":2989,"primaryCompletion":817,"completion":818,"start":819,"conditions":2990,"interventions":2991},[91],[18,30,683],[822,253,255,823],{"nctId":69,"briefTitle":70,"status":152,"phases":2993,"primaryCompletion":71,"completion":929,"start":930,"enrollment":931,"conditions":2994,"interventions":2995},[91],[24],[72,934,935,936,937,938,939,940,941,942,751,943,944,945,946,491,947,948,949],{"trials":2997,"activeCount":102},[],{"trials":2999,"activeCount":102},[],{"trials":3001,"activeCount":102},[],{"intervention":475,"totalTrials":397,"cells":3003},{"EARLY_PHASE1":3004,"PHASE1":3006,"PHASE2":3008,"PHASE3":3018,"PHASE4":3020,"NA":3022},{"trials":3005,"activeCount":102},[],{"trials":3007,"activeCount":102},[],{"trials":3009,"activeCount":309,"soonestReadout":441},[3010,3014],{"nctId":464,"briefTitle":465,"status":110,"phases":3011,"primaryCompletion":467,"completion":468,"start":469,"enrollment":470,"conditions":3012,"interventions":3013},[91],[15],[473,474,396,475,476],{"nctId":504,"briefTitle":505,"status":152,"phases":3015,"primaryCompletion":441,"completion":507,"start":508,"enrollment":509,"conditions":3016,"interventions":3017},[91],[511],[513,475,396,514,515],{"trials":3019,"activeCount":102},[],{"trials":3021,"activeCount":102},[],{"trials":3023,"activeCount":102},[],{"intervention":72,"totalTrials":397,"cells":3025},{"EARLY_PHASE1":3026,"PHASE1":3028,"PHASE2":3030,"PHASE3":3040,"PHASE4":3042,"NA":3044},{"trials":3027,"activeCount":102},[],{"trials":3029,"activeCount":102},[],{"trials":3031,"activeCount":309,"soonestReadout":71},[3032,3036],{"nctId":2718,"briefTitle":2719,"status":110,"phases":3033,"primaryCompletion":2721,"completion":2722,"start":2723,"enrollment":2724,"conditions":3034,"interventions":3035},[91],[2726],[72,934,935,936,937,938,2728,2729,82,2730,940],{"nctId":69,"briefTitle":70,"status":152,"phases":3037,"primaryCompletion":71,"completion":929,"start":930,"enrollment":931,"conditions":3038,"interventions":3039},[91],[24],[72,934,935,936,937,938,939,940,941,942,751,943,944,945,946,491,947,948,949],{"trials":3041,"activeCount":102},[],{"trials":3043,"activeCount":102},[],{"trials":3045,"activeCount":102},[],{"intervention":934,"totalTrials":397,"cells":3047},{"EARLY_PHASE1":3048,"PHASE1":3050,"PHASE2":3052,"PHASE3":3062,"PHASE4":3064,"NA":3066},{"trials":3049,"activeCount":102},[],{"trials":3051,"activeCount":102},[],{"trials":3053,"activeCount":309,"soonestReadout":71},[3054,3058],{"nctId":2718,"briefTitle":2719,"status":110,"phases":3055,"primaryCompletion":2721,"completion":2722,"start":2723,"enrollment":2724,"conditions":3056,"interventions":3057},[91],[2726],[72,934,935,936,937,938,2728,2729,82,2730,940],{"nctId":69,"briefTitle":70,"status":152,"phases":3059,"primaryCompletion":71,"completion":929,"start":930,"enrollment":931,"conditions":3060,"interventions":3061},[91],[24],[72,934,935,936,937,938,939,940,941,942,751,943,944,945,946,491,947,948,949],{"trials":3063,"activeCount":102},[],{"trials":3065,"activeCount":102},[],{"trials":3067,"activeCount":102},[],{"intervention":935,"totalTrials":397,"cells":3069},{"EARLY_PHASE1":3070,"PHASE1":3072,"PHASE2":3074,"PHASE3":3084,"PHASE4":3086,"NA":3088},{"trials":3071,"activeCount":102},[],{"trials":3073,"activeCount":102},[],{"trials":3075,"activeCount":309,"soonestReadout":71},[3076,3080],{"nctId":2718,"briefTitle":2719,"status":110,"phases":3077,"primaryCompletion":2721,"completion":2722,"start":2723,"enrollment":2724,"conditions":3078,"interventions":3079},[91],[2726],[72,934,935,936,937,938,2728,2729,82,2730,940],{"nctId":69,"briefTitle":70,"status":152,"phases":3081,"primaryCompletion":71,"completion":929,"start":930,"enrollment":931,"conditions":3082,"interventions":3083},[91],[24],[72,934,935,936,937,938,939,940,941,942,751,943,944,945,946,491,947,948,949],{"trials":3085,"activeCount":102},[],{"trials":3087,"activeCount":102},[],{"trials":3089,"activeCount":102},[],{"intervention":936,"totalTrials":397,"cells":3091},{"EARLY_PHASE1":3092,"PHASE1":3094,"PHASE2":3096,"PHASE3":3106,"PHASE4":3108,"NA":3110},{"trials":3093,"activeCount":102},[],{"trials":3095,"activeCount":102},[],{"trials":3097,"activeCount":309,"soonestReadout":71},[3098,3102],{"nctId":2718,"briefTitle":2719,"status":110,"phases":3099,"primaryCompletion":2721,"completion":2722,"start":2723,"enrollment":2724,"conditions":3100,"interventions":3101},[91],[2726],[72,934,935,936,937,938,2728,2729,82,2730,940],{"nctId":69,"briefTitle":70,"status":152,"phases":3103,"primaryCompletion":71,"completion":929,"start":930,"enrollment":931,"conditions":3104,"interventions":3105},[91],[24],[72,934,935,936,937,938,939,940,941,942,751,943,944,945,946,491,947,948,949],{"trials":3107,"activeCount":102},[],{"trials":3109,"activeCount":102},[],{"trials":3111,"activeCount":102},[],{"intervention":937,"totalTrials":397,"cells":3113},{"EARLY_PHASE1":3114,"PHASE1":3116,"PHASE2":3118,"PHASE3":3128,"PHASE4":3130,"NA":3132},{"trials":3115,"activeCount":102},[],{"trials":3117,"activeCount":102},[],{"trials":3119,"activeCount":309,"soonestReadout":71},[3120,3124],{"nctId":2718,"briefTitle":2719,"status":110,"phases":3121,"primaryCompletion":2721,"completion":2722,"start":2723,"enrollment":2724,"conditions":3122,"interventions":3123},[91],[2726],[72,934,935,936,937,938,2728,2729,82,2730,940],{"nctId":69,"briefTitle":70,"status":152,"phases":3125,"primaryCompletion":71,"completion":929,"start":930,"enrollment":931,"conditions":3126,"interventions":3127},[91],[24],[72,934,935,936,937,938,939,940,941,942,751,943,944,945,946,491,947,948,949],{"trials":3129,"activeCount":102},[],{"trials":3131,"activeCount":102},[],{"trials":3133,"activeCount":102},[],{"intervention":938,"totalTrials":397,"cells":3135},{"EARLY_PHASE1":3136,"PHASE1":3138,"PHASE2":3140,"PHASE3":3150,"PHASE4":3152,"NA":3154},{"trials":3137,"activeCount":102},[],{"trials":3139,"activeCount":102},[],{"trials":3141,"activeCount":309,"soonestReadout":71},[3142,3146],{"nctId":2718,"briefTitle":2719,"status":110,"phases":3143,"primaryCompletion":2721,"completion":2722,"start":2723,"enrollment":2724,"conditions":3144,"interventions":3145},[91],[2726],[72,934,935,936,937,938,2728,2729,82,2730,940],{"nctId":69,"briefTitle":70,"status":152,"phases":3147,"primaryCompletion":71,"completion":929,"start":930,"enrollment":931,"conditions":3148,"interventions":3149},[91],[24],[72,934,935,936,937,938,939,940,941,942,751,943,944,945,946,491,947,948,949],{"trials":3151,"activeCount":102},[],{"trials":3153,"activeCount":102},[],{"trials":3155,"activeCount":102},[],{"intervention":3157,"totalTrials":309,"cells":3158},"Anti-aromatase inhibitor",{"EARLY_PHASE1":3159,"PHASE1":3161,"PHASE2":3163,"PHASE3":3175,"PHASE4":3177,"NA":3179},{"trials":3160,"activeCount":102},[],{"trials":3162,"activeCount":102},[],{"trials":3164,"activeCount":309,"soonestReadout":3169},[3165],{"nctId":3166,"briefTitle":3167,"status":140,"phases":3168,"primaryCompletion":3169,"completion":3170,"start":3171,"enrollment":3172,"conditions":3173,"interventions":3174},"NCT05297617","Deescalation of Endocrine Therapy Duration in Women With HR+ HER2- Breast Cancer at Very Low Risk",[91],"2030-11-12","2035-11","2022-10-12",696,[15],[3157],{"trials":3176,"activeCount":102},[],{"trials":3178,"activeCount":102},[],{"trials":3180,"activeCount":102},[],{"intervention":3182,"totalTrials":309,"cells":3183},"Panitumumab, oxaliplatin, folinic acid, 5-fluoruracil",{"EARLY_PHASE1":3184,"PHASE1":3186,"PHASE2":3188,"PHASE3":3199,"PHASE4":3201,"NA":3203},{"trials":3185,"activeCount":102},[],{"trials":3187,"activeCount":102},[],{"trials":3189,"activeCount":309,"soonestReadout":929},[3190],{"nctId":3191,"briefTitle":3192,"status":152,"phases":3193,"primaryCompletion":929,"completion":271,"start":3194,"enrollment":3195,"conditions":3196,"interventions":3197},"NCT02980510","Comparison FOLFIRINOX Panitumumab vs mFOLFOX6 Panitumumab in RAS\u002FB-RAF Wild-type Metastatic Colorectal Cancer Patients",[91],"2016-12",219,[27],[3182,3198],"Panitumumab, oxaliplatin, folinic acid, 5-fluoruracil, irinotecan",{"trials":3200,"activeCount":102},[],{"trials":3202,"activeCount":102},[],{"trials":3204,"activeCount":102},[],{"intervention":3198,"totalTrials":309,"cells":3206},{"EARLY_PHASE1":3207,"PHASE1":3209,"PHASE2":3211,"PHASE3":3217,"PHASE4":3219,"NA":3221},{"trials":3208,"activeCount":102},[],{"trials":3210,"activeCount":102},[],{"trials":3212,"activeCount":309,"soonestReadout":929},[3213],{"nctId":3191,"briefTitle":3192,"status":152,"phases":3214,"primaryCompletion":929,"completion":271,"start":3194,"enrollment":3195,"conditions":3215,"interventions":3216},[91],[27],[3182,3198],{"trials":3218,"activeCount":102},[],{"trials":3220,"activeCount":102},[],{"trials":3222,"activeCount":102},[],{"intervention":3224,"totalTrials":309,"cells":3225},"Discontinuation of the anti-HER2 maintenance therapy",{"EARLY_PHASE1":3226,"PHASE1":3228,"PHASE2":3230,"PHASE3":3243,"PHASE4":3245,"NA":3247},{"trials":3227,"activeCount":102},[],{"trials":3229,"activeCount":102},[],{"trials":3231,"activeCount":309,"soonestReadout":3236},[3232],{"nctId":3233,"briefTitle":3234,"status":140,"phases":3235,"primaryCompletion":3236,"completion":3237,"start":3238,"enrollment":3239,"conditions":3240,"interventions":3242},"NCT06450314","Decreasing Treatment for Metastatic HER2-Positive Breast Cancer With Undectable Cancer Levels in Blood Tests.",[91],"2027-12-15","2029-12-15","2025-01-25",170,[24,3241],"HER2-positive Breast Cancer",[3224],{"trials":3244,"activeCount":102},[],{"trials":3246,"activeCount":102},[],{"trials":3248,"activeCount":102},[],{"intervention":136,"totalTrials":309,"cells":3250},{"EARLY_PHASE1":3251,"PHASE1":3253,"PHASE2":3255,"PHASE3":3261,"PHASE4":3263,"NA":3265},{"trials":3252,"activeCount":102},[],{"trials":3254,"activeCount":102},[],{"trials":3256,"activeCount":309,"soonestReadout":129},[3257],{"nctId":125,"briefTitle":126,"status":127,"phases":3258,"primaryCompletion":129,"completion":130,"start":131,"enrollment":132,"conditions":3259,"interventions":3260},[91],[134],[97,136],{"trials":3262,"activeCount":102},[],{"trials":3264,"activeCount":102},[],{"trials":3266,"activeCount":102},[],{"intervention":3268,"totalTrials":309,"cells":3269},"Pemigatinib",{"EARLY_PHASE1":3270,"PHASE1":3272,"PHASE2":3274,"PHASE3":3286,"PHASE4":3288,"NA":3290},{"trials":3271,"activeCount":102},[],{"trials":3273,"activeCount":102},[],{"trials":3275,"activeCount":309,"soonestReadout":3280},[3276],{"nctId":3277,"briefTitle":3278,"status":140,"phases":3279,"primaryCompletion":3280,"completion":3281,"start":3282,"enrollment":892,"conditions":3283,"interventions":3285},"NCT06653777","Efficacy of Pemigatinib in Patients With Solid Tumors Characterized by an Alteration of the Gene FGFR in Tumor Cells",[91],"2027-06-30","2028-06-30","2025-03-27",[3284],"Solid Tumor, Miscellaneous",[3268],{"trials":3287,"activeCount":102},[],{"trials":3289,"activeCount":102},[],{"trials":3291,"activeCount":102},[],{"intervention":2631,"totalTrials":309,"cells":3293},{"EARLY_PHASE1":3294,"PHASE1":3296,"PHASE2":3298,"PHASE3":3304,"PHASE4":3306,"NA":3308},{"trials":3295,"activeCount":102},[],{"trials":3297,"activeCount":102},[],{"trials":3299,"activeCount":309,"soonestReadout":2625},[3300],{"nctId":2622,"briefTitle":2623,"status":127,"phases":3301,"primaryCompletion":2625,"completion":2626,"start":2627,"enrollment":2628,"conditions":3302,"interventions":3303},[91],[27],[226,491,2631],{"trials":3305,"activeCount":102},[],{"trials":3307,"activeCount":102},[],{"trials":3309,"activeCount":102},[],{"intervention":2973,"totalTrials":309,"cells":3311},{"EARLY_PHASE1":3312,"PHASE1":3314,"PHASE2":3316,"PHASE3":3322,"PHASE4":3324,"NA":3326},{"trials":3313,"activeCount":102},[],{"trials":3315,"activeCount":102},[],{"trials":3317,"activeCount":309,"soonestReadout":2968},[3318],{"nctId":2965,"briefTitle":2966,"status":152,"phases":3319,"primaryCompletion":2968,"completion":1791,"start":2969,"enrollment":574,"conditions":3320,"interventions":3321},[91],[2971],[812,2973],{"trials":3323,"activeCount":102},[],{"trials":3325,"activeCount":102},[],{"trials":3327,"activeCount":102},[],{"intervention":3329,"totalTrials":309,"cells":3330},"Each therapeutic NEOREM sub-protocol will mention the description of intervention",{"EARLY_PHASE1":3331,"PHASE1":3333,"PHASE2":3335,"PHASE3":3348,"PHASE4":3350,"NA":3352},{"trials":3332,"activeCount":102},[],{"trials":3334,"activeCount":102},[],{"trials":3336,"activeCount":309,"soonestReadout":3341},[3337],{"nctId":3338,"briefTitle":3339,"status":140,"phases":3340,"primaryCompletion":3341,"completion":3342,"start":3343,"enrollment":3344,"conditions":3345,"interventions":3347},"NCT07262489","Neo-adjuvant Immunotherapy Master Trial for Localized Cancers",[91],"2029-11","2034-11","2026-01-21",200,[3346],"Localized Cancer",[3329],{"trials":3349,"activeCount":102},[],{"trials":3351,"activeCount":102},[],{"trials":3353,"activeCount":102},[],{"intervention":738,"totalTrials":309,"cells":3355},{"EARLY_PHASE1":3356,"PHASE1":3358,"PHASE2":3360,"PHASE3":3366,"PHASE4":3368,"NA":3370},{"trials":3357,"activeCount":102},[],{"trials":3359,"activeCount":102},[],{"trials":3361,"activeCount":309,"soonestReadout":732},[3362],{"nctId":729,"briefTitle":730,"status":140,"phases":3363,"primaryCompletion":732,"completion":732,"start":733,"enrollment":734,"conditions":3364,"interventions":3365},[91],[736],[738,242],{"trials":3367,"activeCount":102},[],{"trials":3369,"activeCount":102},[],{"trials":3371,"activeCount":102},[],{"intervention":841,"totalTrials":309,"cells":3373},{"EARLY_PHASE1":3374,"PHASE1":3376,"PHASE2":3378,"PHASE3":3384,"PHASE4":3386,"NA":3388},{"trials":3375,"activeCount":102},[],{"trials":3377,"activeCount":102},[],{"trials":3379,"activeCount":309,"soonestReadout":828},[3380],{"nctId":825,"briefTitle":826,"status":140,"phases":3381,"primaryCompletion":828,"completion":829,"start":830,"enrollment":831,"conditions":3382,"interventions":3383},[91],[833,834,835,836,837,838,839,276],[841,177],{"trials":3385,"activeCount":102},[],{"trials":3387,"activeCount":102},[],{"trials":3389,"activeCount":102},[],{"intervention":3391,"totalTrials":309,"cells":3392},"METAREM is a master protocol that encompasses multiple therapeutic sub-protocols, each involving distinct interventions. Accordingly, the description of the intervention will be specified within each",{"EARLY_PHASE1":3393,"PHASE1":3395,"PHASE2":3397,"PHASE3":3408,"PHASE4":3410,"NA":3412},{"trials":3394,"activeCount":102},[],{"trials":3396,"activeCount":102},[],{"trials":3398,"activeCount":309,"soonestReadout":129},[3399],{"nctId":3400,"briefTitle":3401,"status":127,"phases":3402,"primaryCompletion":129,"completion":3403,"start":131,"enrollment":132,"conditions":3404,"interventions":3407},"NCT07431073","Immunotherapy Master Trial for Advanced Cancers",[91],"2034-01",[3405,3406],"Advanced \u002F Metastatic Solid Tumors","Advanced Malignancy",[3391],{"trials":3409,"activeCount":102},[],{"trials":3411,"activeCount":102},[],{"trials":3413,"activeCount":102},[],{"intervention":3415,"totalTrials":309,"cells":3416},"trastuzumab derxutecan",{"EARLY_PHASE1":3417,"PHASE1":3419,"PHASE2":3421,"PHASE3":3435,"PHASE4":3437,"NA":3439},{"trials":3418,"activeCount":102},[],{"trials":3420,"activeCount":102},[],{"trials":3422,"activeCount":309,"soonestReadout":3428},[3423],{"nctId":3424,"briefTitle":3425,"status":3426,"phases":3427,"primaryCompletion":3428,"completion":3429,"start":3430,"enrollment":3431,"conditions":3432,"interventions":3434},"NCT06680596","Detecting Tumor DNA in the Blood of HR+\u002FHER2-low Metastatic Breast Cancer Patients to Find Candidates for T-DXd Therapy","ENROLLING_BY_INVITATION",[91],"2028-08-01","2029-08-01","2025-07-30",80,[3433,2971],"Breast Cancer Metastatic",[3415],{"trials":3436,"activeCount":102},[],{"trials":3438,"activeCount":102},[],{"trials":3440,"activeCount":102},[],{"intervention":489,"totalTrials":309,"cells":3442},{"EARLY_PHASE1":3443,"PHASE1":3445,"PHASE2":3447,"PHASE3":3453,"PHASE4":3455,"NA":3457},{"trials":3444,"activeCount":102},[],{"trials":3446,"activeCount":102},[],{"trials":3448,"activeCount":309,"soonestReadout":481},[3449],{"nctId":478,"briefTitle":479,"status":140,"phases":3450,"primaryCompletion":481,"completion":482,"start":483,"enrollment":484,"conditions":3451,"interventions":3452},[91],[27,486,487],[489,281,490,491,396,282],{"trials":3454,"activeCount":102},[],{"trials":3456,"activeCount":102},[],{"trials":3458,"activeCount":102},[],{"intervention":3460,"totalTrials":309,"cells":3461},"Sacituzumab Govitecan \u002F Trastuzumab Deruxtecan",{"EARLY_PHASE1":3462,"PHASE1":3464,"PHASE2":3466,"PHASE3":3479,"PHASE4":3481,"NA":3483},{"trials":3463,"activeCount":102},[],{"trials":3465,"activeCount":102},[],{"trials":3467,"activeCount":309,"soonestReadout":3472},[3468],{"nctId":3469,"briefTitle":3470,"status":127,"phases":3471,"primaryCompletion":3472,"completion":3472,"start":3473,"enrollment":3474,"conditions":3475,"interventions":3478},"NCT07151586","Testing Two Different Drugs (Sacituzumab-govitecan and Trastuzumab-deruxtecan) Combinations Prescribed in an Alterning Pattern to Patients With Metastatic or Locally Advanced Triple-negative Breast Cancer",[91],"2029-10","2025-10",260,[146,3476,3477],"Neoplasm Metastasis","HER 2 Low-expressing Breast Cancer",[3460],{"trials":3480,"activeCount":102},[],{"trials":3482,"activeCount":102},[],{"trials":3484,"activeCount":102},[],{"intervention":3486,"totalTrials":309,"cells":3487},"Mifamurtide",{"EARLY_PHASE1":3488,"PHASE1":3490,"PHASE2":3492,"PHASE3":3504,"PHASE4":3506,"NA":3508},{"trials":3489,"activeCount":102},[],{"trials":3491,"activeCount":102},[],{"trials":3493,"activeCount":309,"soonestReadout":3498},[3494],{"nctId":3495,"briefTitle":3496,"status":152,"phases":3497,"primaryCompletion":3498,"completion":1849,"start":3499,"enrollment":342,"conditions":3500,"interventions":3502},"NCT03643133","Mifamurtide Combined With Post-operative Chemotherapy for Newly Diagnosed High Risk Osteosarcoma Patients",[91],"2026-09","2018-10-23",[3501],"Osteosarcoma",[3486,3503],"EI or M-API regimen depending on patient age",{"trials":3505,"activeCount":102},[],{"trials":3507,"activeCount":102},[],{"trials":3509,"activeCount":102},[],{"intervention":3503,"totalTrials":309,"cells":3511},{"EARLY_PHASE1":3512,"PHASE1":3514,"PHASE2":3516,"PHASE3":3522,"PHASE4":3524,"NA":3526},{"trials":3513,"activeCount":102},[],{"trials":3515,"activeCount":102},[],{"trials":3517,"activeCount":309,"soonestReadout":3498},[3518],{"nctId":3495,"briefTitle":3496,"status":152,"phases":3519,"primaryCompletion":3498,"completion":1849,"start":3499,"enrollment":342,"conditions":3520,"interventions":3521},[91],[3501],[3486,3503],{"trials":3523,"activeCount":102},[],{"trials":3525,"activeCount":102},[],{"trials":3527,"activeCount":102},[],{"intervention":3529,"totalTrials":309,"cells":3530},"prifetrastat monotherapy for 15 days then combination with fulvestrant",{"EARLY_PHASE1":3531,"PHASE1":3533,"PHASE2":3535,"PHASE3":3549,"PHASE4":3551,"NA":3553},{"trials":3532,"activeCount":102},[],{"trials":3534,"activeCount":102},[],{"trials":3536,"activeCount":309,"soonestReadout":3541},[3537],{"nctId":3538,"briefTitle":3539,"status":127,"phases":3540,"primaryCompletion":3541,"completion":3542,"start":3543,"enrollment":3544,"conditions":3545,"interventions":3547},"NCT07340619","Clinical Trial Evaluating the Biological Activity of a New Drug Identified as Prifetrastat (PF-07248144), Combined With Fulvestrant for the Treatment of Patients With Hormone Receptor Positive (HR+) and HER2 Negative (HER2-) Breast Cancer Extended to Other Organs.",[91],"2028-11-18","2029-11-18","2026-05-18",51,[3546],"Metastatic (Stage IV) Melanoma",[3529,3548],"prifetrastat in combination with fulvestrant",{"trials":3550,"activeCount":102},[],{"trials":3552,"activeCount":102},[],{"trials":3554,"activeCount":102},[],{"intervention":3548,"totalTrials":309,"cells":3556},{"EARLY_PHASE1":3557,"PHASE1":3559,"PHASE2":3561,"PHASE3":3567,"PHASE4":3569,"NA":3571},{"trials":3558,"activeCount":102},[],{"trials":3560,"activeCount":102},[],{"trials":3562,"activeCount":309,"soonestReadout":3541},[3563],{"nctId":3538,"briefTitle":3539,"status":127,"phases":3564,"primaryCompletion":3541,"completion":3542,"start":3543,"enrollment":3544,"conditions":3565,"interventions":3566},[91],[3546],[3529,3548],{"trials":3568,"activeCount":102},[],{"trials":3570,"activeCount":102},[],{"trials":3572,"activeCount":102},[],{"intervention":62,"totalTrials":309,"cells":3574},{"EARLY_PHASE1":3575,"PHASE1":3577,"PHASE2":3579,"PHASE3":3586,"PHASE4":3588,"NA":3590},{"trials":3576,"activeCount":102},[],{"trials":3578,"activeCount":102},[],{"trials":3580,"activeCount":309,"soonestReadout":61},[3581],{"nctId":59,"briefTitle":60,"status":152,"phases":3582,"primaryCompletion":61,"completion":3583,"start":649,"enrollment":831,"conditions":3584,"interventions":3585},[91],"2025-03",[1768],[62],{"trials":3587,"activeCount":102},[],{"trials":3589,"activeCount":102},[],{"trials":3591,"activeCount":102},[],{"intervention":1316,"totalTrials":309,"cells":3593},{"EARLY_PHASE1":3594,"PHASE1":3596,"PHASE2":3598,"PHASE3":3604,"PHASE4":3606,"NA":3608},{"trials":3595,"activeCount":102},[],{"trials":3597,"activeCount":102},[],{"trials":3599,"activeCount":309,"soonestReadout":1309},[3600],{"nctId":1306,"briefTitle":1307,"status":140,"phases":3601,"primaryCompletion":1309,"completion":1310,"start":1311,"enrollment":1312,"conditions":3602,"interventions":3603},[91],[1314],[1028,1316],{"trials":3605,"activeCount":102},[],{"trials":3607,"activeCount":102},[],{"trials":3609,"activeCount":102},[],{"intervention":280,"totalTrials":309,"cells":3611},{"EARLY_PHASE1":3612,"PHASE1":3614,"PHASE2":3616,"PHASE3":3622,"PHASE4":3624,"NA":3626},{"trials":3613,"activeCount":102},[],{"trials":3615,"activeCount":102},[],{"trials":3617,"activeCount":309,"soonestReadout":271},[3618],{"nctId":268,"briefTitle":269,"status":140,"phases":3619,"primaryCompletion":271,"completion":272,"start":273,"enrollment":274,"conditions":3620,"interventions":3621},[91],[276,277,278],[280,281,207,282],{"trials":3623,"activeCount":102},[],{"trials":3625,"activeCount":102},[],{"trials":3627,"activeCount":102},[],{"intervention":941,"totalTrials":309,"cells":3629},{"EARLY_PHASE1":3630,"PHASE1":3632,"PHASE2":3634,"PHASE3":3640,"PHASE4":3642,"NA":3644},{"trials":3631,"activeCount":102},[],{"trials":3633,"activeCount":102},[],{"trials":3635,"activeCount":309,"soonestReadout":71},[3636],{"nctId":69,"briefTitle":70,"status":152,"phases":3637,"primaryCompletion":71,"completion":929,"start":930,"enrollment":931,"conditions":3638,"interventions":3639},[91],[24],[72,934,935,936,937,938,939,940,941,942,751,943,944,945,946,491,947,948,949],{"trials":3641,"activeCount":102},[],{"trials":3643,"activeCount":102},[],{"trials":3645,"activeCount":102},[],{"intervention":942,"totalTrials":309,"cells":3647},{"EARLY_PHASE1":3648,"PHASE1":3650,"PHASE2":3652,"PHASE3":3658,"PHASE4":3660,"NA":3662},{"trials":3649,"activeCount":102},[],{"trials":3651,"activeCount":102},[],{"trials":3653,"activeCount":309,"soonestReadout":71},[3654],{"nctId":69,"briefTitle":70,"status":152,"phases":3655,"primaryCompletion":71,"completion":929,"start":930,"enrollment":931,"conditions":3656,"interventions":3657},[91],[24],[72,934,935,936,937,938,939,940,941,942,751,943,944,945,946,491,947,948,949],{"trials":3659,"activeCount":102},[],{"trials":3661,"activeCount":102},[],{"trials":3663,"activeCount":102},[],{"intervention":943,"totalTrials":309,"cells":3665},{"EARLY_PHASE1":3666,"PHASE1":3668,"PHASE2":3670,"PHASE3":3676,"PHASE4":3678,"NA":3680},{"trials":3667,"activeCount":102},[],{"trials":3669,"activeCount":102},[],{"trials":3671,"activeCount":309,"soonestReadout":71},[3672],{"nctId":69,"briefTitle":70,"status":152,"phases":3673,"primaryCompletion":71,"completion":929,"start":930,"enrollment":931,"conditions":3674,"interventions":3675},[91],[24],[72,934,935,936,937,938,939,940,941,942,751,943,944,945,946,491,947,948,949],{"trials":3677,"activeCount":102},[],{"trials":3679,"activeCount":102},[],{"trials":3681,"activeCount":102},[],{"intervention":945,"totalTrials":309,"cells":3683},{"EARLY_PHASE1":3684,"PHASE1":3686,"PHASE2":3688,"PHASE3":3694,"PHASE4":3696,"NA":3698},{"trials":3685,"activeCount":102},[],{"trials":3687,"activeCount":102},[],{"trials":3689,"activeCount":309,"soonestReadout":71},[3690],{"nctId":69,"briefTitle":70,"status":152,"phases":3691,"primaryCompletion":71,"completion":929,"start":930,"enrollment":931,"conditions":3692,"interventions":3693},[91],[24],[72,934,935,936,937,938,939,940,941,942,751,943,944,945,946,491,947,948,949],{"trials":3695,"activeCount":102},[],{"trials":3697,"activeCount":102},[],{"trials":3699,"activeCount":102},[],{"intervention":946,"totalTrials":309,"cells":3701},{"EARLY_PHASE1":3702,"PHASE1":3704,"PHASE2":3706,"PHASE3":3712,"PHASE4":3714,"NA":3716},{"trials":3703,"activeCount":102},[],{"trials":3705,"activeCount":102},[],{"trials":3707,"activeCount":309,"soonestReadout":71},[3708],{"nctId":69,"briefTitle":70,"status":152,"phases":3709,"primaryCompletion":71,"completion":929,"start":930,"enrollment":931,"conditions":3710,"interventions":3711},[91],[24],[72,934,935,936,937,938,939,940,941,942,751,943,944,945,946,491,947,948,949],{"trials":3713,"activeCount":102},[],{"trials":3715,"activeCount":102},[],{"trials":3717,"activeCount":102},[],{"intervention":948,"totalTrials":309,"cells":3719},{"EARLY_PHASE1":3720,"PHASE1":3722,"PHASE2":3724,"PHASE3":3730,"PHASE4":3732,"NA":3734},{"trials":3721,"activeCount":102},[],{"trials":3723,"activeCount":102},[],{"trials":3725,"activeCount":309,"soonestReadout":71},[3726],{"nctId":69,"briefTitle":70,"status":152,"phases":3727,"primaryCompletion":71,"completion":929,"start":930,"enrollment":931,"conditions":3728,"interventions":3729},[91],[24],[72,934,935,936,937,938,939,940,941,942,751,943,944,945,946,491,947,948,949],{"trials":3731,"activeCount":102},[],{"trials":3733,"activeCount":102},[],{"trials":3735,"activeCount":102},[],{"intervention":949,"totalTrials":309,"cells":3737},{"EARLY_PHASE1":3738,"PHASE1":3740,"PHASE2":3742,"PHASE3":3748,"PHASE4":3750,"NA":3752},{"trials":3739,"activeCount":102},[],{"trials":3741,"activeCount":102},[],{"trials":3743,"activeCount":309,"soonestReadout":71},[3744],{"nctId":69,"briefTitle":70,"status":152,"phases":3745,"primaryCompletion":71,"completion":929,"start":930,"enrollment":931,"conditions":3746,"interventions":3747},[91],[24],[72,934,935,936,937,938,939,940,941,942,751,943,944,945,946,491,947,948,949],{"trials":3749,"activeCount":102},[],{"trials":3751,"activeCount":102},[],{"trials":3753,"activeCount":102},[],{"intervention":3755,"totalTrials":309,"cells":3756},"HPV16 Ct-DNA dosing",{"EARLY_PHASE1":3757,"PHASE1":3759,"PHASE2":3761,"PHASE3":3774,"PHASE4":3776,"NA":3778},{"trials":3758,"activeCount":102},[],{"trials":3760,"activeCount":102},[],{"trials":3762,"activeCount":309,"soonestReadout":3767},[3763],{"nctId":3764,"briefTitle":3765,"status":140,"phases":3766,"primaryCompletion":3767,"completion":3768,"start":3769,"enrollment":3770,"conditions":3771,"interventions":3773},"NCT05582122","SURVEILLE-HPV: Evaluation of HPV16 Circulating DNA as Biomarker to Detect the Recurrence, in Order to Improve Post Therapeutic Surveillance of HPV16-driven Oropharyngeal Cancers",[91],"2028-04-01","2031-04-01","2024-04-03",420,[3772],"Oropharynx Squamous Cell Carcinoma",[3755],{"trials":3775,"activeCount":102},[],{"trials":3777,"activeCount":102},[],{"trials":3779,"activeCount":102},[],{"intervention":2575,"totalTrials":309,"cells":3781},{"EARLY_PHASE1":3782,"PHASE1":3784,"PHASE2":3786,"PHASE3":3792,"PHASE4":3794,"NA":3796},{"trials":3783,"activeCount":102},[],{"trials":3785,"activeCount":102},[],{"trials":3787,"activeCount":309,"soonestReadout":2567},[3788],{"nctId":2564,"briefTitle":2565,"status":140,"phases":3789,"primaryCompletion":2567,"completion":2568,"start":2569,"enrollment":2570,"conditions":3790,"interventions":3791},[91],[2572,2573],[2575,282],{"trials":3793,"activeCount":102},[],{"trials":3795,"activeCount":102},[],{"trials":3797,"activeCount":102},[],{"intervention":294,"totalTrials":309,"cells":3799},{"EARLY_PHASE1":3800,"PHASE1":3802,"PHASE2":3804,"PHASE3":3810,"PHASE4":3812,"NA":3814},{"trials":3801,"activeCount":102},[],{"trials":3803,"activeCount":102},[],{"trials":3805,"activeCount":309,"soonestReadout":287},[3806],{"nctId":284,"briefTitle":285,"status":140,"phases":3807,"primaryCompletion":287,"completion":288,"start":289,"enrollment":290,"conditions":3808,"interventions":3809},[91],[292,18],[207,294],{"trials":3811,"activeCount":102},[],{"trials":3813,"activeCount":102},[],{"trials":3815,"activeCount":102},[],{"intervention":3817,"totalTrials":309,"cells":3818},"Chemotherapy TIP",{"EARLY_PHASE1":3819,"PHASE1":3821,"PHASE2":3823,"PHASE3":3835,"PHASE4":3837,"NA":3839},{"trials":3820,"activeCount":102},[],{"trials":3822,"activeCount":102},[],{"trials":3824,"activeCount":309,"soonestReadout":3498},[3825],{"nctId":3826,"briefTitle":3827,"status":152,"phases":3828,"primaryCompletion":3498,"completion":232,"start":3829,"enrollment":3830,"conditions":3831,"interventions":3834},"NCT02817958","Evaluation of Lymphadenectomy and Chemotherapy TIP on Inguinal Lymph Nodes in Squamous Cell Carcinoma of the Penis",[91],"2016-10-17",37,[3832,3833],"Penile Cancer","Squamous Carcinoma",[3817],{"trials":3836,"activeCount":102},[],{"trials":3838,"activeCount":102},[],{"trials":3840,"activeCount":102},[],{"intervention":514,"totalTrials":309,"cells":3842},{"EARLY_PHASE1":3843,"PHASE1":3845,"PHASE2":3847,"PHASE3":3853,"PHASE4":3855,"NA":3857},{"trials":3844,"activeCount":102},[],{"trials":3846,"activeCount":102},[],{"trials":3848,"activeCount":309,"soonestReadout":441},[3849],{"nctId":504,"briefTitle":505,"status":152,"phases":3850,"primaryCompletion":441,"completion":507,"start":508,"enrollment":509,"conditions":3851,"interventions":3852},[91],[511],[513,475,396,514,515],{"trials":3854,"activeCount":102},[],{"trials":3856,"activeCount":102},[],{"trials":3858,"activeCount":102},[],{"intervention":515,"totalTrials":309,"cells":3860},{"EARLY_PHASE1":3861,"PHASE1":3863,"PHASE2":3865,"PHASE3":3871,"PHASE4":3873,"NA":3875},{"trials":3862,"activeCount":102},[],{"trials":3864,"activeCount":102},[],{"trials":3866,"activeCount":309,"soonestReadout":441},[3867],{"nctId":504,"briefTitle":505,"status":152,"phases":3868,"primaryCompletion":441,"completion":507,"start":508,"enrollment":509,"conditions":3869,"interventions":3870},[91],[511],[513,475,396,514,515],{"trials":3872,"activeCount":102},[],{"trials":3874,"activeCount":102},[],{"trials":3876,"activeCount":102},[],{"intervention":3878,"totalTrials":309,"cells":3879},"Regorafenib",{"EARLY_PHASE1":3880,"PHASE1":3882,"PHASE2":3884,"PHASE3":3901,"PHASE4":3903,"NA":3905},{"trials":3881,"activeCount":102},[],{"trials":3883,"activeCount":102},[],{"trials":3885,"activeCount":309,"soonestReadout":3890},[3886],{"nctId":3887,"briefTitle":3888,"status":152,"phases":3889,"primaryCompletion":3890,"completion":3891,"start":3892,"enrollment":3893,"conditions":3894,"interventions":3900},"NCT02389244","A Phase II Study Evaluating Efficacy and Safety of Regorafenib in Patients With Metastatic Bone Sarcomas",[91],"2024-10-25","2026-03-11","2014-09",163,[3895,3896,3897,3898,3899],"Ewing Sarcomas","Chondrosarcomas","Osteosarcomas","Chondroma","CIC-Rearranged Sarcoma",[3878],{"trials":3902,"activeCount":102},[],{"trials":3904,"activeCount":102},[],{"trials":3906,"activeCount":102},[],{"intervention":47,"totalTrials":309,"cells":3908},{"EARLY_PHASE1":3909,"PHASE1":3911,"PHASE2":3913,"PHASE3":3923,"PHASE4":3925,"NA":3927},{"trials":3910,"activeCount":102},[],{"trials":3912,"activeCount":102},[],{"trials":3914,"activeCount":309,"soonestReadout":46},[3915],{"nctId":44,"briefTitle":45,"status":152,"phases":3916,"primaryCompletion":46,"completion":3917,"start":3918,"enrollment":972,"conditions":3919,"interventions":3922},[91],"2027-10-13","2014-10-13",[1091,3920,3921],"Hematologic Cancers","Metastatic Cancers",[47],{"trials":3924,"activeCount":102},[],{"trials":3926,"activeCount":102},[],{"trials":3928,"activeCount":102},[],{"intervention":87,"totalTrials":397,"cells":3930},{"EARLY_PHASE1":3931,"PHASE1":3933,"PHASE2":3935,"PHASE3":3941,"PHASE4":3943,"NA":3945},{"trials":3932,"activeCount":102},[],{"trials":3934,"activeCount":102},[],{"trials":3936,"activeCount":102},[3937],{"nctId":916,"briefTitle":917,"status":110,"phases":3938,"primaryCompletion":919,"completion":920,"start":469,"enrollment":921,"conditions":3939,"interventions":3940},[91],[923],[925,552,550,926,87],{"trials":3942,"activeCount":102},[],{"trials":3944,"activeCount":102},[],{"trials":3946,"activeCount":309,"soonestReadout":86},[3947],{"nctId":84,"briefTitle":85,"status":152,"phases":3948,"primaryCompletion":86,"completion":3949,"start":3950,"enrollment":3344,"conditions":3951,"interventions":3954},[94],"2027-10-23","2019-10-23",[2971,3952,3953],"Radiotherapy","Surgery",[87],{"intervention":253,"totalTrials":3956,"cells":3957},21,{"EARLY_PHASE1":3958,"PHASE1":3960,"PHASE2":3962,"PHASE3":4004,"PHASE4":4055,"NA":4057},{"trials":3959,"activeCount":102},[],{"trials":3961,"activeCount":102},[],{"trials":3963,"activeCount":102},[3964,3968,3972,3976,3980,3984,3988,3992,3996,4000],{"nctId":324,"briefTitle":325,"status":110,"phases":3965,"primaryCompletion":327,"completion":328,"start":329,"enrollment":330,"conditions":3966,"interventions":3967},[91],[18],[333,334,253,254,255],{"nctId":814,"briefTitle":815,"status":375,"phases":3969,"primaryCompletion":817,"completion":818,"start":819,"conditions":3970,"interventions":3971},[91],[18,30,683],[822,253,255,823],{"nctId":244,"briefTitle":245,"status":110,"phases":3973,"primaryCompletion":247,"completion":248,"start":249,"conditions":3974,"interventions":3975},[91],[18],[252,207,253,254,255,256],{"nctId":1097,"briefTitle":1098,"status":110,"phases":3977,"primaryCompletion":1100,"completion":1101,"start":1102,"enrollment":1103,"conditions":3978,"interventions":3979},[91],[639],[42,551,253],{"nctId":1107,"briefTitle":1108,"status":110,"phases":3981,"primaryCompletion":981,"completion":1110,"start":1111,"conditions":3982,"interventions":3983},[91],[36],[42,253],{"nctId":906,"briefTitle":907,"status":110,"phases":3985,"primaryCompletion":909,"completion":910,"start":911,"enrollment":912,"conditions":3986,"interventions":3987},[91],[15],[333,751,551,752,253],{"nctId":258,"briefTitle":259,"status":110,"phases":3989,"primaryCompletion":261,"completion":262,"start":263,"conditions":3990,"interventions":3991},[91],[18,30],[207,253,266,255,256],{"nctId":1115,"briefTitle":1116,"status":110,"phases":3993,"primaryCompletion":1118,"completion":1119,"start":1120,"enrollment":509,"conditions":3994,"interventions":3995},[91],[1122,1123,1124],[42,253],{"nctId":373,"briefTitle":374,"status":375,"phases":3997,"primaryCompletion":377,"completion":377,"start":378,"enrollment":379,"conditions":3998,"interventions":3999},[91],[18],[382,334,253,255,256],{"nctId":1127,"briefTitle":1128,"status":375,"phases":4001,"primaryCompletion":1130,"completion":1130,"start":1131,"enrollment":878,"conditions":4002,"interventions":4003},[91],[1133],[382,42,253],{"trials":4005,"activeCount":102},[4006,4010,4014,4023,4027,4031,4035,4039,4043,4047,4051],{"nctId":1142,"briefTitle":1143,"status":110,"phases":4007,"primaryCompletion":1145,"completion":1146,"start":1147,"enrollment":1148,"conditions":4008,"interventions":4009},[92],[653,1150],[42,253],{"nctId":977,"briefTitle":978,"status":110,"phases":4011,"primaryCompletion":789,"completion":980,"start":981,"enrollment":982,"conditions":4012,"interventions":4013},[92],[15],[751,752,253],{"nctId":4015,"briefTitle":4016,"status":110,"phases":4017,"primaryCompletion":4018,"completion":4019,"start":4020,"conditions":4021,"interventions":4022},"NCT00005979","Combination Chemotherapy With or Without Irinotecan in Treating Patients With Stage III Colon Cancer",[92],"2005-09-26","2007-09-01","1998-07-22",[18],[252,253,254,255],{"nctId":1007,"briefTitle":1008,"status":110,"phases":4024,"primaryCompletion":1010,"completion":1011,"start":1012,"enrollment":1013,"conditions":4025,"interventions":4026},[92],[15],[751,474,752,253,1016],{"nctId":1157,"briefTitle":1158,"status":110,"phases":4028,"primaryCompletion":1160,"completion":339,"start":1161,"enrollment":1162,"conditions":4029,"interventions":4030},[92],[1133],[42,253],{"nctId":1181,"briefTitle":1182,"status":110,"phases":4032,"primaryCompletion":1184,"completion":573,"start":1185,"enrollment":1186,"conditions":4033,"interventions":4034},[92],[36],[42,253],{"nctId":677,"briefTitle":678,"status":110,"phases":4036,"primaryCompletion":41,"start":680,"enrollment":681,"conditions":4037,"interventions":4038},[92],[18,683],[253,255,256],{"nctId":1050,"briefTitle":1051,"status":375,"phases":4040,"primaryCompletion":1053,"start":1054,"conditions":4041,"interventions":4042},[92],[15],[1057,751,551,752,253,1058,1059],{"nctId":1061,"briefTitle":1062,"status":110,"phases":4044,"primaryCompletion":1064,"completion":1064,"start":1065,"enrollment":443,"conditions":4045,"interventions":4046},[92],[15],[749,751,752,253,753],{"nctId":541,"briefTitle":542,"status":110,"phases":4048,"primaryCompletion":544,"completion":545,"start":546,"enrollment":547,"conditions":4049,"interventions":4050},[92],[15],[396,550,551,552,553],{"nctId":703,"briefTitle":704,"status":110,"phases":4052,"primaryCompletion":706,"completion":707,"start":708,"enrollment":709,"conditions":4053,"interventions":4054},[91,92],[639],[253,671,254,255,256],{"trials":4056,"activeCount":102},[],{"trials":4058,"activeCount":102},[],{"intervention":255,"totalTrials":28,"cells":4060},{"EARLY_PHASE1":4061,"PHASE1":4063,"PHASE2":4065,"PHASE3":4087,"PHASE4":4101,"NA":4103},{"trials":4062,"activeCount":102},[],{"trials":4064,"activeCount":102},[],{"trials":4066,"activeCount":102},[4067,4071,4075,4079,4083],{"nctId":324,"briefTitle":325,"status":110,"phases":4068,"primaryCompletion":327,"completion":328,"start":329,"enrollment":330,"conditions":4069,"interventions":4070},[91],[18],[333,334,253,254,255],{"nctId":814,"briefTitle":815,"status":375,"phases":4072,"primaryCompletion":817,"completion":818,"start":819,"conditions":4073,"interventions":4074},[91],[18,30,683],[822,253,255,823],{"nctId":244,"briefTitle":245,"status":110,"phases":4076,"primaryCompletion":247,"completion":248,"start":249,"conditions":4077,"interventions":4078},[91],[18],[252,207,253,254,255,256],{"nctId":258,"briefTitle":259,"status":110,"phases":4080,"primaryCompletion":261,"completion":262,"start":263,"conditions":4081,"interventions":4082},[91],[18,30],[207,253,266,255,256],{"nctId":373,"briefTitle":374,"status":375,"phases":4084,"primaryCompletion":377,"completion":377,"start":378,"enrollment":379,"conditions":4085,"interventions":4086},[91],[18],[382,334,253,255,256],{"trials":4088,"activeCount":102},[4089,4093,4097],{"nctId":4015,"briefTitle":4016,"status":110,"phases":4090,"primaryCompletion":4018,"completion":4019,"start":4020,"conditions":4091,"interventions":4092},[92],[18],[252,253,254,255],{"nctId":677,"briefTitle":678,"status":110,"phases":4094,"primaryCompletion":41,"start":680,"enrollment":681,"conditions":4095,"interventions":4096},[92],[18,683],[253,255,256],{"nctId":703,"briefTitle":704,"status":110,"phases":4098,"primaryCompletion":706,"completion":707,"start":708,"enrollment":709,"conditions":4099,"interventions":4100},[91,92],[639],[253,671,254,255,256],{"trials":4102,"activeCount":102},[],{"trials":4104,"activeCount":102},[],{"intervention":752,"totalTrials":98,"cells":4106},{"EARLY_PHASE1":4107,"PHASE1":4109,"PHASE2":4111,"PHASE3":4121,"PHASE4":4143,"NA":4145},{"trials":4108,"activeCount":102},[],{"trials":4110,"activeCount":102},[],{"trials":4112,"activeCount":102},[4113,4117],{"nctId":740,"briefTitle":741,"status":375,"phases":4114,"primaryCompletion":743,"completion":743,"start":744,"enrollment":368,"conditions":4115,"interventions":4116},[91],[746,694,747,696],[749,750,751,752,699,700,701,753],{"nctId":906,"briefTitle":907,"status":110,"phases":4118,"primaryCompletion":909,"completion":910,"start":911,"enrollment":912,"conditions":4119,"interventions":4120},[91],[15],[333,751,551,752,253],{"trials":4122,"activeCount":102},[4123,4127,4131,4135,4139],{"nctId":967,"briefTitle":968,"status":110,"phases":4124,"primaryCompletion":970,"completion":546,"start":971,"enrollment":972,"conditions":4125,"interventions":4126},[92],[974],[42,751,752,699],{"nctId":977,"briefTitle":978,"status":110,"phases":4128,"primaryCompletion":789,"completion":980,"start":981,"enrollment":982,"conditions":4129,"interventions":4130},[92],[15],[751,752,253],{"nctId":1007,"briefTitle":1008,"status":110,"phases":4132,"primaryCompletion":1010,"completion":1011,"start":1012,"enrollment":1013,"conditions":4133,"interventions":4134},[92],[15],[751,474,752,253,1016],{"nctId":1050,"briefTitle":1051,"status":375,"phases":4136,"primaryCompletion":1053,"start":1054,"conditions":4137,"interventions":4138},[92],[15],[1057,751,551,752,253,1058,1059],{"nctId":1061,"briefTitle":1062,"status":110,"phases":4140,"primaryCompletion":1064,"completion":1064,"start":1065,"enrollment":443,"conditions":4141,"interventions":4142},[92],[15],[749,751,752,253,753],{"trials":4144,"activeCount":102},[],{"trials":4146,"activeCount":102},[],{"intervention":579,"totalTrials":34,"cells":4148},{"EARLY_PHASE1":4149,"PHASE1":4151,"PHASE2":4153,"PHASE3":4167,"PHASE4":4177,"NA":4179},{"trials":4150,"activeCount":102},[],{"trials":4152,"activeCount":102},[],{"trials":4154,"activeCount":102},[4155,4159,4163],{"nctId":568,"briefTitle":569,"status":110,"phases":4156,"primaryCompletion":571,"completion":572,"start":573,"enrollment":574,"conditions":4157,"interventions":4158},[91],[576,577],[281,579,580,581,582],{"nctId":588,"briefTitle":589,"status":110,"phases":4160,"primaryCompletion":41,"completion":591,"start":592,"enrollment":593,"conditions":4161,"interventions":4162},[91],[18],[281,579,596,241,241,491,597],{"nctId":611,"briefTitle":612,"status":110,"phases":4164,"primaryCompletion":614,"completion":615,"start":616,"enrollment":617,"conditions":4165,"interventions":4166},[91],[18],[281,579,580,241,491,597],{"trials":4168,"activeCount":102},[4169,4173],{"nctId":631,"briefTitle":632,"status":110,"phases":4170,"primaryCompletion":634,"completion":635,"start":636,"enrollment":637,"conditions":4171,"interventions":4172},[92],[639,640],[539,579,642,281,241,643],{"nctId":645,"briefTitle":646,"status":110,"phases":4174,"primaryCompletion":648,"completion":649,"start":650,"enrollment":651,"conditions":4175,"interventions":4176},[91,92],[653],[42,596,256,579],{"trials":4178,"activeCount":102},[],{"trials":4180,"activeCount":102},[],{"intervention":254,"totalTrials":295,"cells":4182},{"EARLY_PHASE1":4183,"PHASE1":4185,"PHASE2":4187,"PHASE3":4197,"PHASE4":4207,"NA":4209},{"trials":4184,"activeCount":102},[],{"trials":4186,"activeCount":102},[],{"trials":4188,"activeCount":102},[4189,4193],{"nctId":324,"briefTitle":325,"status":110,"phases":4190,"primaryCompletion":327,"completion":328,"start":329,"enrollment":330,"conditions":4191,"interventions":4192},[91],[18],[333,334,253,254,255],{"nctId":244,"briefTitle":245,"status":110,"phases":4194,"primaryCompletion":247,"completion":248,"start":249,"conditions":4195,"interventions":4196},[91],[18],[252,207,253,254,255,256],{"trials":4198,"activeCount":102},[4199,4203],{"nctId":4015,"briefTitle":4016,"status":110,"phases":4200,"primaryCompletion":4018,"completion":4019,"start":4020,"conditions":4201,"interventions":4202},[92],[18],[252,253,254,255],{"nctId":703,"briefTitle":704,"status":110,"phases":4204,"primaryCompletion":706,"completion":707,"start":708,"enrollment":709,"conditions":4205,"interventions":4206},[91,92],[639],[253,671,254,255,256],{"trials":4208,"activeCount":102},[],{"trials":4210,"activeCount":102},[],{"intervention":1058,"totalTrials":295,"cells":4212},{"EARLY_PHASE1":4213,"PHASE1":4215,"PHASE2":4217,"PHASE3":4219,"PHASE4":4242,"NA":4244},{"trials":4214,"activeCount":102},[],{"trials":4216,"activeCount":102},[],{"trials":4218,"activeCount":102},[],{"trials":4220,"activeCount":102},[4221,4230,4234,4238],{"nctId":4222,"briefTitle":4223,"status":110,"phases":4224,"primaryCompletion":4225,"start":4226,"enrollment":4227,"conditions":4228,"interventions":4229},"NCT00423475","Radiation Therapy With or Without Goserelin in Treating Patients Who Have Undergone Surgery for Recurrent or Refractory Prostate Cancer",[92],"2015-03","2006-10",743,[21],[1058],{"nctId":1533,"briefTitle":1534,"status":110,"phases":4231,"primaryCompletion":1536,"completion":1537,"start":1538,"enrollment":1539,"conditions":4232,"interventions":4233},[92],[21],[1542,551,1058],{"nctId":1050,"briefTitle":1051,"status":375,"phases":4235,"primaryCompletion":1053,"start":1054,"conditions":4236,"interventions":4237},[92],[15],[1057,751,551,752,253,1058,1059],{"nctId":1560,"briefTitle":1561,"status":110,"phases":4239,"primaryCompletion":1563,"completion":1564,"start":1565,"enrollment":1566,"conditions":4240,"interventions":4241},[92],[21],[1569,1570,551,1571,1572],{"trials":4243,"activeCount":102},[],{"trials":4245,"activeCount":102},[],{"intervention":750,"totalTrials":295,"cells":4247},{"EARLY_PHASE1":4248,"PHASE1":4250,"PHASE2":4252,"PHASE3":4266,"PHASE4":4272,"NA":4274},{"trials":4249,"activeCount":102},[],{"trials":4251,"activeCount":102},[],{"trials":4253,"activeCount":102},[4254,4258,4262],{"nctId":1586,"briefTitle":1587,"status":110,"phases":4255,"primaryCompletion":1589,"completion":1110,"start":1590,"enrollment":1591,"conditions":4256,"interventions":4257},[91],[974],[749,750,699,700],{"nctId":464,"briefTitle":465,"status":110,"phases":4259,"primaryCompletion":467,"completion":468,"start":469,"enrollment":470,"conditions":4260,"interventions":4261},[91],[15],[473,474,396,475,476],{"nctId":740,"briefTitle":741,"status":375,"phases":4263,"primaryCompletion":743,"completion":743,"start":744,"enrollment":368,"conditions":4264,"interventions":4265},[91],[746,694,747,696],[749,750,751,752,699,700,701,753],{"trials":4267,"activeCount":102},[4268],{"nctId":1030,"briefTitle":1031,"status":110,"phases":4269,"primaryCompletion":1033,"completion":1034,"start":1035,"enrollment":1036,"conditions":4270,"interventions":4271},[92],[694,696],[750,42,751,699,700,1039],{"trials":4273,"activeCount":102},[],{"trials":4275,"activeCount":102},[],{"intervention":580,"totalTrials":163,"cells":4277},{"EARLY_PHASE1":4278,"PHASE1":4280,"PHASE2":4282,"PHASE3":4292,"PHASE4":4298,"NA":4300},{"trials":4279,"activeCount":102},[],{"trials":4281,"activeCount":102},[],{"trials":4283,"activeCount":102},[4284,4288],{"nctId":568,"briefTitle":569,"status":110,"phases":4285,"primaryCompletion":571,"completion":572,"start":573,"enrollment":574,"conditions":4286,"interventions":4287},[91],[576,577],[281,579,580,581,582],{"nctId":611,"briefTitle":612,"status":110,"phases":4289,"primaryCompletion":614,"completion":615,"start":616,"enrollment":617,"conditions":4290,"interventions":4291},[91],[18],[281,579,580,241,491,597],{"trials":4293,"activeCount":102},[4294],{"nctId":631,"briefTitle":632,"status":110,"phases":4295,"primaryCompletion":634,"completion":635,"start":636,"enrollment":637,"conditions":4296,"interventions":4297},[92],[639,640],[539,579,642,281,241,643],{"trials":4299,"activeCount":102},[],{"trials":4301,"activeCount":102},[],{"intervention":749,"totalTrials":163,"cells":4303},{"EARLY_PHASE1":4304,"PHASE1":4306,"PHASE2":4308,"PHASE3":4318,"PHASE4":4324,"NA":4326},{"trials":4305,"activeCount":102},[],{"trials":4307,"activeCount":102},[],{"trials":4309,"activeCount":102},[4310,4314],{"nctId":1586,"briefTitle":1587,"status":110,"phases":4311,"primaryCompletion":1589,"completion":1110,"start":1590,"enrollment":1591,"conditions":4312,"interventions":4313},[91],[974],[749,750,699,700],{"nctId":740,"briefTitle":741,"status":375,"phases":4315,"primaryCompletion":743,"completion":743,"start":744,"enrollment":368,"conditions":4316,"interventions":4317},[91],[746,694,747,696],[749,750,751,752,699,700,701,753],{"trials":4319,"activeCount":102},[4320],{"nctId":1061,"briefTitle":1062,"status":110,"phases":4321,"primaryCompletion":1064,"completion":1064,"start":1065,"enrollment":443,"conditions":4322,"interventions":4323},[92],[15],[749,751,752,253,753],{"trials":4325,"activeCount":102},[],{"trials":4327,"activeCount":102},[],{"intervention":671,"totalTrials":163,"cells":4329},{"EARLY_PHASE1":4330,"PHASE1":4332,"PHASE2":4334,"PHASE3":4340,"PHASE4":4350,"NA":4352},{"trials":4331,"activeCount":102},[],{"trials":4333,"activeCount":102},[],{"trials":4335,"activeCount":102},[4336],{"nctId":1492,"briefTitle":1493,"status":110,"phases":4337,"primaryCompletion":1495,"completion":1496,"start":1497,"enrollment":1498,"conditions":4338,"interventions":4339},[91],[33],[551,671],{"trials":4341,"activeCount":102},[4342,4346],{"nctId":660,"briefTitle":661,"status":110,"phases":4343,"primaryCompletion":663,"completion":663,"start":664,"enrollment":665,"conditions":4344,"interventions":4345},[92],[667,668,669],[671,256],{"nctId":703,"briefTitle":704,"status":110,"phases":4347,"primaryCompletion":706,"completion":707,"start":708,"enrollment":709,"conditions":4348,"interventions":4349},[91,92],[639],[253,671,254,255,256],{"trials":4351,"activeCount":102},[],{"trials":4353,"activeCount":102},[],{"intervention":552,"totalTrials":163,"cells":4355},{"EARLY_PHASE1":4356,"PHASE1":4358,"PHASE2":4360,"PHASE3":4366,"PHASE4":4376,"NA":4378},{"trials":4357,"activeCount":102},[],{"trials":4359,"activeCount":102},[],{"trials":4361,"activeCount":102},[4362],{"nctId":916,"briefTitle":917,"status":110,"phases":4363,"primaryCompletion":919,"completion":920,"start":469,"enrollment":921,"conditions":4364,"interventions":4365},[91],[923],[925,552,550,926,87],{"trials":4367,"activeCount":102},[4368,4372],{"nctId":1041,"briefTitle":1042,"status":110,"phases":4369,"primaryCompletion":649,"completion":469,"start":1044,"enrollment":1045,"conditions":4370,"interventions":4371},[92],[1047],[474,550,552],{"nctId":541,"briefTitle":542,"status":110,"phases":4373,"primaryCompletion":544,"completion":545,"start":546,"enrollment":547,"conditions":4374,"interventions":4375},[92],[15],[396,550,551,552,553],{"trials":4377,"activeCount":102},[],{"trials":4379,"activeCount":102},[],{"intervention":425,"totalTrials":397,"cells":4381},{"EARLY_PHASE1":4382,"PHASE1":4384,"PHASE2":4386,"PHASE3":4388,"PHASE4":4398,"NA":4400},{"trials":4383,"activeCount":102},[],{"trials":4385,"activeCount":102},[],{"trials":4387,"activeCount":102},[],{"trials":4389,"activeCount":102},[4390,4394],{"nctId":1710,"briefTitle":1711,"status":110,"phases":4391,"primaryCompletion":1713,"completion":1714,"start":1715,"enrollment":1716,"conditions":4392,"interventions":4393},[92],[1718],[425,539],{"nctId":416,"briefTitle":417,"status":110,"phases":4395,"primaryCompletion":419,"completion":419,"start":420,"enrollment":421,"conditions":4396,"interventions":4397},[92],[423],[425,148,426],{"trials":4399,"activeCount":102},[],{"trials":4401,"activeCount":102},[],{"intervention":1002,"totalTrials":397,"cells":4403},{"EARLY_PHASE1":4404,"PHASE1":4406,"PHASE2":4408,"PHASE3":4410,"PHASE4":4420,"NA":4422},{"trials":4405,"activeCount":102},[],{"trials":4407,"activeCount":102},[],{"trials":4409,"activeCount":102},[],{"trials":4411,"activeCount":102},[4412,4416],{"nctId":986,"briefTitle":987,"status":110,"phases":4413,"primaryCompletion":989,"completion":990,"start":991,"enrollment":992,"conditions":4414,"interventions":4415},[92],[994],[996,751,997,998,999,699,1000,1001,1002,1003,1004,1005],{"nctId":1685,"briefTitle":1686,"status":375,"phases":4417,"primaryCompletion":1688,"completion":1688,"start":1185,"enrollment":1186,"conditions":4418,"interventions":4419},[92],[21],[900,1002],{"trials":4421,"activeCount":102},[],{"trials":4423,"activeCount":102},[],{"intervention":252,"totalTrials":397,"cells":4425},{"EARLY_PHASE1":4426,"PHASE1":4428,"PHASE2":4430,"PHASE3":4436,"PHASE4":4442,"NA":4444},{"trials":4427,"activeCount":102},[],{"trials":4429,"activeCount":102},[],{"trials":4431,"activeCount":102},[4432],{"nctId":244,"briefTitle":245,"status":110,"phases":4433,"primaryCompletion":247,"completion":248,"start":249,"conditions":4434,"interventions":4435},[91],[18],[252,207,253,254,255,256],{"trials":4437,"activeCount":102},[4438],{"nctId":4015,"briefTitle":4016,"status":110,"phases":4439,"primaryCompletion":4018,"completion":4019,"start":4020,"conditions":4440,"interventions":4441},[92],[18],[252,253,254,255],{"trials":4443,"activeCount":102},[],{"trials":4445,"activeCount":102},[],{"intervention":596,"totalTrials":397,"cells":4447},{"EARLY_PHASE1":4448,"PHASE1":4450,"PHASE2":4452,"PHASE3":4458,"PHASE4":4464,"NA":4466},{"trials":4449,"activeCount":102},[],{"trials":4451,"activeCount":102},[],{"trials":4453,"activeCount":102},[4454],{"nctId":588,"briefTitle":589,"status":110,"phases":4455,"primaryCompletion":41,"completion":591,"start":592,"enrollment":593,"conditions":4456,"interventions":4457},[91],[18],[281,579,596,241,241,491,597],{"trials":4459,"activeCount":102},[4460],{"nctId":645,"briefTitle":646,"status":110,"phases":4461,"primaryCompletion":648,"completion":649,"start":650,"enrollment":651,"conditions":4462,"interventions":4463},[91,92],[653],[42,596,256,579],{"trials":4465,"activeCount":102},[],{"trials":4467,"activeCount":102},[],{"intervention":1057,"totalTrials":397,"cells":4469},{"EARLY_PHASE1":4470,"PHASE1":4472,"PHASE2":4474,"PHASE3":4480,"PHASE4":4486,"NA":4488},{"trials":4471,"activeCount":102},[],{"trials":4473,"activeCount":102},[],{"trials":4475,"activeCount":102},[4476],{"nctId":2936,"briefTitle":2937,"status":110,"phases":4477,"primaryCompletion":2939,"completion":2940,"start":2941,"enrollment":2942,"conditions":4478,"interventions":4479},[91],[15],[1057,2945],{"trials":4481,"activeCount":102},[4482],{"nctId":1050,"briefTitle":1051,"status":375,"phases":4483,"primaryCompletion":1053,"start":1054,"conditions":4484,"interventions":4485},[92],[15],[1057,751,551,752,253,1058,1059],{"trials":4487,"activeCount":102},[],{"trials":4489,"activeCount":102},[],{"intervention":753,"totalTrials":397,"cells":4491},{"EARLY_PHASE1":4492,"PHASE1":4494,"PHASE2":4496,"PHASE3":4502,"PHASE4":4508,"NA":4510},{"trials":4493,"activeCount":102},[],{"trials":4495,"activeCount":102},[],{"trials":4497,"activeCount":102},[4498],{"nctId":740,"briefTitle":741,"status":375,"phases":4499,"primaryCompletion":743,"completion":743,"start":744,"enrollment":368,"conditions":4500,"interventions":4501},[91],[746,694,747,696],[749,750,751,752,699,700,701,753],{"trials":4503,"activeCount":102},[4504],{"nctId":1061,"briefTitle":1062,"status":110,"phases":4505,"primaryCompletion":1064,"completion":1064,"start":1065,"enrollment":443,"conditions":4506,"interventions":4507},[92],[15],[749,751,752,253,753],{"trials":4509,"activeCount":102},[],{"trials":4511,"activeCount":102},[],{"intervention":4513,"totalTrials":397,"cells":4514},"triptorelin",{"EARLY_PHASE1":4515,"PHASE1":4517,"PHASE2":4519,"PHASE3":4521,"PHASE4":4543,"NA":4545},{"trials":4516,"activeCount":102},[],{"trials":4518,"activeCount":102},[],{"trials":4520,"activeCount":102},[],{"trials":4522,"activeCount":102},[4523,4533],{"nctId":4524,"briefTitle":4525,"status":110,"phases":4526,"primaryCompletion":4527,"completion":4528,"start":4529,"enrollment":4530,"conditions":4531,"interventions":4532},"NCT00667069","Triptorelin and Radiation Therapy in Treating Patients Who Have Undergone Surgery for Intermediate-Risk Stage III or Stage IV Prostate Cancer",[92],"2020-04","2022-05-24","2008-04-07",424,[21],[4513],{"nctId":4534,"briefTitle":4535,"status":110,"phases":4536,"primaryCompletion":614,"completion":4537,"start":4538,"enrollment":4539,"conditions":4540,"interventions":4541},"NCT00104741","Triptorelin, Flutamide, and External-Beam Radiation Therapy or External-Beam Radiation Therapy Alone in Treating Patients With Stage II or Stage III Prostate Cancer",[92],"2015-10-15","2003-09-10",378,[21],[4542,4513],"flutamide",{"trials":4544,"activeCount":102},[],{"trials":4546,"activeCount":102},[],{"intervention":926,"totalTrials":397,"cells":4548},{"EARLY_PHASE1":4549,"PHASE1":4551,"PHASE2":4553,"PHASE3":4559,"PHASE4":4573,"NA":4575},{"trials":4550,"activeCount":102},[],{"trials":4552,"activeCount":102},[],{"trials":4554,"activeCount":102},[4555],{"nctId":916,"briefTitle":917,"status":110,"phases":4556,"primaryCompletion":919,"completion":920,"start":469,"enrollment":921,"conditions":4557,"interventions":4558},[91],[923],[925,552,550,926,87],{"trials":4560,"activeCount":102},[4561],{"nctId":4562,"briefTitle":4563,"status":110,"phases":4564,"primaryCompletion":4565,"completion":2722,"start":4566,"enrollment":3239,"conditions":4567,"interventions":4571},"NCT00673335","Letrozole in Preventing Breast Cancer in Postmenopausal Women With a BRCA1 or BRCA2 Mutation",[92],"2019-06","2008-05",[4568,4569,15,4570],"brca1 Mutation Carrier","brca2 Mutation Carrier","Hereditary Breast\u002FOvarian Cancer (brca1, brca2)",[4572],"letrozole",{"trials":4574,"activeCount":102},[],{"trials":4576,"activeCount":102},[],{"intervention":4578,"totalTrials":309,"cells":4579},"Palbociclib 125mg",{"EARLY_PHASE1":4580,"PHASE1":4582,"PHASE2":4584,"PHASE3":4586,"PHASE4":4600,"NA":4602},{"trials":4581,"activeCount":102},[],{"trials":4583,"activeCount":102},[],{"trials":4585,"activeCount":102},[],{"trials":4587,"activeCount":102},[4588],{"nctId":4589,"briefTitle":4590,"status":110,"phases":4591,"primaryCompletion":4592,"completion":4593,"start":4594,"enrollment":4595,"conditions":4596,"interventions":4597},"NCT03079011","PAlbociclib and Circulating Tumor DNA for ESR1 Mutation Detection",[92],"2021-04-30","2025-09-22","2017-03-22",1017,[24],[4578,4598,4599],"Aromatase Inhibitors","Fulvestrant Injectable Product",{"trials":4601,"activeCount":102},[],{"trials":4603,"activeCount":102},[],{"intervention":4598,"totalTrials":309,"cells":4605},{"EARLY_PHASE1":4606,"PHASE1":4608,"PHASE2":4610,"PHASE3":4612,"PHASE4":4618,"NA":4620},{"trials":4607,"activeCount":102},[],{"trials":4609,"activeCount":102},[],{"trials":4611,"activeCount":102},[],{"trials":4613,"activeCount":102},[4614],{"nctId":4589,"briefTitle":4590,"status":110,"phases":4615,"primaryCompletion":4592,"completion":4593,"start":4594,"enrollment":4595,"conditions":4616,"interventions":4617},[92],[24],[4578,4598,4599],{"trials":4619,"activeCount":102},[],{"trials":4621,"activeCount":102},[],{"intervention":4599,"totalTrials":309,"cells":4623},{"EARLY_PHASE1":4624,"PHASE1":4626,"PHASE2":4628,"PHASE3":4630,"PHASE4":4636,"NA":4638},{"trials":4625,"activeCount":102},[],{"trials":4627,"activeCount":102},[],{"trials":4629,"activeCount":102},[],{"trials":4631,"activeCount":102},[4632],{"nctId":4589,"briefTitle":4590,"status":110,"phases":4633,"primaryCompletion":4592,"completion":4593,"start":4594,"enrollment":4595,"conditions":4634,"interventions":4635},[92],[24],[4578,4598,4599],{"trials":4637,"activeCount":102},[],{"trials":4639,"activeCount":102},[],{"intervention":996,"totalTrials":309,"cells":4641},{"EARLY_PHASE1":4642,"PHASE1":4644,"PHASE2":4646,"PHASE3":4648,"PHASE4":4654,"NA":4656},{"trials":4643,"activeCount":102},[],{"trials":4645,"activeCount":102},[],{"trials":4647,"activeCount":102},[],{"trials":4649,"activeCount":102},[4650],{"nctId":986,"briefTitle":987,"status":110,"phases":4651,"primaryCompletion":989,"completion":990,"start":991,"enrollment":992,"conditions":4652,"interventions":4653},[92],[994],[996,751,997,998,999,699,1000,1001,1002,1003,1004,1005],{"trials":4655,"activeCount":102},[],{"trials":4657,"activeCount":102},[],{"intervention":997,"totalTrials":309,"cells":4659},{"EARLY_PHASE1":4660,"PHASE1":4662,"PHASE2":4664,"PHASE3":4666,"PHASE4":4672,"NA":4674},{"trials":4661,"activeCount":102},[],{"trials":4663,"activeCount":102},[],{"trials":4665,"activeCount":102},[],{"trials":4667,"activeCount":102},[4668],{"nctId":986,"briefTitle":987,"status":110,"phases":4669,"primaryCompletion":989,"completion":990,"start":991,"enrollment":992,"conditions":4670,"interventions":4671},[92],[994],[996,751,997,998,999,699,1000,1001,1002,1003,1004,1005],{"trials":4673,"activeCount":102},[],{"trials":4675,"activeCount":102},[],{"intervention":998,"totalTrials":309,"cells":4677},{"EARLY_PHASE1":4678,"PHASE1":4680,"PHASE2":4682,"PHASE3":4684,"PHASE4":4690,"NA":4692},{"trials":4679,"activeCount":102},[],{"trials":4681,"activeCount":102},[],{"trials":4683,"activeCount":102},[],{"trials":4685,"activeCount":102},[4686],{"nctId":986,"briefTitle":987,"status":110,"phases":4687,"primaryCompletion":989,"completion":990,"start":991,"enrollment":992,"conditions":4688,"interventions":4689},[92],[994],[996,751,997,998,999,699,1000,1001,1002,1003,1004,1005],{"trials":4691,"activeCount":102},[],{"trials":4693,"activeCount":102},[],{"intervention":999,"totalTrials":309,"cells":4695},{"EARLY_PHASE1":4696,"PHASE1":4698,"PHASE2":4700,"PHASE3":4702,"PHASE4":4708,"NA":4710},{"trials":4697,"activeCount":102},[],{"trials":4699,"activeCount":102},[],{"trials":4701,"activeCount":102},[],{"trials":4703,"activeCount":102},[4704],{"nctId":986,"briefTitle":987,"status":110,"phases":4705,"primaryCompletion":989,"completion":990,"start":991,"enrollment":992,"conditions":4706,"interventions":4707},[92],[994],[996,751,997,998,999,699,1000,1001,1002,1003,1004,1005],{"trials":4709,"activeCount":102},[],{"trials":4711,"activeCount":102},[],{"intervention":1000,"totalTrials":309,"cells":4713},{"EARLY_PHASE1":4714,"PHASE1":4716,"PHASE2":4718,"PHASE3":4720,"PHASE4":4726,"NA":4728},{"trials":4715,"activeCount":102},[],{"trials":4717,"activeCount":102},[],{"trials":4719,"activeCount":102},[],{"trials":4721,"activeCount":102},[4722],{"nctId":986,"briefTitle":987,"status":110,"phases":4723,"primaryCompletion":989,"completion":990,"start":991,"enrollment":992,"conditions":4724,"interventions":4725},[92],[994],[996,751,997,998,999,699,1000,1001,1002,1003,1004,1005],{"trials":4727,"activeCount":102},[],{"trials":4729,"activeCount":102},[],{"intervention":1003,"totalTrials":309,"cells":4731},{"EARLY_PHASE1":4732,"PHASE1":4734,"PHASE2":4736,"PHASE3":4738,"PHASE4":4744,"NA":4746},{"trials":4733,"activeCount":102},[],{"trials":4735,"activeCount":102},[],{"trials":4737,"activeCount":102},[],{"trials":4739,"activeCount":102},[4740],{"nctId":986,"briefTitle":987,"status":110,"phases":4741,"primaryCompletion":989,"completion":990,"start":991,"enrollment":992,"conditions":4742,"interventions":4743},[92],[994],[996,751,997,998,999,699,1000,1001,1002,1003,1004,1005],{"trials":4745,"activeCount":102},[],{"trials":4747,"activeCount":102},[],{"intervention":1004,"totalTrials":309,"cells":4749},{"EARLY_PHASE1":4750,"PHASE1":4752,"PHASE2":4754,"PHASE3":4756,"PHASE4":4762,"NA":4764},{"trials":4751,"activeCount":102},[],{"trials":4753,"activeCount":102},[],{"trials":4755,"activeCount":102},[],{"trials":4757,"activeCount":102},[4758],{"nctId":986,"briefTitle":987,"status":110,"phases":4759,"primaryCompletion":989,"completion":990,"start":991,"enrollment":992,"conditions":4760,"interventions":4761},[92],[994],[996,751,997,998,999,699,1000,1001,1002,1003,1004,1005],{"trials":4763,"activeCount":102},[],{"trials":4765,"activeCount":102},[],{"intervention":1005,"totalTrials":309,"cells":4767},{"EARLY_PHASE1":4768,"PHASE1":4770,"PHASE2":4772,"PHASE3":4774,"PHASE4":4780,"NA":4782},{"trials":4769,"activeCount":102},[],{"trials":4771,"activeCount":102},[],{"trials":4773,"activeCount":102},[],{"trials":4775,"activeCount":102},[4776],{"nctId":986,"briefTitle":987,"status":110,"phases":4777,"primaryCompletion":989,"completion":990,"start":991,"enrollment":992,"conditions":4778,"interventions":4779},[92],[994],[996,751,997,998,999,699,1000,1001,1002,1003,1004,1005],{"trials":4781,"activeCount":102},[],{"trials":4783,"activeCount":102},[],{"intervention":643,"totalTrials":309,"cells":4785},{"EARLY_PHASE1":4786,"PHASE1":4788,"PHASE2":4790,"PHASE3":4792,"PHASE4":4798,"NA":4800},{"trials":4787,"activeCount":102},[],{"trials":4789,"activeCount":102},[],{"trials":4791,"activeCount":102},[],{"trials":4793,"activeCount":102},[4794],{"nctId":631,"briefTitle":632,"status":110,"phases":4795,"primaryCompletion":634,"completion":635,"start":636,"enrollment":637,"conditions":4796,"interventions":4797},[92],[639,640],[539,579,642,281,241,643],{"trials":4799,"activeCount":102},[],{"trials":4801,"activeCount":102},[],{"intervention":1016,"totalTrials":309,"cells":4803},{"EARLY_PHASE1":4804,"PHASE1":4806,"PHASE2":4808,"PHASE3":4810,"PHASE4":4816,"NA":4818},{"trials":4805,"activeCount":102},[],{"trials":4807,"activeCount":102},[],{"trials":4809,"activeCount":102},[],{"trials":4811,"activeCount":102},[4812],{"nctId":1007,"briefTitle":1008,"status":110,"phases":4813,"primaryCompletion":1010,"completion":1011,"start":1012,"enrollment":1013,"conditions":4814,"interventions":4815},[92],[15],[751,474,752,253,1016],{"trials":4817,"activeCount":102},[],{"trials":4819,"activeCount":102},[],{"intervention":426,"totalTrials":309,"cells":4821},{"EARLY_PHASE1":4822,"PHASE1":4824,"PHASE2":4826,"PHASE3":4828,"PHASE4":4834,"NA":4836},{"trials":4823,"activeCount":102},[],{"trials":4825,"activeCount":102},[],{"trials":4827,"activeCount":102},[],{"trials":4829,"activeCount":102},[4830],{"nctId":416,"briefTitle":417,"status":110,"phases":4831,"primaryCompletion":419,"completion":419,"start":420,"enrollment":421,"conditions":4832,"interventions":4833},[92],[423],[425,148,426],{"trials":4835,"activeCount":102},[],{"trials":4837,"activeCount":102},[],{"intervention":2870,"totalTrials":309,"cells":4839},{"EARLY_PHASE1":4840,"PHASE1":4842,"PHASE2":4844,"PHASE3":4846,"PHASE4":4852,"NA":4854},{"trials":4841,"activeCount":102},[],{"trials":4843,"activeCount":102},[],{"trials":4845,"activeCount":102},[],{"trials":4847,"activeCount":102},[4848],{"nctId":2861,"briefTitle":2862,"status":110,"phases":4849,"primaryCompletion":1275,"completion":2864,"start":2865,"enrollment":2866,"conditions":4850,"interventions":4851},[92],[2868],[241,2870],{"trials":4853,"activeCount":102},[],{"trials":4855,"activeCount":102},[],{"intervention":1039,"totalTrials":309,"cells":4857},{"EARLY_PHASE1":4858,"PHASE1":4860,"PHASE2":4862,"PHASE3":4864,"PHASE4":4870,"NA":4872},{"trials":4859,"activeCount":102},[],{"trials":4861,"activeCount":102},[],{"trials":4863,"activeCount":102},[],{"trials":4865,"activeCount":102},[4866],{"nctId":1030,"briefTitle":1031,"status":110,"phases":4867,"primaryCompletion":1033,"completion":1034,"start":1035,"enrollment":1036,"conditions":4868,"interventions":4869},[92],[694,696],[750,42,751,699,700,1039],{"trials":4871,"activeCount":102},[],{"trials":4873,"activeCount":102},[],{"intervention":1542,"totalTrials":309,"cells":4875},{"EARLY_PHASE1":4876,"PHASE1":4878,"PHASE2":4880,"PHASE3":4882,"PHASE4":4888,"NA":4890},{"trials":4877,"activeCount":102},[],{"trials":4879,"activeCount":102},[],{"trials":4881,"activeCount":102},[],{"trials":4883,"activeCount":102},[4884],{"nctId":1533,"briefTitle":1534,"status":110,"phases":4885,"primaryCompletion":1536,"completion":1537,"start":1538,"enrollment":1539,"conditions":4886,"interventions":4887},[92],[21],[1542,551,1058],{"trials":4889,"activeCount":102},[],{"trials":4891,"activeCount":102},[],{"intervention":1059,"totalTrials":309,"cells":4893},{"EARLY_PHASE1":4894,"PHASE1":4896,"PHASE2":4898,"PHASE3":4900,"PHASE4":4906,"NA":4908},{"trials":4895,"activeCount":102},[],{"trials":4897,"activeCount":102},[],{"trials":4899,"activeCount":102},[],{"trials":4901,"activeCount":102},[4902],{"nctId":1050,"briefTitle":1051,"status":375,"phases":4903,"primaryCompletion":1053,"start":1054,"conditions":4904,"interventions":4905},[92],[15],[1057,751,551,752,253,1058,1059],{"trials":4907,"activeCount":102},[],{"trials":4909,"activeCount":102},[],{"intervention":4542,"totalTrials":309,"cells":4911},{"EARLY_PHASE1":4912,"PHASE1":4914,"PHASE2":4916,"PHASE3":4918,"PHASE4":4924,"NA":4926},{"trials":4913,"activeCount":102},[],{"trials":4915,"activeCount":102},[],{"trials":4917,"activeCount":102},[],{"trials":4919,"activeCount":102},[4920],{"nctId":4534,"briefTitle":4535,"status":110,"phases":4921,"primaryCompletion":614,"completion":4537,"start":4538,"enrollment":4539,"conditions":4922,"interventions":4923},[92],[21],[4542,4513],{"trials":4925,"activeCount":102},[],{"trials":4927,"activeCount":102},[],{"intervention":698,"totalTrials":309,"cells":4929},{"EARLY_PHASE1":4930,"PHASE1":4932,"PHASE2":4934,"PHASE3":4936,"PHASE4":4942,"NA":4944},{"trials":4931,"activeCount":102},[],{"trials":4933,"activeCount":102},[],{"trials":4935,"activeCount":102},[],{"trials":4937,"activeCount":102},[4938],{"nctId":686,"briefTitle":687,"status":110,"phases":4939,"primaryCompletion":689,"completion":690,"start":691,"enrollment":692,"conditions":4940,"interventions":4941},[92],[694,695,696],[698,42,699,700,256,701],{"trials":4943,"activeCount":102},[],{"trials":4945,"activeCount":102},[],{"intervention":1571,"totalTrials":309,"cells":4947},{"EARLY_PHASE1":4948,"PHASE1":4950,"PHASE2":4952,"PHASE3":4954,"PHASE4":4960,"NA":4962},{"trials":4949,"activeCount":102},[],{"trials":4951,"activeCount":102},[],{"trials":4953,"activeCount":102},[],{"trials":4955,"activeCount":102},[4956],{"nctId":1560,"briefTitle":1561,"status":110,"phases":4957,"primaryCompletion":1563,"completion":1564,"start":1565,"enrollment":1566,"conditions":4958,"interventions":4959},[92],[21],[1569,1570,551,1571,1572],{"trials":4961,"activeCount":102},[],{"trials":4963,"activeCount":102},[],{"intervention":1572,"totalTrials":309,"cells":4965},{"EARLY_PHASE1":4966,"PHASE1":4968,"PHASE2":4970,"PHASE3":4972,"PHASE4":4978,"NA":4980},{"trials":4967,"activeCount":102},[],{"trials":4969,"activeCount":102},[],{"trials":4971,"activeCount":102},[],{"trials":4973,"activeCount":102},[4974],{"nctId":1560,"briefTitle":1561,"status":110,"phases":4975,"primaryCompletion":1563,"completion":1564,"start":1565,"enrollment":1566,"conditions":4976,"interventions":4977},[92],[21],[1569,1570,551,1571,1572],{"trials":4979,"activeCount":102},[],{"trials":4981,"activeCount":102},[],{"intervention":597,"totalTrials":98,"cells":4983},{"EARLY_PHASE1":4984,"PHASE1":4986,"PHASE2":4988,"PHASE3":5038,"PHASE4":5040,"NA":5042},{"trials":4985,"activeCount":102},[],{"trials":4987,"activeCount":102},[],{"trials":4989,"activeCount":102},[4990,5000,5011,5015,5026,5030,5034],{"nctId":4991,"briefTitle":4992,"status":375,"phases":4993,"primaryCompletion":4994,"completion":4994,"start":663,"enrollment":4995,"conditions":4996,"interventions":4998},"NCT02822482","Copanlisib in Association With Cetuximab in Patients With Recurrent and\u002For Metastatic Head and Neck Squamous Cell Carcinomas Harboring a PI3KCA Mutation\u002FAmplification and\u002For a PTEN Loss",[90,91],"2019-10-09",11,[4997],"Carcinoma, Squamous Cell of Head and Neck",[4999,597],"Copanlisib",{"nctId":5001,"briefTitle":5002,"status":110,"phases":5003,"primaryCompletion":5004,"completion":5005,"start":5006,"enrollment":5007,"conditions":5008,"interventions":5009},"NCT02404935","Treatment After Irinotecan-based Frontline Therapy: Maintenance With Erbitux (in Patients wtRAS mCRC)",[91],"2020-11-01","2021-10-25","2013-11-22",139,[27],[597,5010],"FOLFIRI and cetuximab",{"nctId":588,"briefTitle":589,"status":110,"phases":5012,"primaryCompletion":41,"completion":591,"start":592,"enrollment":593,"conditions":5013,"interventions":5014},[91],[18],[281,579,596,241,241,491,597],{"nctId":5016,"briefTitle":5017,"status":110,"phases":5018,"primaryCompletion":5019,"completion":5020,"start":5021,"enrollment":5022,"conditions":5023,"interventions":5024},"NCT01919879","Dual Targeting of EGFR With Cetuximab and Afatinib to Treat Refractory wtKRAS Metastatic Colorectal Cancer",[91],"2015-11","2017-12","2012-10",75,[27],[5025,597],"Cetuximab + Afatinib",{"nctId":611,"briefTitle":612,"status":110,"phases":5027,"primaryCompletion":614,"completion":615,"start":616,"enrollment":617,"conditions":5028,"interventions":5029},[91],[18],[281,579,580,241,491,597],{"nctId":373,"briefTitle":374,"status":375,"phases":5031,"primaryCompletion":377,"completion":377,"start":378,"enrollment":379,"conditions":5032,"interventions":5033},[91],[18],[382,334,253,255,256],{"nctId":1127,"briefTitle":1128,"status":375,"phases":5035,"primaryCompletion":1130,"completion":1130,"start":1131,"enrollment":878,"conditions":5036,"interventions":5037},[91],[1133],[382,42,253],{"trials":5039,"activeCount":102},[],{"trials":5041,"activeCount":102},[],{"trials":5043,"activeCount":102},[],{"intervention":5045,"totalTrials":397,"cells":5046},"pazopanib",{"EARLY_PHASE1":5047,"PHASE1":5049,"PHASE2":5055,"PHASE3":5066,"PHASE4":5068,"NA":5070},{"trials":5048,"activeCount":102},[],{"trials":5050,"activeCount":102},[5051],{"nctId":1084,"briefTitle":1085,"status":110,"phases":5052,"primaryCompletion":1087,"completion":1088,"start":706,"enrollment":1089,"conditions":5053,"interventions":5054},[90],[1091,30],[42,1093],{"trials":5056,"activeCount":102},[5057],{"nctId":5058,"briefTitle":5059,"status":110,"phases":5060,"primaryCompletion":5061,"completion":5062,"start":5063,"enrollment":222,"conditions":5064,"interventions":5065},"NCT02393820","Pazopanib in Patients With Progressive Recurrent and\u002For Metastatic Salivary Gland Carcinoma",[91],"2015-12-31","2019-10","2013-08-26",[2542],[5045],{"trials":5067,"activeCount":102},[],{"trials":5069,"activeCount":102},[],{"trials":5071,"activeCount":102},[],{"intervention":899,"totalTrials":309,"cells":5073},{"EARLY_PHASE1":5074,"PHASE1":5076,"PHASE2":5078,"PHASE3":5084,"PHASE4":5086,"NA":5088},{"trials":5075,"activeCount":102},[],{"trials":5077,"activeCount":102},[],{"trials":5079,"activeCount":102},[5080],{"nctId":887,"briefTitle":888,"status":110,"phases":5081,"primaryCompletion":340,"completion":890,"start":891,"enrollment":892,"conditions":5082,"interventions":5083},[91],[15,894,895,896,897],[899,751,900],{"trials":5085,"activeCount":102},[],{"trials":5087,"activeCount":102},[],{"trials":5089,"activeCount":102},[],{"intervention":582,"totalTrials":309,"cells":5091},{"EARLY_PHASE1":5092,"PHASE1":5094,"PHASE2":5096,"PHASE3":5102,"PHASE4":5104,"NA":5106},{"trials":5093,"activeCount":102},[],{"trials":5095,"activeCount":102},[],{"trials":5097,"activeCount":102},[5098],{"nctId":568,"briefTitle":569,"status":110,"phases":5099,"primaryCompletion":571,"completion":572,"start":573,"enrollment":574,"conditions":5100,"interventions":5101},[91],[576,577],[281,579,580,581,582],{"trials":5103,"activeCount":102},[],{"trials":5105,"activeCount":102},[],{"trials":5107,"activeCount":102},[],{"intervention":5109,"totalTrials":309,"cells":5110},"hydroxyurea",{"EARLY_PHASE1":5111,"PHASE1":5113,"PHASE2":5115,"PHASE3":5126,"PHASE4":5128,"NA":5130},{"trials":5112,"activeCount":102},[],{"trials":5114,"activeCount":102},[],{"trials":5116,"activeCount":102},[5117],{"nctId":5118,"briefTitle":5119,"status":110,"phases":5120,"primaryCompletion":5121,"completion":340,"start":5122,"conditions":5123,"interventions":5125},"NCT00006119","Hydroxyurea in Treating Patients With Recurrent and\u002For Unresectable Meningioma",[91],"2004-12","1999-07",[5124],"Brain and Central Nervous System Tumors",[5109],{"trials":5127,"activeCount":102},[],{"trials":5129,"activeCount":102},[],{"trials":5131,"activeCount":102},[],{"intervention":5133,"totalTrials":309,"cells":5134},"Regorafenib then Trifluridine\u002FTipiracil",{"EARLY_PHASE1":5135,"PHASE1":5137,"PHASE2":5139,"PHASE3":5152,"PHASE4":5154,"NA":5156},{"trials":5136,"activeCount":102},[],{"trials":5138,"activeCount":102},[],{"trials":5140,"activeCount":102},[5141],{"nctId":5142,"briefTitle":5143,"status":375,"phases":5144,"primaryCompletion":5145,"completion":5146,"start":5147,"enrollment":5148,"conditions":5149,"interventions":5150},"NCT04450836","Sequences Of REGorafenib And Trifluridine\u002FTipiracil in Patients With Metastatic Colorectal Cancer",[91],"2024-03-23","2024-12-31","2020-11-23",234,[27],[5133,5151],"Trifluridine\u002FTipiracil then Regorafenib",{"trials":5153,"activeCount":102},[],{"trials":5155,"activeCount":102},[],{"trials":5157,"activeCount":102},[],{"intervention":5151,"totalTrials":309,"cells":5159},{"EARLY_PHASE1":5160,"PHASE1":5162,"PHASE2":5164,"PHASE3":5170,"PHASE4":5172,"NA":5174},{"trials":5161,"activeCount":102},[],{"trials":5163,"activeCount":102},[],{"trials":5165,"activeCount":102},[5166],{"nctId":5142,"briefTitle":5143,"status":375,"phases":5167,"primaryCompletion":5145,"completion":5146,"start":5147,"enrollment":5148,"conditions":5168,"interventions":5169},[91],[27],[5133,5151],{"trials":5171,"activeCount":102},[],{"trials":5173,"activeCount":102},[],{"trials":5175,"activeCount":102},[],{"intervention":2841,"totalTrials":309,"cells":5177},{"EARLY_PHASE1":5178,"PHASE1":5180,"PHASE2":5182,"PHASE3":5188,"PHASE4":5190,"NA":5192},{"trials":5179,"activeCount":102},[],{"trials":5181,"activeCount":102},[],{"trials":5183,"activeCount":102},[5184],{"nctId":2831,"briefTitle":2832,"status":375,"phases":5185,"primaryCompletion":2834,"completion":2834,"start":2835,"enrollment":2836,"conditions":5186,"interventions":5187},[90,91],[2838,2839],[2841,241],{"trials":5189,"activeCount":102},[],{"trials":5191,"activeCount":102},[],{"trials":5193,"activeCount":102},[],{"intervention":4999,"totalTrials":309,"cells":5195},{"EARLY_PHASE1":5196,"PHASE1":5198,"PHASE2":5200,"PHASE3":5206,"PHASE4":5208,"NA":5210},{"trials":5197,"activeCount":102},[],{"trials":5199,"activeCount":102},[],{"trials":5201,"activeCount":102},[5202],{"nctId":4991,"briefTitle":4992,"status":375,"phases":5203,"primaryCompletion":4994,"completion":4994,"start":663,"enrollment":4995,"conditions":5204,"interventions":5205},[90,91],[4997],[4999,597],{"trials":5207,"activeCount":102},[],{"trials":5209,"activeCount":102},[],{"trials":5211,"activeCount":102},[],{"intervention":5010,"totalTrials":309,"cells":5213},{"EARLY_PHASE1":5214,"PHASE1":5216,"PHASE2":5218,"PHASE3":5224,"PHASE4":5226,"NA":5228},{"trials":5215,"activeCount":102},[],{"trials":5217,"activeCount":102},[],{"trials":5219,"activeCount":102},[5220],{"nctId":5001,"briefTitle":5002,"status":110,"phases":5221,"primaryCompletion":5004,"completion":5005,"start":5006,"enrollment":5007,"conditions":5222,"interventions":5223},[91],[27],[597,5010],{"trials":5225,"activeCount":102},[],{"trials":5227,"activeCount":102},[],{"trials":5229,"activeCount":102},[],{"intervention":5231,"totalTrials":309,"cells":5232},"Docetaxel every 3 weeks + Prednisone",{"EARLY_PHASE1":5233,"PHASE1":5235,"PHASE2":5237,"PHASE3":5249,"PHASE4":5251,"NA":5253},{"trials":5234,"activeCount":102},[],{"trials":5236,"activeCount":102},[],{"trials":5238,"activeCount":102},[5239],{"nctId":5240,"briefTitle":5241,"status":110,"phases":5242,"primaryCompletion":5243,"completion":5244,"start":5245,"enrollment":9,"conditions":5246,"interventions":5247},"NCT01254513","Feasibility of a Chemotherapy With Docetaxel-Prednisone for Castration-resistant Metastatic Prostate Cancer Elderly Patients",[91],"2014-05-10","2017-04-27","2010-12-09",[21],[5231,5248],"Docetaxel weekly+ Prednisone",{"trials":5250,"activeCount":102},[],{"trials":5252,"activeCount":102},[],{"trials":5254,"activeCount":102},[],{"intervention":5248,"totalTrials":309,"cells":5256},{"EARLY_PHASE1":5257,"PHASE1":5259,"PHASE2":5261,"PHASE3":5267,"PHASE4":5269,"NA":5271},{"trials":5258,"activeCount":102},[],{"trials":5260,"activeCount":102},[],{"trials":5262,"activeCount":102},[5263],{"nctId":5240,"briefTitle":5241,"status":110,"phases":5264,"primaryCompletion":5243,"completion":5244,"start":5245,"enrollment":9,"conditions":5265,"interventions":5266},[91],[21],[5231,5248],{"trials":5268,"activeCount":102},[],{"trials":5270,"activeCount":102},[],{"trials":5272,"activeCount":102},[],{"intervention":5274,"totalTrials":309,"cells":5275},"sunitinib malate",{"EARLY_PHASE1":5276,"PHASE1":5278,"PHASE2":5280,"PHASE3":5291,"PHASE4":5293,"NA":5295},{"trials":5277,"activeCount":102},[],{"trials":5279,"activeCount":102},[],{"trials":5281,"activeCount":102},[5282],{"nctId":5283,"briefTitle":5284,"status":110,"phases":5285,"primaryCompletion":592,"completion":5286,"start":5287,"enrollment":5288,"conditions":5289,"interventions":5290},"NCT00541008","Sunitinib as First-Line Therapy in Treating Patients With Locally Advanced Metastatic Papillary Renal Cell Cancer",[91],"2013-04","2007-09-05",92,[959],[5274],{"trials":5292,"activeCount":102},[],{"trials":5294,"activeCount":102},[],{"trials":5296,"activeCount":102},[],{"intervention":5298,"totalTrials":309,"cells":5299},"Tislelizumab",{"EARLY_PHASE1":5300,"PHASE1":5302,"PHASE2":5304,"PHASE3":5315,"PHASE4":5317,"NA":5319},{"trials":5301,"activeCount":102},[],{"trials":5303,"activeCount":102},[],{"trials":5305,"activeCount":102},[5306],{"nctId":5307,"briefTitle":5308,"status":110,"phases":5309,"primaryCompletion":1275,"completion":5310,"start":5311,"enrollment":2570,"conditions":5312,"interventions":5314},"NCT05622071","Testing Immunotherapy for Patients With Liver Cancer and Moderately Altered Liver Functions",[91],"2025-09-04","2023-10-12",[5313],"Hepatocellular Carcinoma by BCLC Stage",[5298],{"trials":5316,"activeCount":102},[],{"trials":5318,"activeCount":102},[],{"trials":5320,"activeCount":102},[],{"intervention":5322,"totalTrials":309,"cells":5323},"Oxaliplatin, Cetuximab, Bevacizumab, Panitumumab, Irinotecan, Leucovorin, 5-Fluorouracil",{"EARLY_PHASE1":5324,"PHASE1":5326,"PHASE2":5328,"PHASE3":5341,"PHASE4":5343,"NA":5345},{"trials":5325,"activeCount":102},[],{"trials":5327,"activeCount":102},[],{"trials":5329,"activeCount":102},[5330],{"nctId":5331,"briefTitle":5332,"status":110,"phases":5333,"primaryCompletion":5334,"completion":5335,"start":5336,"enrollment":5337,"conditions":5338,"interventions":5340},"NCT03164655","Improving SUrgery of Liver Metastases: a Trial of the Arterial Chemotherapy Network",[91],"2021-07-15","2021-11-15","2018-07-25",20,[5339],"Colorectal Cancer Metastatic",[5322],{"trials":5342,"activeCount":102},[],{"trials":5344,"activeCount":102},[],{"trials":5346,"activeCount":102},[],{"intervention":5348,"totalTrials":309,"cells":5349},"bintrafusp alfa",{"EARLY_PHASE1":5350,"PHASE1":5352,"PHASE2":5354,"PHASE3":5365,"PHASE4":5367,"NA":5369},{"trials":5351,"activeCount":102},[],{"trials":5353,"activeCount":102},[],{"trials":5355,"activeCount":102},[5356],{"nctId":5357,"briefTitle":5358,"status":375,"phases":5359,"primaryCompletion":5360,"completion":5361,"start":5362,"enrollment":98,"conditions":5363,"interventions":5364},"NCT04428047","Evaluation of Bintrafusp Alfa in Operable and Untreated Head and Neck Squamous Cell Carcinoma",[91],"2021-09-04","2022-01-07","2021-02-04",[175],[5348],{"trials":5366,"activeCount":102},[],{"trials":5368,"activeCount":102},[],{"trials":5370,"activeCount":102},[],{"intervention":5372,"totalTrials":309,"cells":5373},"Crizotinib",{"EARLY_PHASE1":5374,"PHASE1":5376,"PHASE2":5378,"PHASE3":5389,"PHASE4":5391,"NA":5393},{"trials":5375,"activeCount":102},[],{"trials":5377,"activeCount":102},[],{"trials":5379,"activeCount":102},[5380],{"nctId":5381,"briefTitle":5382,"status":110,"phases":5383,"primaryCompletion":4565,"completion":5384,"start":5385,"enrollment":5386,"conditions":5387,"interventions":5388},"NCT02034981","Phase 2 Study Assessing Efficacy and Safety of Crizotinib in Patients Harboring an Alteration on ALK, MET or ROS1",[91],"2023-12-06","2013-08",246,[3920,1091,30],[5372],{"trials":5390,"activeCount":102},[],{"trials":5392,"activeCount":102},[],{"trials":5394,"activeCount":102},[],{"intervention":5396,"totalTrials":309,"cells":5397},"pazopanib + gemcitabine",{"EARLY_PHASE1":5398,"PHASE1":5400,"PHASE2":5402,"PHASE3":5413,"PHASE4":5415,"NA":5417},{"trials":5399,"activeCount":102},[],{"trials":5401,"activeCount":102},[],{"trials":5403,"activeCount":102},[5404],{"nctId":5405,"briefTitle":5406,"status":110,"phases":5407,"primaryCompletion":1713,"completion":5408,"start":648,"enrollment":5409,"conditions":5410,"interventions":5412},"NCT01442662","Efficacy of Gemcitabine With Pazopanib as Second Line Treatment in Patient With Metastatic or Relapsed Uterine",[91],"2019-05-28",106,[5411],"Leiomyosarcoma",[5396],{"trials":5414,"activeCount":102},[],{"trials":5416,"activeCount":102},[],{"trials":5418,"activeCount":102},[],{"intervention":5420,"totalTrials":309,"cells":5421},"Abiraterone",{"EARLY_PHASE1":5422,"PHASE1":5424,"PHASE2":5426,"PHASE3":5436,"PHASE4":5438,"NA":5440},{"trials":5423,"activeCount":102},[],{"trials":5425,"activeCount":102},[],{"trials":5427,"activeCount":102},[5428],{"nctId":5429,"briefTitle":5430,"status":110,"phases":5431,"primaryCompletion":5361,"completion":5361,"start":649,"enrollment":5432,"conditions":5433,"interventions":5435},"NCT01780220","Radiotherapy Plus Hormone Therapy in Biochemically-relapsing Prostate Cancer Patients Following Surgery",[90,91],47,[5434],"Biochemically-relapsing Prostate Adenocarcinoma Following Radical Prostatectomy",[5420],{"trials":5437,"activeCount":102},[],{"trials":5439,"activeCount":102},[],{"trials":5441,"activeCount":102},[],{"intervention":5443,"totalTrials":309,"cells":5444},"lapatinib + capecitabine",{"EARLY_PHASE1":5445,"PHASE1":5447,"PHASE2":5449,"PHASE3":5460,"PHASE4":5462,"NA":5464},{"trials":5446,"activeCount":102},[],{"trials":5448,"activeCount":102},[],{"trials":5450,"activeCount":102},[5451],{"nctId":5452,"briefTitle":5453,"status":110,"phases":5454,"primaryCompletion":5455,"completion":990,"start":545,"enrollment":295,"conditions":5456,"interventions":5459},"NCT01262469","Evaluating Lapatinib + Capecitabine in Patients Aged 70 and Over With HER2 Metastatic Breast Cancer.",[91],"2011-12",[24,5457,5458],"70 Years Old Patients and Over","After One Line of Chemotherapy With Trastuzumab",[5443],{"trials":5461,"activeCount":102},[],{"trials":5463,"activeCount":102},[],{"trials":5465,"activeCount":102},[],{"intervention":473,"totalTrials":309,"cells":5467},{"EARLY_PHASE1":5468,"PHASE1":5470,"PHASE2":5472,"PHASE3":5478,"PHASE4":5480,"NA":5482},{"trials":5469,"activeCount":102},[],{"trials":5471,"activeCount":102},[],{"trials":5473,"activeCount":102},[5474],{"nctId":464,"briefTitle":465,"status":110,"phases":5475,"primaryCompletion":467,"completion":468,"start":469,"enrollment":470,"conditions":5476,"interventions":5477},[91],[15],[473,474,396,475,476],{"trials":5479,"activeCount":102},[],{"trials":5481,"activeCount":102},[],{"trials":5483,"activeCount":102},[],{"intervention":5485,"totalTrials":309,"cells":5486},"DS-8201a",{"EARLY_PHASE1":5487,"PHASE1":5489,"PHASE2":5491,"PHASE3":5504,"PHASE4":5506,"NA":5508},{"trials":5488,"activeCount":102},[],{"trials":5490,"activeCount":102},[],{"trials":5492,"activeCount":102},[5493],{"nctId":5494,"briefTitle":5495,"status":110,"phases":5496,"primaryCompletion":5497,"completion":5498,"start":5499,"enrollment":5500,"conditions":5501,"interventions":5503},"NCT04132960","Study of DS-8201a, an Antibody Drug Conjugate for Advanced Breast Cancer Patients, With Biomarkers Analysis",[91],"2021-10-29","2024-12-26","2019-10-21",186,[5502],"Breast Tumors",[5485],{"trials":5505,"activeCount":102},[],{"trials":5507,"activeCount":102},[],{"trials":5509,"activeCount":102},[],{"intervention":2728,"totalTrials":309,"cells":5511},{"EARLY_PHASE1":5512,"PHASE1":5514,"PHASE2":5516,"PHASE3":5522,"PHASE4":5524,"NA":5526},{"trials":5513,"activeCount":102},[],{"trials":5515,"activeCount":102},[],{"trials":5517,"activeCount":102},[5518],{"nctId":2718,"briefTitle":2719,"status":110,"phases":5519,"primaryCompletion":2721,"completion":2722,"start":2723,"enrollment":2724,"conditions":5520,"interventions":5521},[91],[2726],[72,934,935,936,937,938,2728,2729,82,2730,940],{"trials":5523,"activeCount":102},[],{"trials":5525,"activeCount":102},[],{"trials":5527,"activeCount":102},[],{"intervention":2729,"totalTrials":309,"cells":5529},{"EARLY_PHASE1":5530,"PHASE1":5532,"PHASE2":5534,"PHASE3":5540,"PHASE4":5542,"NA":5544},{"trials":5531,"activeCount":102},[],{"trials":5533,"activeCount":102},[],{"trials":5535,"activeCount":102},[5536],{"nctId":2718,"briefTitle":2719,"status":110,"phases":5537,"primaryCompletion":2721,"completion":2722,"start":2723,"enrollment":2724,"conditions":5538,"interventions":5539},[91],[2726],[72,934,935,936,937,938,2728,2729,82,2730,940],{"trials":5541,"activeCount":102},[],{"trials":5543,"activeCount":102},[],{"trials":5545,"activeCount":102},[],{"intervention":2730,"totalTrials":309,"cells":5547},{"EARLY_PHASE1":5548,"PHASE1":5550,"PHASE2":5552,"PHASE3":5558,"PHASE4":5560,"NA":5562},{"trials":5549,"activeCount":102},[],{"trials":5551,"activeCount":102},[],{"trials":5553,"activeCount":102},[5554],{"nctId":2718,"briefTitle":2719,"status":110,"phases":5555,"primaryCompletion":2721,"completion":2722,"start":2723,"enrollment":2724,"conditions":5556,"interventions":5557},[91],[2726],[72,934,935,936,937,938,2728,2729,82,2730,940],{"trials":5559,"activeCount":102},[],{"trials":5561,"activeCount":102},[],{"trials":5563,"activeCount":102},[],{"intervention":5565,"totalTrials":309,"cells":5566},"Durvalumab + Tremelimumab + metronomic Vinorelbine",{"EARLY_PHASE1":5567,"PHASE1":5569,"PHASE2":5571,"PHASE3":5584,"PHASE4":5586,"NA":5588},{"trials":5568,"activeCount":102},[],{"trials":5570,"activeCount":102},[],{"trials":5572,"activeCount":102},[5573],{"nctId":5574,"briefTitle":5575,"status":110,"phases":5576,"primaryCompletion":2526,"completion":5577,"start":5578,"enrollment":5579,"conditions":5580,"interventions":5583},"NCT03518606","Metronomic Oral Vinorelbine Plus Anti-PD-L1\u002FAnti-CTLA4 ImmunothErapy in Patients With Advanced Solid Tumours",[90,91],"2024-12-19","2018-06-20",126,[5581,15,36,5582,21],"Advanced Solid Tumours","Cervix Cancer",[5565],{"trials":5585,"activeCount":102},[],{"trials":5587,"activeCount":102},[],{"trials":5589,"activeCount":102},[],{"intervention":371,"totalTrials":309,"cells":5591},{"EARLY_PHASE1":5592,"PHASE1":5594,"PHASE2":5596,"PHASE3":5602,"PHASE4":5604,"NA":5606},{"trials":5593,"activeCount":102},[],{"trials":5595,"activeCount":102},[],{"trials":5597,"activeCount":102},[5598],{"nctId":363,"briefTitle":364,"status":110,"phases":5599,"primaryCompletion":366,"start":367,"enrollment":368,"conditions":5600,"interventions":5601},[91],[15,30],[334,371],{"trials":5603,"activeCount":102},[],{"trials":5605,"activeCount":102},[],{"trials":5607,"activeCount":102},[],{"intervention":266,"totalTrials":309,"cells":5609},{"EARLY_PHASE1":5610,"PHASE1":5612,"PHASE2":5614,"PHASE3":5620,"PHASE4":5622,"NA":5624},{"trials":5611,"activeCount":102},[],{"trials":5613,"activeCount":102},[],{"trials":5615,"activeCount":102},[5616],{"nctId":258,"briefTitle":259,"status":110,"phases":5617,"primaryCompletion":261,"completion":262,"start":263,"conditions":5618,"interventions":5619},[91],[18,30],[207,253,266,255,256],{"trials":5621,"activeCount":102},[],{"trials":5623,"activeCount":102},[],{"trials":5625,"activeCount":102},[],{"intervention":925,"totalTrials":309,"cells":5627},{"EARLY_PHASE1":5628,"PHASE1":5630,"PHASE2":5632,"PHASE3":5638,"PHASE4":5640,"NA":5642},{"trials":5629,"activeCount":102},[],{"trials":5631,"activeCount":102},[],{"trials":5633,"activeCount":102},[5634],{"nctId":916,"briefTitle":917,"status":110,"phases":5635,"primaryCompletion":919,"completion":920,"start":469,"enrollment":921,"conditions":5636,"interventions":5637},[91],[923],[925,552,550,926,87],{"trials":5639,"activeCount":102},[],{"trials":5641,"activeCount":102},[],{"trials":5643,"activeCount":102},[],{"intervention":5645,"totalTrials":309,"cells":5646},"Riluzole",{"EARLY_PHASE1":5647,"PHASE1":5649,"PHASE2":5651,"PHASE3":5664,"PHASE4":5666,"NA":5668},{"trials":5648,"activeCount":102},[],{"trials":5650,"activeCount":102},[],{"trials":5652,"activeCount":102},[5653],{"nctId":5654,"briefTitle":5655,"status":5656,"phases":5657,"primaryCompletion":5658,"completion":5659,"start":5660,"enrollment":3431,"conditions":5661,"interventions":5663},"NCT03722680","Effectiveness Assessment of Riluzole in the Prevention of Oxaliplatin-induced Peripheral Neuropathy.","SUSPENDED",[91],"2024-08-01","2026-12-31","2020-10-28",[5662],"Oxaliplatin-induced Peripheral Neuropathy",[5645],{"trials":5665,"activeCount":102},[],{"trials":5667,"activeCount":102},[],{"trials":5669,"activeCount":102},[],{"intervention":5025,"totalTrials":309,"cells":5671},{"EARLY_PHASE1":5672,"PHASE1":5674,"PHASE2":5676,"PHASE3":5682,"PHASE4":5684,"NA":5686},{"trials":5673,"activeCount":102},[],{"trials":5675,"activeCount":102},[],{"trials":5677,"activeCount":102},[5678],{"nctId":5016,"briefTitle":5017,"status":110,"phases":5679,"primaryCompletion":5019,"completion":5020,"start":5021,"enrollment":5022,"conditions":5680,"interventions":5681},[91],[27],[5025,597],{"trials":5683,"activeCount":102},[],{"trials":5685,"activeCount":102},[],{"trials":5687,"activeCount":102},[],{"intervention":5689,"totalTrials":309,"cells":5690},"imatinib mesylate",{"EARLY_PHASE1":5691,"PHASE1":5693,"PHASE2":5695,"PHASE3":5706,"PHASE4":5708,"NA":5710},{"trials":5692,"activeCount":102},[],{"trials":5694,"activeCount":102},[],{"trials":5696,"activeCount":102},[5697],{"nctId":5698,"briefTitle":5699,"status":110,"phases":5700,"primaryCompletion":5701,"completion":706,"start":5702,"enrollment":892,"conditions":5703,"interventions":5705},"NCT00287846","Imatinib Mesylate in Treating Patients With Recurrent or Refractory Fibromatosis",[90,91],"2006-02","2004-09",[5704],"Desmoid Tumor",[5689],{"trials":5707,"activeCount":102},[],{"trials":5709,"activeCount":102},[],{"trials":5711,"activeCount":102},[],{"intervention":5713,"totalTrials":309,"cells":5714},"Fentanyl citrate",{"EARLY_PHASE1":5715,"PHASE1":5717,"PHASE2":5719,"PHASE3":5731,"PHASE4":5733,"NA":5735},{"trials":5716,"activeCount":102},[],{"trials":5718,"activeCount":102},[],{"trials":5720,"activeCount":102},[5721],{"nctId":5722,"briefTitle":5723,"status":869,"phases":5724,"primaryCompletion":5725,"completion":5726,"start":5727,"enrollment":102,"conditions":5728,"interventions":5730},"NCT03809455","Effectiveness and Tolerance of Fentanyl Citrate in Painful Pain Induced During Diagnostic or Therapeutic Examinations in Cancer Patients",[91],"2022-02-01","2023-02-01","2020-02-01",[5729],"Breakthrough Pain",[5713],{"trials":5732,"activeCount":102},[],{"trials":5734,"activeCount":102},[],{"trials":5736,"activeCount":102},[],{"intervention":2753,"totalTrials":309,"cells":5738},{"EARLY_PHASE1":5739,"PHASE1":5741,"PHASE2":5743,"PHASE3":5749,"PHASE4":5751,"NA":5753},{"trials":5740,"activeCount":102},[],{"trials":5742,"activeCount":102},[],{"trials":5744,"activeCount":102},[5745],{"nctId":2742,"briefTitle":2743,"status":110,"phases":5746,"primaryCompletion":2745,"completion":2746,"start":2747,"enrollment":2748,"conditions":5747,"interventions":5748},[91],[2750,2751],[82,2753],{"trials":5750,"activeCount":102},[],{"trials":5752,"activeCount":102},[],{"trials":5754,"activeCount":102},[],{"intervention":5756,"totalTrials":309,"cells":5757},"pembrolizumab; vorinostat",{"EARLY_PHASE1":5758,"PHASE1":5760,"PHASE2":5762,"PHASE3":5775,"PHASE4":5777,"NA":5779},{"trials":5759,"activeCount":102},[],{"trials":5761,"activeCount":102},[],{"trials":5763,"activeCount":102},[5764],{"nctId":5765,"briefTitle":5766,"status":110,"phases":5767,"primaryCompletion":5768,"completion":5769,"start":5660,"enrollment":2748,"conditions":5770,"interventions":5774},"NCT04357873","Efficacy of Immunotherapy Plus a Drug in Patients With Progressive Advanced Mucosal Cancer of Different Locations",[91],"2022-12-15","2024-11-26",[5771,5772,3832,5582,5773,1133],"Squamous Cell Lung Cancer","Vulvar Cancer","Head and Neck Squamous Cell Carcinoma",[5756],{"trials":5776,"activeCount":102},[],{"trials":5778,"activeCount":102},[],{"trials":5780,"activeCount":102},[],{"intervention":961,"totalTrials":309,"cells":5782},{"EARLY_PHASE1":5783,"PHASE1":5785,"PHASE2":5787,"PHASE3":5793,"PHASE4":5795,"NA":5797},{"trials":5784,"activeCount":102},[],{"trials":5786,"activeCount":102},[],{"trials":5788,"activeCount":102},[5789],{"nctId":951,"briefTitle":952,"status":110,"phases":5790,"primaryCompletion":954,"completion":955,"start":956,"enrollment":957,"conditions":5791,"interventions":5792},[91],[959],[961,751,962,963],{"trials":5794,"activeCount":102},[],{"trials":5796,"activeCount":102},[],{"trials":5798,"activeCount":102},[],{"intervention":962,"totalTrials":309,"cells":5800},{"EARLY_PHASE1":5801,"PHASE1":5803,"PHASE2":5805,"PHASE3":5811,"PHASE4":5813,"NA":5815},{"trials":5802,"activeCount":102},[],{"trials":5804,"activeCount":102},[],{"trials":5806,"activeCount":102},[5807],{"nctId":951,"briefTitle":952,"status":110,"phases":5808,"primaryCompletion":954,"completion":955,"start":956,"enrollment":957,"conditions":5809,"interventions":5810},[91],[959],[961,751,962,963],{"trials":5812,"activeCount":102},[],{"trials":5814,"activeCount":102},[],{"trials":5816,"activeCount":102},[],{"intervention":963,"totalTrials":309,"cells":5818},{"EARLY_PHASE1":5819,"PHASE1":5821,"PHASE2":5823,"PHASE3":5829,"PHASE4":5831,"NA":5833},{"trials":5820,"activeCount":102},[],{"trials":5822,"activeCount":102},[],{"trials":5824,"activeCount":102},[5825],{"nctId":951,"briefTitle":952,"status":110,"phases":5826,"primaryCompletion":954,"completion":955,"start":956,"enrollment":957,"conditions":5827,"interventions":5828},[91],[959],[961,751,962,963],{"trials":5830,"activeCount":102},[],{"trials":5832,"activeCount":102},[],{"trials":5834,"activeCount":102},[],{"intervention":5836,"totalTrials":309,"cells":5837},"Afatinib",{"EARLY_PHASE1":5838,"PHASE1":5840,"PHASE2":5842,"PHASE3":5851,"PHASE4":5853,"NA":5855},{"trials":5839,"activeCount":102},[],{"trials":5841,"activeCount":102},[],{"trials":5843,"activeCount":102},[5844],{"nctId":5845,"briefTitle":5846,"status":110,"phases":5847,"primaryCompletion":5848,"completion":5848,"start":420,"enrollment":2761,"conditions":5849,"interventions":5850},"NCT01415674","Research of Biomarkers of Activity and Efficacy of BIBW2992 in Untreated Non-metastatic HNSCC Patients",[91],"2021-12",[4997],[5836],{"trials":5852,"activeCount":102},[],{"trials":5854,"activeCount":102},[],{"trials":5856,"activeCount":102},[],{"intervention":5858,"totalTrials":309,"cells":5859},"rucaparib",{"EARLY_PHASE1":5860,"PHASE1":5862,"PHASE2":5864,"PHASE3":5876,"PHASE4":5878,"NA":5880},{"trials":5861,"activeCount":102},[],{"trials":5863,"activeCount":102},[],{"trials":5865,"activeCount":102},[5866],{"nctId":5867,"briefTitle":5868,"status":110,"phases":5869,"primaryCompletion":5870,"completion":5871,"start":5872,"enrollment":5873,"conditions":5874,"interventions":5875},"NCT02505048","A Study to Assess the Efficacy of Rucaparib in Metastatic Breast Cancer Patients With a BRCAness Genomic Signature",[91],"2019-02","2019-12","2016-03",41,[24],[5858],{"trials":5877,"activeCount":102},[],{"trials":5879,"activeCount":102},[],{"trials":5881,"activeCount":102},[],{"intervention":2767,"totalTrials":309,"cells":5883},{"EARLY_PHASE1":5884,"PHASE1":5886,"PHASE2":5888,"PHASE3":5894,"PHASE4":5896,"NA":5898},{"trials":5885,"activeCount":102},[],{"trials":5887,"activeCount":102},[],{"trials":5889,"activeCount":102},[5890],{"nctId":2755,"briefTitle":2756,"status":110,"phases":5891,"primaryCompletion":2758,"completion":2759,"start":2760,"enrollment":2761,"conditions":5892,"interventions":5893},[91],[15,2763,2764,2765],[2767,82],{"trials":5895,"activeCount":102},[],{"trials":5897,"activeCount":102},[],{"trials":5899,"activeCount":102},[],{"intervention":5901,"totalTrials":309,"cells":5902},"Combination of ribociclib + capecitabine",{"EARLY_PHASE1":5903,"PHASE1":5905,"PHASE2":5917,"PHASE3":5919,"PHASE4":5921,"NA":5923},{"trials":5904,"activeCount":102},[],{"trials":5906,"activeCount":102},[5907],{"nctId":5908,"briefTitle":5909,"status":110,"phases":5910,"primaryCompletion":5911,"completion":5912,"start":5913,"enrollment":5914,"conditions":5915,"interventions":5916},"NCT02754011","Phase I Evaluating the Combination of Ribociclib+Capecitabine in Locally Advanced\u002FMetastatic Breast Cancer HER2 Negative",[90],"2022-02-28","2022-12-23","2017-02-02",18,[15],[5901],{"trials":5918,"activeCount":102},[],{"trials":5920,"activeCount":102},[],{"trials":5922,"activeCount":102},[],{"trials":5924,"activeCount":102},[],{"intervention":5926,"totalTrials":309,"cells":5927},"Lapatinib",{"EARLY_PHASE1":5928,"PHASE1":5930,"PHASE2":5942,"PHASE3":5944,"PHASE4":5946,"NA":5948},{"trials":5929,"activeCount":102},[],{"trials":5931,"activeCount":102},[5932],{"nctId":5933,"briefTitle":5934,"status":110,"phases":5935,"primaryCompletion":5936,"completion":1753,"start":5937,"enrollment":5938,"conditions":5939,"interventions":5940},"NCT00513058","Lapatinib and Vinorelbine in Treating Women With HER2-Overexpressing Locally Advanced or Metastatic Breast Cancer",[90],"2010-05","2007-06",33,[15],[5926,5941],"vinorelbine",{"trials":5943,"activeCount":102},[],{"trials":5945,"activeCount":102},[],{"trials":5947,"activeCount":102},[],{"trials":5949,"activeCount":102},[],{"intervention":5941,"totalTrials":309,"cells":5951},{"EARLY_PHASE1":5952,"PHASE1":5954,"PHASE2":5960,"PHASE3":5962,"PHASE4":5964,"NA":5966},{"trials":5953,"activeCount":102},[],{"trials":5955,"activeCount":102},[5956],{"nctId":5933,"briefTitle":5934,"status":110,"phases":5957,"primaryCompletion":5936,"completion":1753,"start":5937,"enrollment":5938,"conditions":5958,"interventions":5959},[90],[15],[5926,5941],{"trials":5961,"activeCount":102},[],{"trials":5963,"activeCount":102},[],{"trials":5965,"activeCount":102},[],{"trials":5967,"activeCount":102},[],{"intervention":5969,"totalTrials":309,"cells":5970},"patent blue V dye",{"EARLY_PHASE1":5971,"PHASE1":5973,"PHASE2":5975,"PHASE3":5977,"PHASE4":5979,"NA":5981},{"trials":5972,"activeCount":102},[],{"trials":5974,"activeCount":102},[],{"trials":5976,"activeCount":102},[],{"trials":5978,"activeCount":102},[],{"trials":5980,"activeCount":102},[],{"trials":5982,"activeCount":102},[5983],{"nctId":5984,"briefTitle":5985,"status":375,"phases":5986,"primaryCompletion":5987,"completion":5987,"start":5988,"enrollment":3344,"conditions":5989,"interventions":5990},"NCT00003654","Diagnostic Study to Identify Sentinel Lymph Nodes in Women With Stage I or Stage II Breast Cancer",[94],"2000-01","1997-09",[15],[5969]]